WO2003035077A1 - N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase - Google Patents

N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase Download PDF

Info

Publication number
WO2003035077A1
WO2003035077A1 PCT/GB2002/004753 GB0204753W WO03035077A1 WO 2003035077 A1 WO2003035077 A1 WO 2003035077A1 GB 0204753 W GB0204753 W GB 0204753W WO 03035077 A1 WO03035077 A1 WO 03035077A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
oxo
methyl
hydroxy
dihydropyrimidine
Prior art date
Application number
PCT/GB2002/004753
Other languages
French (fr)
Inventor
Benedetta Crescenzi
Cristina Gardelli
Ester Muraglia
Emanuela Nizi
Federica Orvieto
Paola Pace
Giovanna Pescatore
Alessia Petrocchi
Marco Poma
Michael Rowley
Rita Scarpelli
Vincenzo Summa
Original Assignee
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003035077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP02801950A priority Critical patent/EP1441735B1/en
Priority to BRPI0213522A priority patent/BRPI0213522C1/en
Priority to AU2002334207A priority patent/AU2002334207B8/en
Priority to NZ533057A priority patent/NZ533057A/en
Priority to IL16133702A priority patent/IL161337A0/en
Priority to SI200230296T priority patent/SI1441735T1/en
Priority to DE60209381T priority patent/DE60209381T2/en
Priority to HU0401740A priority patent/HU230248B1/en
Priority to CN028257650A priority patent/CN1700918B/en
Priority to US10/493,280 priority patent/US7169780B2/en
Priority to EA200400585A priority patent/EA007060B1/en
Priority to MEP-2008-637A priority patent/ME00427B/en
Priority to UA20040503960A priority patent/UA77454C2/en
Priority to MXPA04003932A priority patent/MXPA04003932A/en
Priority to JP2003537644A priority patent/JP3927175B2/en
Priority to CA002463976A priority patent/CA2463976C/en
Priority to DE200812000016 priority patent/DE122008000016I1/en
Priority to DE122009000048C priority patent/DE122009000048I1/en
Priority to KR1020047006234A priority patent/KR100862879B1/en
Application filed by Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa filed Critical Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa
Publication of WO2003035077A1 publication Critical patent/WO2003035077A1/en
Priority to IS7213A priority patent/IS2436B/en
Priority to IL161337A priority patent/IL161337A/en
Priority to ZA2004/02796A priority patent/ZA200402796B/en
Priority to HRP20040373AA priority patent/HRP20040373B1/en
Priority to NO20042165A priority patent/NO325206B1/en
Priority to HK06105678.2A priority patent/HK1085665A1/en
Priority to US11/491,815 priority patent/US7217713B2/en
Priority to US11/641,508 priority patent/US7435734B2/en
Priority to NL300340C priority patent/NL300340I2/en
Priority to LU91428C priority patent/LU91428I2/en
Priority to CY200800008C priority patent/CY2008008I1/en
Priority to LTPA2008007C priority patent/LTC1441735I2/en
Priority to NO2008007C priority patent/NO2008007I1/en
Priority to FR08C0026C priority patent/FR08C0026I2/en
Priority to US12/214,595 priority patent/US7820660B2/en
Priority to US12/884,734 priority patent/US20110034449A1/en
Priority to HUS1600016C priority patent/HUS1600016I1/en
Priority to NO2020026C priority patent/NO2020026I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention is directed to N-substituted 5-hydroxy-6-oxo- l,6-dihydropyrimidine-4-carboxamides and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of the HTV integrase enzyme.
  • the compounds and pharmaceutically acceptable salts thereof of the present invention are useful for preventing or treating infection by HTV and for treating or delaying the onset of AIDS.
  • a retrovirus designated human immunodeficiency virus is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system.
  • This virus was previously known as LAN, HTLN-IH, or ARV.
  • a common feature of retrovirus replication is the insertion by virally-encoded integrase of proviral D ⁇ A into the host cell genome, a required step in HTV replication in human T-lymphoid and monocytoid cells.
  • Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral D ⁇ A sequences; cleavage of two nucleotides from the 3' termini of the linear proviral D ⁇ A; covalent joining of the recessed 3' OH termini of the proviral D ⁇ A at a staggered cut made at the host target site.
  • the fourth step in the process, repair synthesis of the resultant gap may be accomplished by cellular enzymes.
  • Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)].
  • Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al., Science, 231, 1567 (1986); Pearl, L.H. et al., Nature, 329, 351 (1987)]. All three enzymes have been shown to be essential for the replication of HIV.
  • antiviral compounds which act as inhibitors of HIN replication are effective agents in the treatment of AIDS and similar diseases, including reverse transcriptase inhibitors such as azidothymidine (AZT) and efavirenz and protease inhbitors such as indinavir and nelfinavir.
  • the compounds of this invention are inhibitors of HIN integrase and inhibitors of HIV replication.
  • the inhibition of integrase in vitro and HTV replication in cells is a direct result of inhibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro in HTV infected cells.
  • the particular advantage of the present invention is highly specific inhibition of HTV integrase and HTV replication.
  • the present invention is directed to novel hydroxypyrimidinone carboxamides. These compounds are useful in the inhibition of HIV integrase, the prevention of infection by HTV, the treatment of infection by HTV and in the prevention, treatment, and delay in the onset of AIDS and/or ARC, either as compounds or their pharmaceutically acceptable salts or hydrates (when appropriate), or as pharmaceutical composition ingredients, whether or not in combination with other HTV/ AIDS antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. More particularly, the present invention includes a compound of Formula (I):
  • aryl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -C ⁇ _6 alkyl, -C ⁇ _6 alkyl-ORa, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl;
  • substituents e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted
  • (b) a 4- to 8- membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -C ⁇ _6 alkyl, -C ⁇ . ⁇ alkyl-ORa, -Ci_6 haloalkyl, -O-C ⁇ _6 alkyl, -O-Ci-6 haloalkyl, -C( O)Ra,
  • substituents e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted
  • substituents e.g., optionally 1 to 5, or 1 to 4, or 1
  • R2 is -C ⁇ _6 alkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently
  • substituents e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted
  • aryl wherein the aryl is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -C ⁇ _6 alkyl, -Ci_6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C ⁇ -6 alkyl-N(RaRb), 0 r -Ci-6 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Ci-6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S
  • a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heterocycle is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently -Ci_6 alkyl, -O-C ⁇ _6 alkyl, oxo, phenyl, or naphthyl;
  • substituents e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted
  • R3 is -H or -C 1-6 alkyl
  • a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S (v) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (vi) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic, (4) C2-5 alkynyl optionally substituted with aryl, (5) C3_8 cycloalkyl optionally substituted with aryl,
  • each aryl in (3)(ii) or the aryl (4), (5) or (6) or each fused carbocycle in (3)(iii) or the fused carbocycle in (7) is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono- substituted) each of which is independently halogen, -OH, -Ci-6 alkyl, -Ci -6 alkyl-ORa, _C ⁇ _6 haloalkyl, -O-C ⁇ _6 alkyl, -O-Ci-6 haloalkyl, -CN, -NO2, -N(RaRb), -C ⁇ _6 alkyl-N(R a Rb),
  • het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently -C ⁇ _6 alkyl, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, oxo, or -CO2R a ; each saturated heterocyclic ring in (3)
  • each R a , Rb RC ; and Rd is independently -H or -Ci-6 alkyl
  • Rk is carbocycle or heterocycle, wherein the carbocycle or heterocycle is optionally substituted with one or more substituents (e.g., optionally from 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently
  • substituents e.g., optionally from 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted
  • carbocycle in Rk is (i) a C3 to Cs monocyclic, saturated or unsaturated ring, (ii) a C7 to C ⁇ 2 bicyclic ring system, or (iii) a C ⁇ to C ⁇ 6 tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated;
  • heterocycle in Rk is (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring,
  • each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated; the monocyclic ring, bicyclic ring system, or tricyclic ring system contains from 1 to 6 heteroatoms selected from
  • N, O and S and a balance of carbon atoms and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally be oxidized, and any one or more of the nitrogen heteroatoms is optionally quatemized;
  • each Rm is independently C3-8 cycloalkyl; aryl; a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; or a 9- to 10-membered bicyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein any one or more of the nitrogen and sulfur heteroatoms in the heterocycle or bicyclic heterocycle is optionally oxidized and any one or more of the nitrogen heteroatoms is optionally quatemized; and wherein the cycloalkyl or the aryl defined in Rm is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -C ⁇ _6 alkyl optionally substituted with -O-C ⁇ _4 alkyl,
  • each n is independently an integer equal to zero, 1 or 2;
  • the present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions.
  • the present invention further includes methods of treating AIDS, methods of delaying the onset of ADDS, methods of preventing ADDS, methods of preventing infection by HIN, and methods of treating infection by HIN.
  • Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
  • the present invention includes the N-substituted hydroxypyrimidinone carboxamides of Formula (I) above. These compounds and pharmaceutically acceptable salts thereof are HIV integrase inhibitors.
  • An embodiment of the present invention is a compound of Formula (I) exactly as defined above, except that in the definition of Rk Rk is optionally substituted with one or more substituents each of which is independently one of the substituents (1) to (18), and is optionally mono-substituted with one of the substituents (19) to (34).
  • Another embodiment of the present invention is a compound of
  • Rl is one of substitutents (1) to (16) and in the definition of Rk, Rk 1S optionally substituted with one or more substituents (e.g., optionally from 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 to 2 substituents, or is optionally monosubstituted) each of which is independently one of substitutents (1) to (31).
  • substituents e.g., optionally from 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 to 2 substituents, or is optionally monosubstituted
  • Another embodiment of the present invention is a compound of Formula (I), wherein Rl is:
  • the -(CH2)l-3- moiety is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -O-C ⁇ -6 alkyl, -O-C ⁇ -6 haloalkyl, -N(RaRb),
  • Ra is (a) aryl which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -C ⁇ -6 alkyl, -C ⁇ _6 alkyl-ORa, -C ⁇ _6 haloalkyl, -O-C ⁇ -6 alkyl, -O-C ⁇ _6 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl;
  • Rl is one of groups (1) to (16).
  • Another embodiment of the present invention is a compound of
  • heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C ⁇ _4 alkyl, -C ⁇ _4 alkyl-ORa, -C ⁇ _4 haloalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ _4 haloalkyl, oxo, or phenyl; or (c) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C ⁇ -4 alkyl, -C ⁇ -4 alkyl-ORa, -C ⁇ -4 haloalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ _4 haloalkyl, -C(
  • Rl is one of groups (1) to (5).
  • Another embodiment of the present invention is a compound of Formula (I), wherein Rl is:
  • Rl is one of groups (1) to (5).
  • Another embodiment of the present invention is a compound of Formula (I), wherein
  • Rk is C3-8 cycloalkyl; aryl selected from phenyl and naphthyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently
  • the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently selected from the groups (1) to (27).
  • Rk i.e., the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle
  • Rk is optionally substituted with from 1 to 4 substituents each of which is independently one of the substituents (1) to (19), and is optionally mono-substituted with one of the substituents (20) to (28).
  • Rk is optionally substituted with from 1 to 4 substituents each of which is independently one of the substituents (1) to (19), and is mono-substituted with one of the substituents (20) to (28).
  • each Rm is independently C3_7 cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein any N is optionally oxidized to form an N-oxide; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6- membered, saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S; wherein the cycloalkyl or the aryl defined in Rm is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C ⁇ _4 alkyl, -C ⁇ _4 haloalkyl, -O-C ⁇ -4 alkyl, -O
  • Another embodiment of the present invention is a compound of Formula (I), wherein Rk is phenyl; a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; a 5- or 6-membered heteroaromatic ring containing 1 or 2 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 nitrogen atoms;
  • the saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally mono- or di-substituted with
  • each R m is independently cyclopropyl; phenyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, imidazolidinyl, pyrazoUdinyl, piperidinyl, piperazinyl, and morpholinyl; or a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl optionally in the form of an N-oxide, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; wherein the cyclopropyl is unsubstituted; the phenyl is optionally
  • -C ⁇ _6 alkyl substituted with phenyl wherein the phenyl is: (a) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C ⁇ _4 alkyl, -C ⁇ _4 haloalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ -4 haloalkyl, or -Co-4 alkyl-N(RaRb) ; an d (b) optionally mono-substituted with -C ⁇ _4 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C ⁇ _6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring
  • -C ⁇ -6 alkyl optionally substituted with -OH and substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently -C _6 alkyl, -O-C ⁇ -6 alkyl, oxo, or phenyl; or (5) -C ⁇ _6 alkyl substituted with a 5- or 6-membered heteroaromatic ring which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms,
  • heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C ⁇ _6 alkyl, -O-C ⁇ _6 alkyl, oxo, or phenyl;
  • Another embodiment of the present invention is a compound of Formula (I) exactly as defined in the immediately preceding embodiment, except that when R2 is -C ⁇ _6 alkyl substituted with -N(R a Rb), it is with the proviso that -N(R a Rb) is not attached to the carbon atom in the -C ⁇ _6 alkyl group that is attached to the ring nitrogen (i.e., that the -N(RaRb) group is not attached to the carbon atom alpha to the ring nitrogen).
  • Another embodiment of the present invention is a compound of Formula (I), wherein R2 is methyl;
  • Another embodiment of the present invention is a compound of Formula (I), wherein R3 is -H or -C ⁇ _4 alkyl;
  • R3 is -H or methyl. In another aspect of this embodiment, R3 is -H.
  • R is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ -4 fluoroalkyl, -0-C ⁇ _4 alkyl, -O-C ⁇ -4 fluoroalkyl, -(CH 2 )l-2-N(RaRb), -SO 2 Ra, -(CH 2 ) ⁇ -2-CO 2 Ra, -(CH2) ⁇ -2-N(Ra)CO 2 Rb, -NO2, -SRa, -N(RaRb) or phenyl;
  • each R a and Rb is independently is H or -C ⁇ _4 alkyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents, each of which is independently -F, -Br, -CI, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ .4 alkyl, -SO2- C ⁇ _4 alkyl, -S-C ⁇ _4 alkyl, -N(CH3)2 or -O-C ⁇ _4 fluoroalkyl.
  • R4 is p-fluorobenzyl or 2,3-dimethoxybenzyl.
  • the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ _4 fluoroalkyl, -(CH2)l-2-N(R a Rb), -SO2R a -(CH2)0-2-CO2R a ⁇ (CH2)0-2 ⁇ N(R a )CO2Rb, -NO2, or phenyl.
  • the phenyl is optionally substituted with from 1 to 3 substituents, each of which is independently -F, -Br, -CI, -OH, -C ⁇ _4 alkyl, -C ⁇ -4 fluoroalkyl, -O-C ⁇ _4 alkyl, or -O-C ⁇ _4 fluoroalkyl.
  • R4 is p-fluorobenzyl or 2,3- dimethoxybenzyl .
  • a class of compounds of the present invention includes any compound of Formula (I), wherein
  • Rl is -Rk
  • Rk is phenyl which is
  • heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; and the heteroaromatic ring defined in Rm is optionally substituted with 1 or 2 substituents each of which is independently -C ⁇ _4 alkyl or oxo;
  • a sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein
  • R2 is methyl
  • R3 is -H
  • R4 is: (1) -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ .4 fluoroalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ .4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2R a -(CH2)0-2-CO 2 R a , -(CH 2 )0-2-N(R a )CO2Rb, -NO 2 , -SR a , - N(RaRb) or phenyl; or
  • each R a and Rb is independently is H or -C ⁇ _4 alkyl
  • Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein R is 4-fluorobenzyl or 2,3-dimethoxybenzyl;
  • Still another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein R2 is methyl; R3 is -H; R4 is 4-fluorobenzyl or 2,3-dimethoxybenzyl; each R a and Rb is independently is H or -C ⁇ -4 alkyl; and all other variables are as defined in the class; or a pharmaceutically acceptable salt thereof.
  • Another class of the present invention includes any compound of Formula (I), wherein R2 is methyl; R3 is -H; R4 is 4-fluorobenzyl or 2,3-dimethoxybenzyl; each R a and Rb is independently is H or -C ⁇ -4 alkyl; and all other variables are as defined in the class; or a pharmaceutically acceptable salt thereof.
  • Another class of the present invention includes any compound of
  • phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently -F, -CI, Br, -C ⁇ _4 alkyl, -CF3, -O-C ⁇ -4 alkyl, -OCF3, methylenedioxy attached to two adjacent carbon atoms, or phenyl, or
  • T is:
  • phenyl optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C ⁇ _4 alkyl, -C ⁇ _4 alkyl-ORa, -C ⁇ _4 haloalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ -4 haloalkyl, or -N(RaRb) ;
  • a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with from 1 to 4 substituents each of which is independently -C ⁇ _4 alkyl, -C ⁇ -4 alkyl-ORa, -C ⁇ _4 haloalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ _4 haloalkyl, -C( O)Ra oxo, phenyl, or -CH2-phenyl; or
  • R3 is -H or -C ⁇ -4 alkyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ _4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2R a , -(CH2)0-2-C ⁇ 2R a , -(CH2)0-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) or phenyl;
  • each R a and Rb is independently is H or -C ⁇ _4 alkyl
  • s is an integer equal to zero, 1, or 2; or a pharmaceutically acceptable salt thereof.
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ -4 alkyl, -C ⁇ .4 fluoroalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ _4 fluoroalkyl, -(CH2)l-2 ⁇ N(RaRb), -SO 2 R a , -(CH2) ⁇ -2-CO 2 R -(CH2)0-2-N(Ra)C ⁇ 2Rb -NO2, or phenyl
  • a sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (II) exactly as defined in the preceding class, except that when R is -C ⁇ .4 alkyl substituted with -N(R a Rb), it is with the proviso that -N(RaRb) is not attached to the carbon atom in the -C ⁇ -4 alkyl group that is attached to the ring nitrogen (i.e., that the -N(R a Rb) group is not attached to the carbon atom alpha to the ring nitrogen).
  • Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (II), wherein
  • Q is phenyl
  • T is:
  • heteroaromatic is a 5- or 6-membered ring containing 1 or 2 N atoms
  • R2 is methyl
  • each Ra and Rb is independently -H, methyl or ethyl
  • s is an integer equal to zero or 1;
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents each of which is independently -F, -CI, -Br, -C ⁇ _4 alkyl, -CF3, -O-C ⁇ -4 alkyl, or -OCF3.
  • Another class of compounds of the present invention includes any compound of Formula (I) , wherein
  • Rl is -Rk
  • Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen
  • each R m is independently -C3-6 cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein any N is optionally oxidized to form an N-oxide; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C ⁇ _4 alkyl, -CF3, -O-C ⁇ _4 alkyl, -OCF3, or -N(RaRb); the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C ⁇ _4 alkyl or oxo, and is additionally optionally mono-substituted with phenyl, -(CH2)l-2-phenyl
  • heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently halogen, -C ⁇ _4 alkyl, or oxo; and all other variables are as originally defined above;
  • a sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein
  • Rl is:
  • R8 i is:
  • RlO is -H, -OH, -C ⁇ -4 alkyl, -O-C ⁇ -4 alkyl, -N(R a Rb), or -O-(CH2)l-2-R m ;
  • R2 is methyl
  • R3 is -H or methyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ .4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2R a , -(CH2)0-2-CO2R a , -(CH2)0-2-N(R a )CO2R b , -NO2, -SRa, -N(RaRb) or phenyl; and
  • each R a and Rb is independently -H or -C ⁇ _4 alkyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ _4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2R a , -(CH2) ⁇ -2-C ⁇ 2R a , -(CH2)0-2-N(R )CO2Rb, -NO2, or phenyl.
  • Another class of the present invention includes any compound of
  • R2 is:
  • a sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (III) exactly as defined in the preceding class, except that when R is -C ⁇ _6 alkyl substituted with -N(RaRb), it is with the proviso that -N(R a Rb) is not attached to the carbon atom in the -C ⁇ _6 alkyl group that is attached to the ring nitrogen (i.e., that the -N(R a Rb) group is not attached to the carbon atom alpha to the ring nitrogen).
  • Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (Dl), wherein
  • R2 is:
  • the -(CH2) 1-3- moiety is optionally substituted with an -OH and the saturated heterocycle is a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently a -C ⁇ _4 alkyl; or
  • R3 is -H or methyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ -4 fluoroalkyl, -(CH2) ⁇ _2-N(RaRb), -SO2R a , -(CH2)0-2-C ⁇ 2R a , -(CH2)0-2-N(Ra)CO2R , -NO2, -SR a -N(R a Rb) or phenyl; and
  • each R a and Rb is independently is H or -C ⁇ _4 alkyl
  • R4 is ⁇ CH2 ⁇ phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ -4 alkyl, -O-C ⁇ -4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2R a -(CH2) ⁇ -2-C ⁇ 2R a , -(CH2)0-2-N(Ra)CO2Rb, -NO2, or phenyl.
  • Another class of compounds of the present invention includes any compound of Formula (I), wherein
  • Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S;
  • a sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein
  • Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S;
  • R2 is methyl
  • R3 is -H or methyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ _4 alkyl, -O-C ⁇ .4 fluoroalkyl, -(CH2)l-2-N(R a Rb), -SO2R a , -(CH2)0-2-CO2R -(CH2) ⁇ -2-N(R a )C ⁇ 2Rb -NO2, -SR a -N(R a Rb) or phenyl; and
  • each R a and Rb is independently -H or -C ⁇ _4 alkyl
  • R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -C ⁇ _4 alkyl, -C ⁇ _4 fluoroalkyl, -O-C ⁇ .4 alkyl, -O-C ⁇ _4 fluoroalkyl, -(CH2)l-2-N(R Rb), -SO2R a , -(CH2)0-2-CO2R a , -(CH2)0-2-N(Ra)CO2Rb -NO2, or phenyl.
  • additional embodiments of the present invention include, but are not limited to, compounds of Formula I wherein each of two or three or more of R 1 , R 2 , R3, R4 Ra Rb C ? d R k an d R m is independently defined in accordance with its definition in one of the embodiments or an aspect 5 thereof as set forth above, or in accordance with its definition in one of the foregoing classes set forth above or a sub-class or feature thereof. Any and all possible combinations of these variables in Formula I are additional embodiments within the scope of the present invention.
  • An aspect of the present invention is a compound selected from the group consisting of
  • Another aspect of the present invention is a compound selected from the group consisting of:
  • composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.
  • composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula
  • an HIN infection/ ADDS treatment agent selected from the group consisting of HIN/ ADDS antiviral agents, immunomodulators, and anti-infective agents.
  • HTV infection/ ADDS treatment agent is an antiviral selected from the group consisting of HIN protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors.
  • a combination useful for inhibiting HIN integrase, for treating or preventing infection by HTV, or for preventing, treating or delaying the onset of ADDS which is a therapeutically effective amount of a compound of Formula (I) and a therapeutically effective amount of an HIV infection/ADDS treatment agent selected from the group consisting of HIV/ ADDS antiviral agents, immunomodulators, and anti-infective agents.
  • HIN infection/ADDS treatment agent is an antiviral selected from the group consisting of HTV protease inhibitors, non-nucleoside HTV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.
  • a method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).
  • (j) A method of preventing, treating or delaying the onset of ADDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).
  • a method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • (m) A method of preventing or treating infection by HIV in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • (n) A method of preventing, treating or delaying the onset of ADDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • the present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) inhibiting HTV protease, (b) preventing or treating infection by HIN, or (c) preventing, treating or delaying the onset of ADDS.
  • the compounds of the present invention can optionally be employed in combination with one or more EON/ ADDS treatment agents selected from HIN/ ADDS antiviral agents, anti-infective agents, and immunomodulators.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub- classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt.
  • C ⁇ _6 alkyl (or “C ⁇ -C6 alkyl”) means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • C ⁇ _4 alkyl means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • Co as employed in expressions such as "C ⁇ -6 alkyl” means a direct covalent bond.
  • Rl in Compound I is -C ⁇ -6 alkyl-O-C ⁇ -6 alkyl-Rk
  • Rl is -O-Rk when both alkyl groups are Co alkyl.
  • an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond.
  • the compound of Formula (II) has as a substituent at the 2- position of the pyrimidinone ring, wherein s is an integer equal to zero, 1 or 2.
  • -C ⁇ _6 alkyl- refers to a Cx to C linear or branched alkyl group as just defined which is bivalent. It can alternatively be referred to as "C ⁇ _6 alkylene” or "C ⁇ -6 alkanediyl".
  • a class of alkylenes of particular interest with respect to the invention is -(CH2)X-6 ⁇ , and sub-classes of particular interest include -(CH2)l- 4-, -(CH 2 )X-3-, -(CH 2 )X-2-, and -CH -.
  • C2-5 alkynyl (or “C2-C5 alkynyl”) means linear or branched chain alkynyl groups having from 2 to 5 carbon atoms and includes all of the pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-butynyl, 1-propynyl, 2-propynyl, and ethynyl (or acetylenyl). Similar terms such as “C2-3 alkynyl” have an analogous meaning.
  • C3.8 cycloalkyl (or “C3-C8 cycloalkyl”) means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl).
  • C3-7 cycloalkyl "C3-6 cycloalkyl”
  • C5-7 cycloalkyl and the like have analogous meanings.
  • C3-7 azacycloalkyl (or “C3-C7 azacycloalkyl”) means a saturated cyclic ring consisting of one nitrogen and from three to seven carbon atoms (i.e., azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl).
  • halogen refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
  • C ⁇ _6 haloalkyl (which may alternatively be referred to as “C ⁇ -C6 haloalkyl” or “halogenated C ⁇ -C6 alkyl”) means a Cx to C ⁇ linear or branched alkyl group as defined above with one or more halogen substituents.
  • C ⁇ -4 haloalkyl has an analogous meaning.
  • C ⁇ _6 fluoroalkyl has an analogous meaning except that the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH2) ⁇ -4CF3 (i.e., trifluoromethyl, 2,2,2- trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
  • carbocycle refers to (i) a C3 to C8 monocyclic, saturated or unsaturated ring, (ii) a C7 to C ⁇ 2 bicyclic ring system, or (iii) a C ⁇ to C ⁇ 6 tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated.
  • the carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
  • fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term "fused bicyclic carbocycle” generally refers to a C7 to C ⁇ o bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system. Fused tricyclic carbocycles have an analogous meaning.
  • a subset of the fused bicyclic carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following:
  • aryl refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond.
  • Suitable aryl groups include phenyl, naphthyl, and biphenylenyl.
  • heterocycle broadly refers to (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16- membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring, bicyclic ring system, or tricyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocylic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optional
  • the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.
  • the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • saturated heterocyclics form a subset of the heterocycles; i.e., the term “saturated heterocyclic” generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated.
  • saturated heterocyclic ring refers to a 4- to 8-membered saturated monocyclic ring which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
  • Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazoUdinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl).
  • Heteroaromatics form another subset of the heterocycles; i.e., the term “heteroaromatic” (alternatively “heteroaryl”) generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system.
  • heteroaryl generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system.
  • heteroaryl refers a 5- or 6-membered monocyclic aromatic ring which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
  • heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-
  • phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms.
  • tricyclic heterocycles include phenothiazinyl, carbazolyl, beta-carbolinyl, tetrahydro-beta-carbolinyl, acridinyl, phenazinyl, and phenoxazinyl.
  • an “unsaturated” ring is a partially or fully unsaturated ring.
  • an “unsaturated monocyclic C ⁇ carbocycle” refers to cyclohexene, cyclohexadiene, and benzene.
  • a heterocycle described as containing from “1 to 4 heteroatoms” means the heterocycle can contain 1, 2, 3 or 4 heteroatoms.
  • any variable e.g., R a , Rb, Re, Rk etc.
  • R a , Rb, Re, Rk etc. occurs more than one time in any constituent or in Formula I or in any other formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence.
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • substituted e.g., as in "aryl which is optionally substituted with one or more substituents "
  • substituents include mono- and poly-substitution by a named substituent to the extent such single and multiple substitution (including multiple substitution at the same site) is chemically allowed.
  • the compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.
  • N-substituted hydroxypyrimidinone compounds of the present invention may also occur as tautomers thereof. It is understood that the present invention includes all tautomers of the hydroxypyrimidinone compounds of Formula I, both singly and in mixtures.
  • the compounds of the present invention are useful in the inhibition of HTV integrase, the prevention or treatment of infection by human immunodeficiency virus (HTV) and the prevention, treatment or the delay in the onset of consequent pathological conditions such as ADDS.
  • Preventing ADDS, treating ADDS, delaying the onset of ADDS, or preventing or treating infection by HTV is defined as including, but not limited to, treatment of a wide range of states of HTV infection: ADDS, ARC (ADDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HTV.
  • the compounds of this invention are useful in treating infection by HTV after suspected past exposure to HIV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV integrase, e.g., by competitive inhibition.
  • the compounds of this invention are commercial products to be sold for these purposes.
  • Representative compounds tested in the integrase assay demonstrated ICso's of about 5 micromolar or less. Further description on conducting the assay using preassembled complexes is found in Hazuda et al., J. Virol. 1997, 71: 7005-7011; Hazuda et al, Drug Design and Discovery 1997, 15: 17-24; and Hazuda et al., Science 2000, 287: 646-650.
  • Certain compounds representative of the present invention have also been tested in an assay for inhibition of acute HIN infection of T-lymphoid cells, conducted in accordance with Vacca, J.P. et al., Proc. Natl. Acad. Sci. USA 1994, 91: 4096. These compounds demonstrated IC95's of about 20 micromolar or less.
  • the compounds of the present invention may be administered in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • alkali metal salts e.g., sodium or potassium salts
  • alkaline earth metal salts e.g., calcium or magnesium salts
  • suitable organic ligands such as quaternary ammonium salts.
  • pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
  • the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing a therapeutically effective amount of the compound and conventional non-toxic pharmaceutically-acceptabie carriers, adjuvants and vehicles.
  • administration and variants thereof (e.g., “administering” a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment.
  • a compound of the invention or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating EQN infection or AIDS)
  • “administration” and its variants are each understood to include concurrent and sequential provision of the compound or prodrug and other agents.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combining the specified ingredients in the specified amounts.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated.
  • active compound i.e., active ingredient
  • references to the amount of active ingredient are to the free acid or free base form of the compound.
  • compositions may be in the form of orally- administrable suspensions or tablets or capsules, nasal sprays, sterile injectible preparations, for example, as sterile injectible aqueous or oleagenous suspensions or suppositories.
  • sterile injectible preparations for example, as sterile injectible aqueous or oleagenous suspensions or suppositories.
  • These compositions can be prepared by methods and contain excipients which are well known in the art. Suitable methods and ingredients are described in Remington's Pharmaceutical Sciences, 18 th edition, edited by A. R. Gennaro, Mack Publishing Co., 1990, which is herein incorporated by reference in its entirety.
  • the compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
  • mammal e.g., human
  • One preferred dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
  • Another preferred dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
  • the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
  • the present invention is also directed to use of the HIV integrase inhibitor compounds of the present invention with one or more agents useful in the treatment of HTV infection or ADDS.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more of the HTV/ ADDS antivirals, imunomodulators, antiinfectives, or vaccines useful for treating HIN infection or AIDS.
  • Suitable antiviral agents include those listed in the following Table:
  • Drug Name Manufacturer Indication (Tradename and/or Location) abacavir Glaxo Welcome HTV infection, AIDS, ARC GW 1592 (ZIAGEN®) (nRTI) 1592U89 abacavir + lamivudine + GlaxoSmithKline HTV infection, AIDS, ARC zidovudine (TRIZIVIR®) (nnRTI) acemannan Carrington Labs ARC (Irving, TX) ACH 126443 Achillion Pharm.
  • Active Drug Name Manufacturer Indication
  • HTV infections AIDS, ARC (nucleoside reverse transcriptase inhibitor) acyclovir Burroughs Wellcome HTV infection, AIDS, ARC, in combination with AZT AD-439 Tanox Biosystems HTV infection, AIDS, ARC
  • VX478 (Vertex) ansamycin Adria Laboratories ARC
  • LM 427 (Dublin, OH) Erbamont (Stamford, CT) antibody which neutralizes Advanced Biotherapy ADDS, ARC pH labile alpha aberrant Concepts (Rockville, Interferon MD)
  • DPC 961 & DPC 083 DuPont HIV infection ADDS, ARC (nnRTRI) emvirine Triangle Pharmaceuticals HTV infection, AIDS, ARC (COACTINON®) (non-nucleoside reverse transcriptase inhibitor)
  • HBY097 Hoechst Marion Roussel HIV infection AIDS, ARC (nnRTI) hypericin VIMRx Pharm. HTV infection, ADDS, ARC recombinant human Triton Biosciences ADDS, Kaposi's sarcoma, interferon beta (Almeda, CA) ARC interferon alfa-n3 Interferon Sciences ARC, AIDS indinavir Merck (CRDOVAN®) EON infection, ADDS, ARC, asymptomatic HIV positive, also in combination with
  • ISIS 2922 ISIS Pharmaceuticals CMV retinitis JE2147/AG1776 Agouron HIN infection, ADDS, ARC
  • PI lopinavir + ritonavir Abbott
  • KALETRA® mozenavir AVID
  • ADDS ARC
  • DMP-450 mozenavir Agouron HIN infection
  • ADDS ADDS
  • VIRACEPT® ARC
  • PI nevirapine Boeheringer HIN infection
  • ADDS Ingleheim ARC
  • HIN inhibitor (Akron, OH) pentafusaide Trimeris HIN infection, AIDS, ARC T-20 (fusion inhibitor) peptide T Peninsula Labs AIDS octapeptide (Belmont, CA) sequence
  • PRO 542 Progenies HIN infection, AIDS, ARC (attachment inhibitor)
  • PRO 140 Progenies HTV infection, AIDS, ARC (CCR5 co-receptor inhibitor) trisodium Astra Pharm. Products, CMV retinitis, HIV infection, phosphonoformate Inc other CMV infections
  • TAK-779 Takeda HTV infection, ADDS, ARC (injectable CCR5 receptor antagonist) tenofovir Gilead (VIREAD®) HTV infection, A DS, ARC (nRTI) tipranavir (PNU-140690) Boehringer Ingelheim HIV infection, ADDS, ARC ' (PD
  • a compound of the present invention can also be administered in combination with another HTV integrase inhibitor such as a compound described in WO 99/62513,WO 99/62520, or WO 99/62897.
  • a compound of the present invention can also be administered in combination with a CCR5 receptor antagonist, such as a compound described in WO 99/04794, WO 99/09984, WO 99/38514, WO 00/59497, WO 00/59498, WO 00/59502, WO 00/59503, WO 00/76511,
  • WO 00/76512 WO 00/76513, WO 00/76514 , WO 00/76792, or WO 00/76793.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more HTV/ ADDS antivirals, immunomodulators, antiinfectives, or vaccines useful for treating HIV infection or ADDS disclosed in the Table in WO 01/38332, which is herein incorporated by reference in its entirety.
  • ADDS acquired immunodeficiency syndrome
  • ARC AIDS related complex
  • CBZ or Cbz carbobenzoxy (alternatively, benzyloxycarbonyl)
  • DMAD dimethylacetylenedicarboxylate
  • DMAP dimethylaminopyridine
  • HIV human immunodeficiency virus
  • HPLC high performance liquid chromatography
  • m-CPBA meta-chloroperbenzoic acid
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • the compounds of the present invention can be prepared by coupling suitable substituted alkyl l-alkyl-l,6-dihydro-5-hydroxy-6-oxopyrimidine-4- carboxylates (or carboxylic acids or halides) with the appropriate amines, as represented by Scheme 1.
  • P is H or a protective group, typically an ester (e.g., benzoate or pivalate) that is normally removed under the conditions employed to convert the the methyl ester to the amide.
  • the ester protective group is typically used to purify the 2-substituted-5,6 dihydroxypyrimidine-4-carboxylates after their synthesis when the unprotected product cannot be crystallized from the reaction crude and/or for synthetic reasons.
  • Methyl 1 -alkyl- 1 ,6-dihydro-5-hydroxy-6-oxopyrimidine-4-carboxylates of formula 1-2 can be prepared as shown in Scheme 2, wherein amidoxime 2-1 can be reacted with DMAD in an appropriate solvent and at a suitable temperature to give the intermediate dihydroxypyrimidine 2-2, followed by protection of the 5-hydroxy group in 2-2 with a suitable protecting agent such as benzoate or pivalate to give 2-3, and then alkylation of nitrogen- 1 to afford 1-2.
  • a suitable protecting agent such as benzoate or pivalate
  • Dihydroxypyrimidine 2-2 can be isolated or directly protected to give 2-3.
  • the alkyl group can be introduced on N ⁇ by reaction of 2-3 with an alkylating agent in the presence of an inorganic base (e.g., cesium carbonate). If a mixture of N- and O- alkylated derivatives results, the desired N-alkylated product 1-2 can be separated by flash chromatography.
  • Scheme 2 is exemplified in Example 1.
  • the unprotected compound can be isolated as such or it can be converted to 1-2 by reaction with a suitable protecting group.
  • Scheme 3 is exemplified in Example 2.
  • Amidoximes 2-1 and 3-1 are prepared from the corresponding nitriles by chemistry described herein (see Example 1, Step 1 and Example 2, Step 2).
  • Nitriles can be prepared from carboxylic acids by various procedures known in the art, including, for example, conversion to carboxamides by the procedure of of Pozdnev (Tetrahedron Lett. 1989, 30: 5193) (see also, Example 6, Step 2), and dehydration of the amide by the procedure of Waldmann (Tetrahedron 1994, 50: 11865) (see also, Example 6, Step 3).
  • haloderivative 3-1 or 3-4 can be synthesized by the bromination or chlorination of a suitable substrate affording a -CH2Br, -CH2CI, -CHBr-, or -CHCl- group, followed by displacement of the halogen with a nucleophile ("Nu") such as an amine, thiol, or alcoholate to obtain the nucleophile-substituted methyl ester intermediate 3-2 or 3-5, which need not be isolated.
  • Nu nucleophile
  • Elaboration of the methyl ester functionality into the carboxamide will afford the final product 3-3 or 3-6.
  • Scheme 3 is exemplified in Example 5.
  • Scheme 4 depicts the preparation of compounds of the invention that contain an alkylated aliphatic amine in the substituent at the 2 position.
  • Nitrogen alkylation is achieved via a reductive amination or alkylation.
  • the nitrogen alkylation can be performed before formation of the amide (via 4-3) or after formation of the amide (via 4-2) depending on the substrate, with suitable deprotection as necessary.
  • Scheme 4 is exemplified in Examples 6 to 8 below.
  • ⁇ absent, alkyl, or aryl
  • R w H, alkyl, or aryl
  • R x H, alkyl, or aryl
  • R y alkyl or aryl, or R x and R y together with the N to which they are attached form an N-containing heterocycle
  • the protecting groups can be removed at a convenient subsequent stage using methods known in the art. For example, in preparing the compounds of the invention it is sometimes necessary to protect one or more amino groups (e.g., amino groups present in substituents at the 2-position of the pyrimidinone ring) with, for example, a Boc or Cbz group or to protect hydroxy (e.g., the 5-hydroxy group on the pyrimidinone ring) with, for example, a benzoyl or benzyl group.
  • the Boc group can be removed by acid treatment (e.g., TFA) either before or after formation of the final amide at C-6 of the pyrimidinone nucleus.
  • the Cbz and benzyl groups are typically removed by catalytic hydrogenation or under strong acid conditions, either prior to or following formation of the final amide.
  • the benzoyl group can be removed concurrently with the formation of the final amide. Examples 6 and 12 below illustrate the use of a Boc protective group and of Boc, benzoyl and benzyl protective groups in the preparation of compounds of the invention.
  • Step 1 Tert-butyl-2-[amino(hydroxyimino)methyl]pyrrolidine-l-carboxylate
  • Step 2 Methyl 5-(benzoyloxy)-2-[l-(tert-butoxycarbonyl)pyrrolidin-2-yl]-6- hydroxypyrimidine-4-carboxylate
  • the reaction mixture was concentrated, and the resulting oil was diluted with ethyl acetate and washed with IN HCl solution, saturated NaHCO 3 solution, saturated NaCl solution.
  • the crude oil obtained after organic solvent evaporation was purified by flash chromatography to obtain the title compound as a yellow solid.
  • Step 3 Methyl 5-(benzoyloxy)-2-[ 1 -(tert-butoxycarbonyl)pyrrolidin-2-yl]- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
  • Cs 2 CO 3 was added (1.2 eq.) followed by the addition of CH 3 I (2.0 eq.).
  • the reaction was stirred at 40°C until the starting material was consumed as determined by MS analysis.
  • the reaction was concentrated and the residue taken up with EtOAc, washed with 1 N HCl, saturated solution of NaHCO 3 and brine.
  • Step 1 Benzyl 2-[[hydroxy(methyl)amino](imino)methyl]indoline-l- carboxylate
  • Step 2 Benzyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-l-methyl-6-oxo-l ,6- dihydropyrimidi-2-yl]indoline- 1 -carboxylate
  • Step 1 The product of Step 1 was dissolved in CHC1 3 and dimethylacetylenedicarboxylate was added dropwise (1.2 eq.) at room temperature. After 4 h the mixture was evaporated, and the residue was dissolved in xylene and stirred at 160 °C for 2 days. The solvent was then evaporated, and the residue was dissolved in pyridine, after which (PhCO) O (2 eq.) was added and the reaction mixture was stirred for 2 days. After evaporation, the resulting crude oil was diluted with EtOAc, washed with HCl IN, dried over Na 2 SO 4 and evaporated. The product was purified by flash chromatography on silica gel (EtOAc/ petroleum ether, 1 :4) to afford the title product.
  • Step 1 4,5-Dihydroxy-6-(methoxycarbonyl)pyrimidine-2-carboxylic acid
  • Step 4 Methyl 5-[(2,2-dimethylpropanoyl)oxy]-l-methyl-6-oxo-l, 6- dihydropyrimidine-4-carboxylate
  • Step 3 (1 eq.) in THF containing cesium carbonate (1.5 eq.). The reaction was carried out at 50°C for thirty minutes. The solvent was evaporated and the resulting oil was dissolved in ethyl acetate, washed with IN HCl solution. The crude title compound was recovered as yellow solid and used in the next step without purification.
  • Step 5 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-
  • Step 1 Methyl 2-[4-(bromomethyl)phenyl]-5-[(2,2-dimethylpropanoyl)oxy]-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
  • Step 2 N-(4-Fluorobenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4- ylmethyl)phenyl]-6-oxo-l,6-dihydropyrimidine-4-carboxamide
  • Step 4 tert-Butyl 3-[(Z)-amino(hydroxyimino)methyl]mo holine-4- carboxylate
  • Step 5 Dimethyl-2-( ⁇ 2-amino-2-[4-(tert-butoxyca ⁇ -bonyl)morpholin-3- yl]ethenyl ⁇ oxy)but-2-enedioate
  • Step 6 tert-Butyl-3-[4,5-dihydroxy-6-(methoxycarbonyl)pyrimidin-2- yl]morpholine-4-carboxylate
  • Step 5 The adducts of Step 5 were refluxed in xylenes for 24 hours. Then the reaction was cooled down and concentrated in vacuo. Ethyl ether was added until precipitation of a solid that was filtered, washed with ethyl ether and dried to give the title pyrimidine as an orange solid.
  • Step 7 tert-Butyl-3-[5-(benzoyloxy)-4-hydroxy-6-
  • Step 8 Alkylated derivatives 8 A and 8B.
  • Step 9 tert-Butyl-3-(4- ⁇ [(4-fluorobenzyl)amino]carbonyl ⁇ -5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidin-2-yl]-morpholine-4-carboxylate
  • Step 10 N-(4-fluoroben ⁇ yl)-5-hydroxy-l-methyl-2-morpholin-3-yl-6-oxo-l,6- dihydropyrimidine-4-carboxamide
  • the compound from Step 10 was dissolved in MeOH and treated with triethylamine (1 eq.), sodium acetate (1.6 eq.), formaldehyde 37% w/w aq. soln. (3 eq.), and sodium cyanoborohydride (1.43 eq.). The mixture was left stirring at room temperature for 1 hour. The reaction mixture was concentrated and the title compound was obtained by RP-HPLC purification (C 18 , eluting with water and acetonitrile containing 0.1 % TFA), as its trifluoroacetate salt.
  • N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylrnorpholin-3-yl)- 6-oxo- l,6-dihydropyrimidine-4-carboxamide has been resolved into its enantiomers by semi preparative chiral HPLC using the following conditions:
  • Solvents a mixture of 1 : 1 0.2%TFA in Hexanes : EtOH Column: chiralpak AS column, 250 x 46 mm at l.Oml/min, collected by absorbtion at 260 nM
  • Step 1 Methyl l-methyl-2-(4-tert-butoxycarbonylpiperazin-2-yl))-5- benzoyloxy-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
  • Methyl l-methyl-2-(4-tert-butoxycarbonyl-l-benzyloxycarbonylpiperazin-2-yl))-5- benzoyloxy-6-oxo-l,6-dihydropyrimidine-4-carboxylate prepared from 1- [(benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid (Bigge et al, Tetrahedron Lett. 1989, 30: 5193) by procedures similar to those set forth in Examples 2 or 3 in combination with a deprotection step) was dissolved in MeOH and hydrogenated at atm pressure on 10% Pd/C for 1 hour. The crude title product was obtained after filtration and evaporation.
  • Step 2 N-(4-fluorobenzyl) 1 -methyl-2-(4-tert-butoxycarbonylpiperazin-2-yl))-
  • Step 3 N-(4-fluorobenzyl) l-methyl-2-(4-tert-butoxycarbonyl-l- methylpiperazin-2-yl))-5-hydroxy-6-oxo-l,6-dihydropyrimidine-4-carboxamide
  • Step 4 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methylpiperazin-2-yl)-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide
  • Step 5 2-(4-ethyl-l-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
  • Triethylamine (2 eq.) NaCNBH 3 (1.4 eq.), AcONa (1.6 eq.) and CH 3 CHO (1 eq.) were added to a methanolic solution of the crude product obtained in step 4. The reaction was stirred at room temperature for 1 hour.
  • the title product was obtained as its trifluroacetate salt by preparative RP-HPLC purification (C18, gradient of CH 3 CN/H 2 O + 0.01 %TFA).
  • Methyl 5-(benzoyloxy)-l-methyl-6-oxo-2-piperidin-2-yl-l,6- dihydropyrimidine-4-carboxylate (prepared from l-(benzyloxycarbonyl)piperidine-2- carboxylic acid by procedures similar to those set forth in Examples 1 or 2 in combination with a deprotection step) was suspended in THF and treated with 3 eq. of triethylamine and 3 eq. of methyl iodide at 40 °C. After stirring for 5 h, THF was evaporated and residue poured into EtOAc and washed with brine. Organic phase was dried ( ⁇ a 2 SO 4 ), filtered and concentrated under reduced pressure.
  • Step 1 Methyl 5-(benzoyloxy)-l-methyl-6-oxo-2-pyrrolidin-2-yl-l,6- dihydropyrimidine-4-carboxylate
  • Step 2 2-(l-Acetylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide
  • triethylamine 3.0 eq.
  • acetyl chloride 1.5 eq.
  • Step 1 Methyl 2-(2,3-dihydro- lH-indol-2-yl)- 1 -methyl-5-benzoyloxy-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
  • Step 2 Methyl 2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-5-benzoyloxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
  • Step 3 2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide
  • the crude product of Step 2 was dissolved in MeO ⁇ and 4- fluorobenzylamine (3.5 eq.) added. The solution was stirred at 60 °C over night.
  • the title product was obtained by preparative RP- ⁇ PLC (C18, gradient of C ⁇ 3 C ⁇ / ⁇ 2 O +
  • Step 1 Methyl 2-(l,2,3,4-tetrahydroquinolin-2-yl)-l-methyl-5-benzoyloxy-6- oxo- 1 ,6-dihydropyrimidine-4-carboxylate
  • Step 2 Methyl 5-benzoyloxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)- l,2,3,4-tetrahydroquinolin-2-yl]-l,6-dihydropyrimidine-4-carboxylate
  • Step 1 The residue of Step 1 was dissolved in dichloromethane. Pyridine, picolinoyl chloride hydrochloride and a catalytic amount of DMAP were added. A further addition of the reactants was made after two hours. After evaporation of the solvent, the residue was diluted with EtOAc, the organic phase washed with water, dried (Na 2 SO ) and evaporated to afford the title product.
  • Step 3 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2- ylcarbonyl)- 1 ,2,3 ,4-tetrahydroquinolin-2-yl]- 1 ,6-dihydropyrimidine-4- carboxamide
  • Step 2 The residue of Step 2 was dissolved in DMF and 4-fluorobenzylamine (3 eq.) was added. The reaction mixture was stirred at 90°C for 1 h. The title compound was purified by preparative HPLC and isolated as its trifluoroacetic salt (C18, gradient of CH 3 C ⁇ /H 2 O + 0.01% TFA).
  • Step 1 Methyl 2-[(2S,4R)-l-benzoyl-4-(benzyloxy) ⁇ yrrolidin-2-yl]-5-
  • Step 2 2-[(2S,4R)-l-benzoyl-4-(benzyloxy) ⁇ yrrolidin-2-yl]-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxamide
  • Step 1 The compound of Step 1 was dissolved in methanol and 4- fluorobenzylamine (5 eq.) was added. The mixture was refluxed overnight. After cooling, the reaction mixture was filtered and washed with ethyl ether to obtain the title product as a white solid.
  • Step 3 2-[(2S,4R)-l-benzoyl-4-hydroxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide
  • the title compound of Step 2 was dissolved in AcOH and 10% Pd/C
  • Step 1 2-(2,2-dimethoxyethyl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
  • Methyl 2-(2,2-dimethoxyethyl)-5-benzoyloxy-l-methyl-6-oxo-l ,6- dihydropyrimidine-4-carboxylate (1.0 eq.) (prepared from 3,3-dimethoxypropionitrile by procedure similar to those set forth in Examples 1 or 2) in dry MeOH was treated with 4-fluorobenzyl amine (2.5 eq.) at reflux for 2 hours. Solvent was removed in vacuo and residue triturated with Et 2 O to obtain the title product.
  • Step 2 ⁇ -(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-(2-oxoethyl)-l,6- dihydropyrimidine-4-carboxamide
  • Step 1 The product of Step 1 was treated with a mixture HCl 1N/THF for 1 hour at 40 °C. Organics were removed in vacuo and residue extracted in DCM, dried over Na 2 SO 4 and concentrated to give the title compound as a foam which was immediately reacted in the following reductive amination. MS: m/z 320 (M + H)+.
  • Step 3 2-[2-(4-benzoylpiperazin-l-yl)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
  • the product of Step 2 was dissolved in MeOH and treated with sodium acetate (1.6 eq.), 1-benzoylpiperazine (2 eq.), and sodium cyanoborohydride (1.43 eq.). The mixture was left stirring at room temperature for lhour. The reaction mixture was concentrated and the title compound was obtained by RP-HPLC purification ( C 18 , eluting with water and acetonitrile containing 0.1 % TFA).
  • Step 1 Methyl l-allyl-5-[(2,2-dimethylpropanoyl)oxy]-6-oxo-l,6- dihydropyrimidine-4-carboxylate
  • Step 2 N-(4-fluorobenzyl)-5-hydroxy- 1 -(2-hydroxy-3-morpholin-4-ylpropyl)- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
  • Step 2a The compound of Step 1 was dissolved in dichloroethane and m-CPBA was added (5 eq.). The reaction mixture was refluxed until the starting material was completely consumed, then evaporated. MS m/z 311 (M+H) + .
  • Stepl 1 -Benzyl-2-methyl-(2S ,4S)-4-fluoropyrrolidine- 1 ,2-dicarboxylate
  • Step 3 Benzyl-(2S ,4S)-2-aminocarbonyl-4-fluoropyrrolidine- 1 -carboxylate
  • Step 5 Benzyl-(2S,4S)-2-[amino(hydroxyimino)methyl]-4-fluoropyrrolidine-
  • Step 6 Dimethyl-2- ⁇ [(amino- ⁇ (2S,4S)-l-[(benzyloxy)carbonyl]-4- fluoropyrrolidin-2-yl ⁇ methylidene)amino] oxy ⁇ but-2-enedioate
  • Step 7 Methyl-2- ⁇ (2S,4S)-l-[(benzyloxy)carbonyl]-4-fluoropyrrolidin-2-yl ⁇ -
  • Step 8 Methyl-5-(benzoyloxy)-2- ⁇ (2S,4S)-l-[(benzyloxy)carbonyl]-4- fluoropyrrolidin-2-yl ⁇ -6-hydroxypyrimidine-4-carboxylate
  • Step 9 Methyl-5-(benzoyloxy)-2- ⁇ (2S ,4S)- l-[(benzyloxy)carbonyl] -4- fluoropyrrolidin-2-yl ⁇ - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4- carboxylate .
  • reaction mixture was then cooled down and glacial acetic acid (0.2 eq.) was added, followed by water and ethyl acetate.
  • the aqueous layer was separated and extracted with ethyl acetate; the organic phase was dried over Na 2 SO 4 and filtered to give, after concentration, a crade that was purified by flash chromatography (eluent petroleum ether: ethyl acetate from 4:6 to 2:8) to give the title compound as a 4.6:5.4 mixture of rotamers by NMR.
  • Step 10 Methyl-2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-5-(benzoyloxy)-6- hydroxypyrimidine-4-carboxylate.
  • Step 11 2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide.
  • Methyl-2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-5-(benzoyloxy)-6- hydroxypyrimidine-4-carboxylate was dissolved in MeOH (0.12 N) and treated with 4-F-benzylamine (3 eq.) in a sealed tube. The reaction mixture was stirred at 65 °C for 18 hours, then it was cooled down. The solvent was evaporated and the residue was washed with ethyl ether several times to obtain a solid that was recrystallized from ethanol and washed again with ethyl ether to give the title compound as a 7.3:2.7 mixture of rotamers by NMR.
  • Step 2 Benzyl-(2S,4R)-2-cyano-4-methoxypyrrolidine-l-carboxylate
  • Step 3 Benzyl-(2S,4R)-2-[amino(hydroxyimino)methyl]-4methoxypyrrolidine
  • Step 5 Methyl 5-(benzoyloxy)-2- ⁇ (2S,4R)-l-[(benzyloxy)carbonyl]-4- methoxypyrrolidin-2-yl ⁇ -6-hydroxypyrimidine-4-carboxylate
  • the solution was concentrated in vacuo and the crade dissolved in ethyl acetate washed with 1 N HCl, saturated aqueous NaHCO 3 and brine, dried on Na 2 SO 4 , filtered and evaporated in vacuo.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

Description

TITLE OF THE INVENTION
N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS
OF HIV INTEGRASE
FIELD OF THE INVENTION
The present invention is directed to N-substituted 5-hydroxy-6-oxo- l,6-dihydropyrimidine-4-carboxamides and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of the HTV integrase enzyme. The compounds and pharmaceutically acceptable salts thereof of the present invention are useful for preventing or treating infection by HTV and for treating or delaying the onset of AIDS.
BACKGROUND OF THE INVENTION
A retrovirus designated human immunodeficiency virus (HIN) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAN, HTLN-IH, or ARV. A common feature of retrovirus replication is the insertion by virally-encoded integrase of proviral DΝA into the host cell genome, a required step in HTV replication in human T-lymphoid and monocytoid cells. Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral DΝA sequences; cleavage of two nucleotides from the 3' termini of the linear proviral DΝA; covalent joining of the recessed 3' OH termini of the proviral DΝA at a staggered cut made at the host target site. The fourth step in the process, repair synthesis of the resultant gap, may be accomplished by cellular enzymes.
Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)]. Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al., Science, 231, 1567 (1986); Pearl, L.H. et al., Nature, 329, 351 (1987)]. All three enzymes have been shown to be essential for the replication of HIV.
It is known that some antiviral compounds which act as inhibitors of HIN replication are effective agents in the treatment of AIDS and similar diseases, including reverse transcriptase inhibitors such as azidothymidine (AZT) and efavirenz and protease inhbitors such as indinavir and nelfinavir. The compounds of this invention are inhibitors of HIN integrase and inhibitors of HIV replication. The inhibition of integrase in vitro and HTV replication in cells is a direct result of inhibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro in HTV infected cells. The particular advantage of the present invention is highly specific inhibition of HTV integrase and HTV replication.
SUMMARY OF THE INVENTION The present invention is directed to novel hydroxypyrimidinone carboxamides. These compounds are useful in the inhibition of HIV integrase, the prevention of infection by HTV, the treatment of infection by HTV and in the prevention, treatment, and delay in the onset of AIDS and/or ARC, either as compounds or their pharmaceutically acceptable salts or hydrates (when appropriate), or as pharmaceutical composition ingredients, whether or not in combination with other HTV/ AIDS antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. More particularly, the present invention includes a compound of Formula (I):
Figure imgf000003_0001
wherein
RU is
(1) -H,
(2) -Cι_6 alkyl, which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -CN, -O-Ci_6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra, -Cθ2Ra, -SRa, -S(=O)Ra -N(RaRb), -C(=O)-Co-6 alkyl-N(RaRb), N(Ra)-C(=O)-C()-6 alkyl-N(RbRc), -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), -N(Ra)-C(=O)Rb,
Figure imgf000004_0001
, or -N(R2)C(=O)C(=O)N(RaRb),
(3) -Rk,
(4) -Ci-6 alkyl-Rk, wherein: (i) the alkyl is optionally substituted with one or more substituents(e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -CN, -O-Cι_6 alkyl, -O-Ci-6 haloalkyl, -N(RaRb), -N(Ra)CO2Rb, -N(Ra)C(=O)-Cθ-6 alkyl-N(RbRC), or -N(Ra)-C2-6 alkyl-OH with the proviso that the -OH is not attached to the carbon alpha to N(Ra); and (ii) the alkyl is optionally mono-substituted with -Rs, -Ci_6 alkyl-Rs, -N(Ra)-C(=O)-Cθ-6 alkyl-Rs, -N(Ra)-Cθ-6 alkyl-Rs, -O-Co-6 alkyl-Rs, or -N(Ra)-C(=O)-Cθ-6 alkyl-RS; wherein Rs is
(a) aryl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -Cι_6 alkyl, -Cι_6 alkyl-ORa, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl;
(b) a 4- to 8- membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -Cι_6 alkyl, -C\.β alkyl-ORa, -Ci_6 haloalkyl, -O-Cι_6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra,
-CO2Ra, -C(=O)-Co-6 alkyl-N(RaRb), -SO2R , oxo, aryl, or -Ci-6 alkyl-aryl; or (c) a 5- to 7-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with one or more substituents (e.g., optionally 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -C1.-6 alkyl, -Cι_6 alkyl-OR _Cι_6 haloalkyl, -O-Ci-6 alkyl, -O-Cι_6 haloalkyl, oxo, or aryl;
(5) -Co-6 alkyl-O-Co-6 alkyl-Rk, (6) -Co-6 alkyl-S(O)n-Co-6 alkyl-Rk,
(7) -O-Ci-6 alkyl-ORk,
(8) -O-Ci-6 alkyl-O-Ci-6 alkyl-Rk,
(9) -O-Ci-6 alkyl-S(O)nRk
(10) -Co-6 alkyl-N(Ra)-Rk (11) -Co-6 alkyl-N(Ra)-Ci_6 alkyl-Rk,
(12) -Co-6 alkyl-N(Ra)-Ci_6 alkyl-ORk,
(13) -Co-6 alkyl-C(=O)-Rk
(14) -Co-6 alkyl-Rk,
(15) -Co-6 alkyl-Rk, (16) -Co-6 alkyl-N(Ra)C(=O)-O-Co-6 alkyl-Rk, or
(17) -Co-6 alkyl-N(Ra)C(=O)C(=O)Rk;
R2 is -Cι_6 alkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently
(1) halogen,
(2) -OH,
(3) -CN,
(4) -O-Ci-6 alkyl, (5) -O-Ci-6 haloalkyl,
(6) -C(=O)Ra,
Figure imgf000005_0002
(8) -SRa
(9) -S(=O)Ra, (10) -N(RaRb), (11) -C(=O)N(RaRb),
(12) -N(Ra)-C(=O)-Cι _6 alkyl-N(RbRC),
(13) -SO2Ra,
Figure imgf000006_0001
(16) -N(Ra)-C(Rb)=O,
(17) -C3-8 cycloalkyl,
(18) aryl, wherein the aryl is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -Cι_6 alkyl, -Ci_6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -Cθ-6 alkyl-N(RaRb), 0r -Ci-6 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Ci-6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or
(19) a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heterocycle is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently -Ci_6 alkyl, -O-Cι_6 alkyl, oxo, phenyl, or naphthyl;
R3 is -H or -C 1-6 alkyl;
R4 is
(1) H,
(2) Ci_6 alkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, O-Ci-6 alkyl, -O-Cχ-6 haloalkyl, -NO2, -N(RaRb), -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -SO2Ra, or
Figure imgf000007_0001
(3) Ci-6 alkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, or O-Ci-4 alkyl, and which is substituted with 1 or 2 substituents each of which is independently: (i) C3-8 cycloalkyl,
(ii) aryl,
(iii) a fused bicyclic carbocycle consisting of a benzene ring fused to a C5-7 cycloalkyl,
(iv) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, (v) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or (vi) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic, (4) C2-5 alkynyl optionally substituted with aryl, (5) C3_8 cycloalkyl optionally substituted with aryl,
(6) aryl,
(7) a fused bicyclic carbocycle consisting of a benzene ring fused to a C5_7 cycloalkyl,
(8) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(9) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
(10) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic; wherein each aryl in (3)(ii) or the aryl (4), (5) or (6) or each fused carbocycle in (3)(iii) or the fused carbocycle in (7) is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono- substituted) each of which is independently halogen, -OH, -Ci-6 alkyl, -Ci -6 alkyl-ORa, _Cι_6 haloalkyl, -O-Cι_6 alkyl, -O-Ci-6 haloalkyl, -CN, -NO2, -N(RaRb), -Cι_6 alkyl-N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -Cθ2Ra, -Cι_6 alkyl-CO2R -OCO2Ra -SRa -S(=O)Ra, -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), -N(Ra)C(=O)Rb,
-N(Ra)CO2Rb, -Ci-6 alkyl-N(Ra)CO2Rb, aryl, -Cι_6 alkyl-aryl, -O-aryl, or -Cθ-6 alkyl-het wherein het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently -Cι_6 alkyl, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, oxo, or -CO2Ra; each saturated heterocyclic ring in (3)(iv) or the saturated heterocyclic ring in (8) is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -Ci_6 alkyl, -Cχ_6 haloalkyl, -O-Ci-6 alkyl, -O-Cχ-6 haloalkyl, oxo, aryl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and each heteroaromatic ring in (3)(v) or the heteroaromatic ring in (9) or each fused bicyclic heterocycle in (3)(vi) or the fused bicyclic heterocycle in (10) is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -Ci-6 alkyl, -Ci_6 haloalkyl, -O-Cι_6 alkyl, -O-Cι_6 haloalkyl, oxo, aryl, or -Cι_6 alkyl-aryl; or alternatively R and R4 together with the N to which both are attached form a C3-.7 azacycloalkyl which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently -Cχ_6 alkyl or oxo;
each Ra, Rb RC; and Rd is independently -H or -Ci-6 alkyl;
Rk is carbocycle or heterocycle, wherein the carbocycle or heterocycle is optionally substituted with one or more substituents (e.g., optionally from 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently
(1) halogen,
(2) -OH,
(3) -CN, (4) -Ci-6 alkyl, which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -CN, -O-Ci_6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra -N(RaRb), -C(=O)-(CH2)θ-2N(RaRb),
N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O, (5) -O-Cχ-6 alkyl, which is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -CN, -O-Cχ_6 alkyl, -O-Cχ_6 haloalkyl, -C(=O)Ra -CO2R , -SRa, -S(=O)Ra -N(RaRb), -C(=O)-(CH2)0-2N(RaRb), N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra, -N(Ra)SO2Rb,
Figure imgf000009_0001
(6) -NO2,
(7) oxo,
(8) -C(=O)Ra.
Figure imgf000009_0002
(10) -SRa,
(11) -S(=O)Ra,
(12) -N(RaRb),
(13) -C(=O)N(RaRb),
(14) -C(=O)-Cχ_6 alkyl-N(RaRb),
(15) -N(Ra)C(=O)Rb,
(16) -SO2Ra
Figure imgf000010_0001
(19) -R ,
(20) -Cχ-6 alkyl-Rm, wherein the alkyl is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono- substituted) each of which is independently halogen, -OH, -CN, -Cχ-6 haloalkyl, -O-Cχ-6 alkyl, -O-Cχ_6 haloalkyl, -C(=O)Ra -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -N(Ra)CO2Rb, -SO2Ra -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(21) -Co-6 alkyl-N(Ra)-Co-6 alkyl-Rm,
(22) -Co-6 alkyl-O-Co-6 alkyl-Rm,
(23) -Co-6 alkyl-S-Co-6 alkyl-Rm,
(24) -Co-6 alkyl-C(=O)-Co-6 alkyl-Rm,
(25) -C(=O)-O-C0-6 alkyl-Rm,
(26) -C(=O)N(Ra)-Co-6 alkyl-Rm,
(27) -N(Ra)C(=O)-Rm,
(28) -N(Ra)C(=O)-Cχ_6 alkyl-Rm, wherein the alkyl is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -OH, -CN, -Cχ_6 haloalkyl, -O-Cχ-6 alkyl, -O-Cχ_6 haloalkyl, -C(=O)Ra, -Cθ2Ra, -SRa, -S(=O)Ra, -N(RaRb), -N(Ra)CO2Rb, -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(29) -N(Ra)-C(=0)-N(Rb)-Co-6 alkyl-Rm, (30) -N(Ra)-C(=O)-O-Co-6 alkyl-Rm,
(31) -N(Ra)-C(=O)-N(Rb)-SO2-Co-6 alkyl-Rm,
(32) -C(=O)-C(=O)-N(RaRb),
(33) -C(=O)-Cχ_6 alkyl-SO2Ra, or (34) -C(=0)-C(=O)Rm;
carbocycle in Rk is (i) a C3 to Cs monocyclic, saturated or unsaturated ring, (ii) a C7 to Cχ2 bicyclic ring system, or (iii) a Cχχ to Cχ6 tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated;
heterocycle in Rk is (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring,
(ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16-membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated; the monocyclic ring, bicyclic ring system, or tricyclic ring system contains from 1 to 6 heteroatoms selected from
N, O and S and a balance of carbon atoms; and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally be oxidized, and any one or more of the nitrogen heteroatoms is optionally quatemized;
each Rm is independently C3-8 cycloalkyl; aryl; a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; or a 9- to 10-membered bicyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein any one or more of the nitrogen and sulfur heteroatoms in the heterocycle or bicyclic heterocycle is optionally oxidized and any one or more of the nitrogen heteroatoms is optionally quatemized; and wherein the cycloalkyl or the aryl defined in Rm is optionally substituted with one or more substituents (e.g., optionally from 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -Cχ_6 alkyl optionally substituted with -O-Cχ_4 alkyl, -Cχ_6 haloalkyl, -O-Cχ-6 alkyl, -O-Cχ-6 haloalkyl, -N(RaRb), aryl, or -Cχ_6 alkyl-aryl; and the monocyclic or bicyclic heterocycle defined in Rm is optionally substituted with one or more substituents (e.g., optionally from 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 or 2 substituents; or is optionally mono-substituted) each of which is independently halogen, -Cχ_6 alkyl, -Cχ_6 haloalkyl, -O-Cχ_6 alkyl, -O-Cχ-6 haloalkyl, oxo, aryl, -Cχ_6 alkyl-aryl, -C(=O)-aryl, -Cθ2-aryl, -Cθ2-Cχ_6 alkyl-aryl, a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and
each n is independently an integer equal to zero, 1 or 2;
or a pharmaceutically acceptable salt thereof.
The present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions. The present invention further includes methods of treating AIDS, methods of delaying the onset of ADDS, methods of preventing ADDS, methods of preventing infection by HIN, and methods of treating infection by HIN. Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
DETAILED DESCRIPTION OF THE INVENTION The present invention includes the N-substituted hydroxypyrimidinone carboxamides of Formula (I) above. These compounds and pharmaceutically acceptable salts thereof are HIV integrase inhibitors.
An embodiment of the present invention is a compound of Formula (I) exactly as defined above, except that in the definition of Rk Rk is optionally substituted with one or more substituents each of which is independently one of the substituents (1) to (18), and is optionally mono-substituted with one of the substituents (19) to (34).
Another embodiment of the present invention is a compound of
Formula (I) as originally defined above, except that the definition of R includes a proviso that none of the following optional substituents is attached to the carbon atom in the -C _6 alkyl group that is attached to the ring nitrogen: halogen, -OH, -O-Cχ_6 alkyl, -O-Cχ_6 haloalkyl, -SRa, -S(=O)Ra, or -N(Ra)-C(Rb)=O. Stated another way, none of these substituents is attached to the carbon atom alpha to the ring nitrogen. Another embodiment of the present invention is a compound of
Formula (I) as originally defined above except that in the definition of Rl, Rl is one of substitutents (1) to (16) and in the definition of Rk, Rk 1S optionally substituted with one or more substituents (e.g., optionally from 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 to 2 substituents, or is optionally monosubstituted) each of which is independently one of substitutents (1) to (31).
Another embodiment of the present invention is a compound of Formula (I), wherein Rl is:
(1) -H,
(2) -Cχ_6 alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN,
-O-Cχ-6 alkyl, -O-Cχ-6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-(CH2)θ-3-N(RaRb),
Figure imgf000013_0001
or -N(R2)C(=O)C(=O)N(RaRb),
(3) -Rk,
(4) -(CH2)l-3-Rk, wherein:
(i) the -(CH2)l-3- moiety is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -O-Cχ-6 alkyl, -O-Cχ-6 haloalkyl, -N(RaRb),
-N(Ra)CO2Rb, -N(Ra)C(=O)-(CH2)θ-3-N(RbRc), or -N(Ra)-(CH2)2-3-OH with the proviso that the -OH is not attached to the carbon alpha to N(Ra); and (ii) the -(CH2)l-3- moiety is optionally mono-substituted with -Rs, -Cχ_6 alkyl-Rs, -N(Ra)-C(=O)-(CH2)θ-3-Rs,
-N(Ra)-(CH2)0-3-Rs, -O-(CH2)θ-3-Rs, or -N(Ra)-C(=O)-(CH2)0-3-Rs; wherein Rs is (a) aryl which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -Cχ-6 alkyl, -Cχ_6 alkyl-ORa, -Cχ_6 haloalkyl, -O-Cχ-6 alkyl, -O-Cχ_6 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl;
(b) a 4- to 8- membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with one or more substituents each of which is independently halogen, -Cχ_6 alkyl, -Cχ_6 alkyl-ORa,
-Cχ-6 haloalkyl, -O-Cχ_6 alkyl, -O-Cχ_6 haloalkyl, -C(=O)Ra, -Cθ2Ra, -C(=O)-(CH2)0-3-N(RaRb), -SO2Ra, oxo, aryl, or -(CH2)l-3-aryl; or
(c) a 5- to 7-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with one or more substituents each of which is independently halogen, -Cχ_6 alkyl, -C _6 alkyl-ORa, -Cχ_6 haloalkyl, -O-Cχ-6 alkyl, -O-Cχ_6 haloalkyl, oxo, or aryl; (5) -(CH2)0-3-O-(CH2)0-3-Rk,
(6) -(CH2)0-3-S(O)n-(CH2)0-3-Rk,
Figure imgf000014_0001
(8) -(CH2)X-3-O-(CH2)l-3-Rk,
(9) -O-(CH2)X-3-S(O)nRk (10) -(CH2)0-3-N(Ra)-Rk
(11) -(CH2)0-3-N(Ra)-(CH2)l-3-Rk,
(12) -(CH2)0-3-N(Ra)-(CH2)l-3-ORk
(13) -(CH2)0-3-C(=O)-Rk,
(14) -(CH2)0-3-C(=O)N(Ra)-(CH2)0-3-Rk, (15) -(CH2)0-3-N(Ra)C(=O)-(CH2)0-3-Rk,
(16) -(CH2)0-3-N(Ra)C(=O)-O-(CH2)0-3-Rk,
(17) -C(CH3)2N(Ra)C(=O)Rb,
(18) -C(CH3)2N(Ra)C(=O)Rk, or
(19) -C(CH3)2N(Ra)C(=O)C(=O)N(RbRc); and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
In an aspect of this embodiment, Rl is one of groups (1) to (16). Another embodiment of the present invention is a compound of
Formula (I), wherein Rl is:
(1) -H,
(2) -Cχ_4 alkyl, which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -CN, -O-Cχ_4 alkyl, -O-Cχ-4 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa,
-S(=O)Ra, -N(RaRb), -C(=O)-C()-4 alkyl-N(RaRb), N(Ra)-C(=O)-Co-4 alkyl-N(RbRc), -SO2Ra, -N(Ra)SO2Rb,
-SO2N(R Rb), -N(Ra)-C(=O)Rb
Figure imgf000015_0001
, or
-N(R2)C(=O)C(=O)N(RaRb), (3) -Rk
(4) -Cχ-4 alkyl-Rk, wherein:
(i) the alkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -CN, -O-Cχ_4 alkyl, -O-Cχ_4 haloalkyl, -N(RaRb), -N(Ra)CO2Rb, -N(Ra)C(=O)-Co-4 alkyl-N(RbRC), or -N(Ra)-(CH2)2-4-OH; and (ii) the alkyl is optionally mono-substituted with -Rs,
-N(Ra)-C(=O)-Co-4 alkyl-Rs, -N(Ra)-Cθ-4 alkyl-Rs, -O-Cθ-4 alkyl-Rs, or -N(Ra)-C(=O)-Cθ-4 alkyl-RS; wherein Rs is (a) aryl which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -OH, -Cχ_4 alkyl, -Cχ_4 alkyl-ORa, _Cχ_4 haloalkyl, -O-Cχ.4 alkyl,
-O-Cχ-4 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or phenyl; (b) a 5- or 6-membered heteroaromatic ring
1 containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 alkyl-ORa, -Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ_4 haloalkyl, oxo, or phenyl; or (c) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ-4 alkyl, -Cχ-4 alkyl-ORa, -Cχ-4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ_4 haloalkyl, -C(=O)Ra, -Cθ2Ra, -C(=O)-Co-4 alkyl-N(RaRb), -SO2Ra oxo, or phenyl,
(5) -(CH2)0-3-C(=O)N(Ra)-(CH2)0-3-Rk,
(6) -C(Cl-4 alkyl)2N(Ra)C(=O)Rb
(7) -C(Cl-4 alkyl)2N(Ra)C(=O)Rk, or
(8) -C(Cl_4 alkyl)2N(Ra)C(=O)C(=O)N(RbRc);
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
In an aspect of this embodiment, Rl is one of groups (1) to (5).
Another embodiment of the present invention is a compound of Formula (I), wherein Rl is:
(1) -H,
(2) -Cχ_4 alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -O-Cχ-4 alkyl,
-O-Cχ-4 haloalkyl, -C(=O)Ra -CO2Ra, -N(RaRb), or -C(=O)-(CH2)0-2-N(RaRb),
(3) -Rk,
(4) -(CH2)l-4-Rk, wherein: (i) the -(CH2)l-4- moiety is optionally substituted with 1 or 2 substituents each of which is independently halogen, -OH, -O-Cχ_4 alkyl, -O-Cχ-4 haloalkyl, or -N(RaRb); and (ii) the -(CH2)l-4- moiety is optionally mono-substituted with -Rs or -N(Ra)-(CH2)l-2-Rs; wherein Rs is (a) phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 alkyl-ORa, -Cχ.4 haloalkyl, -O-Cχ-4 alkyl, or -O-Cχ_4 haloalkyl; or (b) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ-4 alkyl, -Cχ_4 alkyl-ORa, -Cχ-4 haloalkyl, -O-Cχ.4 alkyl, or -O-Cχ-4 haloalkyl; or
(c) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C .4 alkyl, -C -4 alkyl-ORa,
-Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ-4 haloalkyl, -C(=O)Ra or -CO2Ra,
(5) -C(=O)N(Ra)-(CH2)0-3-Rk.
(6) -C(CH3)2N(Ra)C(=O)Rb,
Figure imgf000017_0001
(8) -C(CH3)2N(Ra)C(=O)C(=O)N(RbRc);
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
In an aspect of this embodiment, Rl is one of groups (1) to (5). Another embodiment of the present invention is a compound of Formula (I), wherein
Rk is C3-8 cycloalkyl; aryl selected from phenyl and naphthyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently
(1) halogen,
(2) -OH,
(3) -CN,
(4) -Cχ_4 haloalkyl, (5) -Cχ-4 alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently -OH, -CN, -O-Cχ-4 alkyl, -O-Cχ.4 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-(CH2)θ-2N(RaRb), N(Ra)-C(=O)-(CH2)0-2N(RbRC), -SO2Ra, -N(Ra)SO2Rb -SO2N(RaRb), 0r -N(Ra)-C(Rb)=O,
(6) -O-Cχ-4 haloalkyl
(7) -O-Cχ-4 alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently -OH, -CN, -O-Cχ-6 alkyl, -O-Cχ-6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-(CH2)θ-2N(RaRb),
N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra, -N(Ra)SO2Rb -SO2N(RaRb), 0r -N(Ra)-C(Rb)=O,
(8) -NO2,
(9) oxo, (10) -C(=O)Ra,
(11) -CO2Ra,
(12) -SRa
(13) -S(=O)Ra,
(14) -N(RaRb), (15) -C(=O)N(RaRb),
(16) -C(=O)-Cχ_6 alkyl-N(RaRb),
(17) -N(Ra)C(=O)Rb,
(18) -SO2Ra,
Figure imgf000018_0001
(20 -Rm, (21 -Cχ-4 alkyl-Rm,
(22; -(CH2)0-2-N(Ra)-(CH2)0-2-Rm,
(23 -(CH2)0-2-O-(CH2)0-2-Rm, (24; -(CH2)0-2-S-(CH2)0-2-R , (25 -(CH2)0-2-C(=O)-(CH2)0-2-Rm,
(26; -C(=O)-O-(CH2)0-2-Rm.
(27 -C(=O)N(Ra)-Rm, 0r (28) -C(=O)-C(=O)N(RaRb);
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
In an aspect of this embodiment, the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently selected from the groups (1) to (27).
In an aspect of this embodiment, Rk (i.e., the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle) is optionally substituted with from 1 to 4 substituents each of which is independently one of the substituents (1) to (19), and is optionally mono-substituted with one of the substituents (20) to (28). In a feature of this aspect, Rk is optionally substituted with from 1 to 4 substituents each of which is independently one of the substituents (1) to (19), and is mono-substituted with one of the substituents (20) to (28).
In another aspect of this embodiment, each Rm is independently C3_7 cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein any N is optionally oxidized to form an N-oxide; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6- membered, saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S; wherein the cycloalkyl or the aryl defined in Rm is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 haloalkyl, -O-Cχ-4 alkyl, -O-Cχ.4 haloalkyl, -N(RaRb), phenyl, or -(CH2)l-2-phenyl; the saturated heterocyclic ring defined in R is optionally substituted with from 1 to 4 substituents each of which is independently -Cχ_4 alkyl optionally substituted with -O-Cχ_4 alkyl, -Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ-4 haloalkyl, oxo, phenyl, -(CH2)X-2-phenyl, -C(=O)-phenyl, -CO2-phenyl, -CO2-(CH2)l-2-phenyl, a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and the heteroaromatic ring or the bicyclic heterocycle defined in Rm is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ_4 haloalkyl, oxo, phenyl, or -(CH2)l-2-phenyl.
Another embodiment of the present invention is a compound of Formula (I), wherein Rk is phenyl; a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; a 5- or 6-membered heteroaromatic ring containing 1 or 2 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 nitrogen atoms;
and all other variables are as originally defined;
or a pharmaceutically acceptable salt thereof.
In an aspect of this embodiment,
(a) the phenyl, the saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently
(1) fluoro, (2) chloro,
(3) bromo,
(4) -OH
(5) -CF3,
(6) -Cχ_4 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -OH, -CN, -O-Cχ_4 alkyl, -OCF3, -N(RaRb), -C(=O)N(RaRb), or N(Ra)-C(=O)-(CH2)0-2N(RbRc),
(7) -OCF3,
(8) -O-Cχ.4 alkyl
(9) -C(=O)Ra
(10) -CO2Ra,
(11) -SRa,
(12) -SRa,
(13) -N(RaRb),
(14) -C(=O)N(RaRb),
(15) -C(=O)-(CH2)X-2-N(RaRb),
(16) -N(Ra)C(=O)Rb, or
(17) -SO2Ra;
(b) the phenyl is optionally mono-substituted with
(1) -(CH2)l-2-Rm. or
(2) -(CH2)0-2-N(Ra)-(CH2)0-2-Rm; and
(c) the saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally mono- or di-substituted with
(1) oxo
(2) -(CH2)l-2~Rm.
(3) -O-(CH2)X-2-Rm, or
(4) -(CH2)0-l-C(=O)-(CH2)0-2-Rm.
In a feature of the preceding aspect, each Rm is independently cyclopropyl; phenyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, imidazolidinyl, pyrazoUdinyl, piperidinyl, piperazinyl, and morpholinyl; or a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl optionally in the form of an N-oxide, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; wherein the cyclopropyl is unsubstituted; the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ_4 alkyl, -CF3, -O-Cχ_4 alkyl, -OCF3, or -N(RaRb); the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently -Cχ_4 alkyl, -CF3, -O-Cχ_4 alkyl, -OCF3, oxo, phenyl, -(CH2)l-2-phenyl, -C(=O)-phenyl, -CO2-phenyl, or -Cθ2-CH2-ρhenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently -Cχ_4 alkyl, -CF3, -O-Cχ_4 alkyl, -OCF3, oxo, phenyl, or -(CH2)l-2-phenyl.
Another embodiment of the present invention is a compound of
Formula (I), wherein R2 is:
(1) -Cχ_6 alkyl,
(2) -C -6 alkyl substituted with -N(RaRb),
(3) -Cχ_6 alkyl substituted with phenyl, wherein the phenyl is: (a) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ-4 haloalkyl, or -Co-4 alkyl-N(RaRb); and (b) optionally mono-substituted with -Cχ_4 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Cχ_6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atom, and 0 or 1 S atom; or
(4) -Cχ-6 alkyl optionally substituted with -OH and substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently -C _6 alkyl, -O-Cχ-6 alkyl, oxo, or phenyl; or (5) -Cχ_6 alkyl substituted with a 5- or 6-membered heteroaromatic ring which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms,
0 or 1 O atoms, and 0 or 1 S atoms; wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -Cχ_6 alkyl, -O-Cχ_6 alkyl, oxo, or phenyl;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
Another embodiment of the present invention is a compound of Formula (I) exactly as defined in the immediately preceding embodiment, except that when R2 is -Cχ_6 alkyl substituted with -N(RaRb), it is with the proviso that -N(RaRb) is not attached to the carbon atom in the -Cχ_6 alkyl group that is attached to the ring nitrogen (i.e., that the -N(RaRb) group is not attached to the carbon atom alpha to the ring nitrogen).
Another embodiment of the present invention is a compound of Formula (I), wherein R2 is methyl;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
Another embodiment of the present invention is a compound of Formula (I), wherein R3 is -H or -Cχ_4 alkyl;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof. In an aspect of this embodiment, R3 is -H or methyl. In another aspect of this embodiment, R3 is -H.
Another embodiment of the present invention is a compound of Formula (I), wherein R4 is Cχ-4 alkyl substituted with an aryl, which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -Cχ_4 alkyl, -Cχ_4 alkyl-ORa, _C _4 haloalkyl, -O-Cχ.4 alkyl, -O-Cχ.4 haloalkyl, -CN, -NO2, -N(RaRb), -Cχ.4 alkyl-N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO2Ra -Cχ-4 alkyl-CO2Ra, -OCO2R -SRa, -S(=O)Ra -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO2Rb, -Cχ-4 alkyl-N(Ra)CO2Rb, methylenedioxy attached to two adjacent ring carbon atoms, phenyl, -Cχ-4 alkyl-phenyl, -O-phenyl, or -(CH2)θ-2-het; wherein het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with 1 or 2 substituents each of which is independently -Cχ_4 alkyl, -Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ_4 haloalkyl, or -CO2Ra;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
Another embodiment of the present invention is a compound of Formula (I), wherein R is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ-4 fluoroalkyl, -0-Cχ_4 alkyl, -O-Cχ-4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)θ-2-CO2Ra, -(CH2)θ-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) or phenyl;
each Ra and Rb is independently is H or -Cχ_4 alkyl;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof. In an aspect of the preceding embodiment, R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents, each of which is independently -F, -Br, -CI, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ.4 alkyl, -SO2- Cχ_4 alkyl, -S-Cχ_4 alkyl, -N(CH3)2 or -O-Cχ_4 fluoroalkyl. In another aspect of the preceding embodiment, R4 is p-fluorobenzyl or 2,3-dimethoxybenzyl.
In another aspect of the preceding embodiment, the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ_4 alkyl, -O-Cχ_4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra -(CH2)0-2-CO2Ra ~(CH2)0-2~N(Ra)CO2Rb, -NO2, or phenyl.
In an aspect of the preceding embodiment, the phenyl is optionally substituted with from 1 to 3 substituents, each of which is independently -F, -Br, -CI, -OH, -Cχ_4 alkyl, -Cχ-4 fluoroalkyl, -O-Cχ_4 alkyl, or -O-Cχ_4 fluoroalkyl. In another aspect of the preceding embodiment, R4 is p-fluorobenzyl or 2,3- dimethoxybenzyl .
A class of compounds of the present invention includes any compound of Formula (I), wherein
Rl is -Rk;
Rk is phenyl which is
(a) optionally substituted with from 1 to 3 substituents each of which is independently: (1) halogen,
(2) -Cχ-6 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -O-Cχ-6 alkyl, -O-Cχ_6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa,
Figure imgf000025_0001
N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra
-N(Ra)SO2Rb, -SO2N(RaRb), or -N(R )-C(Rb)=O,
(3) -Cχ_6 haloalkyl,
(4) -O-Cχ-6 haloalkyl,
(5) -C(=O)R (6) -CO2Ra (7) -C(=O)N(R Rb), or
(8) -C(=O)-Cχ-6 alkyl-N(RaRb); and
(b) optionally mono-substituted with (1) -Cχ-4 alkyl-Rm, 0r (2) -Co-4 alkyl-N(Ra)-Co-4 alkyl-Rm;
wherein Rm is aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the aryl defined in Rm is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ_4 alkyl, -CF3, -O-Cχ-4 alkyl, -OCF3, or -N(R Rb); the saturated heterocyclic ring defined in Rm is optionally substituted with from 1 to 3 substituents each of which is independently -Cχ_4 alkyl or oxo, and is additionally optionally mono-substituted with phenyl, -(CH2)l-2-phenyl, -C(=O)-phenyl, -CO2-phenyl, -CO2-(CH2)l-2-phenyl, or a
5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; and the heteroaromatic ring defined in Rm is optionally substituted with 1 or 2 substituents each of which is independently -Cχ_4 alkyl or oxo;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein
R2 is methyl;
R3 is -H;
R4 is: (1) -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ.4 fluoroalkyl, -O-Cχ_4 alkyl, -O-Cχ.4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra -(CH2)0-2-CO2Ra, -(CH2)0-2-N(Ra)CO2Rb, -NO2, -SRa, - N(RaRb) or phenyl; or
(2) a fused bicyclic carbocycle selected from
Figure imgf000027_0001
wherein Zl is -H or -OH; and
each Ra and Rb is independently is H or -Cχ_4 alkyl;
and all other variables are as defined in the class;
or a pharmaceutically acceptable salt thereof.
Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein R is 4-fluorobenzyl or 2,3-dimethoxybenzyl;
and all other variables are as defined in the class;
or a pharmaceutically acceptable salt thereof.
Still another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein R2 is methyl; R3 is -H; R4 is 4-fluorobenzyl or 2,3-dimethoxybenzyl; each Ra and Rb is independently is H or -Cχ-4 alkyl; and all other variables are as defined in the class; or a pharmaceutically acceptable salt thereof. Another class of the present invention includes any compound of
Formula (II):
Figure imgf000028_0001
wherein
Q is:
(1) methyl which is optionally substituted with 1 or 2 of -O-Cχ-4 alkyl,
(2) phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently -F, -CI, Br, -Cχ_4 alkyl, -CF3, -O-Cχ-4 alkyl, -OCF3, methylenedioxy attached to two adjacent carbon atoms, or phenyl, or
(3) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently -F, -CI, -Br, -Cχ_4 alkyl, oxo, phenyl, or -C(=O)-phenyl;
T is:
(1) -H,
(2) -OH,
(3) methyl or ethyl, optionally substituted with -OH or -O-Cχ-4 alkyl,
(4) -O-Cχ-4 alkyl
(5) -N(RaRb),
Figure imgf000028_0002
(8) -N(Ra)-C(=O)-(CH2)X-2-N(RaRb),
(9) -Rs,
(10) -(CH2)X-2-Rs, or
(11) -(CH2)0-2-N(Ra)-(CH2)0-3-Rs; Rs is:
(1) phenyl optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 alkyl-ORa, -Cχ_4 haloalkyl, -O-Cχ_4 alkyl, -O-Cχ-4 haloalkyl, or -N(RaRb);
(2) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with from 1 to 4 substituents each of which is independently -Cχ_4 alkyl, -Cχ-4 alkyl-ORa, -Cχ_4 haloalkyl, -O-Cχ-4 alkyl, -O-Cχ_4 haloalkyl, -C(=O)Ra oxo, phenyl, or -CH2-phenyl; or
(3) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with from 1 to 4 substituents each of which is independently -Cχ_4 alkyl, -Cχ_4 alkyl-ORa, _Cχ_4 haloalkyl, -O-Cχ-4 alkyl, -O-Cχ_4 haloalkyl, or oxo;
R2 IS
(1) -Cχ_4 alkyl,
(2) -Cχ-4 alkyl substituted with -N(RaRb), 0r (3) -Cχ-4 alkyl substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the saturated heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently a -Cχ_4 alkyl;
R3 is -H or -Cχ-4 alkyl;
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ-4 alkyl, -O-Cχ_4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)0-2-Cθ2Ra, -(CH2)0-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) or phenyl;
each Ra and Rb is independently is H or -Cχ_4 alkyl; and
s is an integer equal to zero, 1, or 2; or a pharmaceutically acceptable salt thereof.
In an aspect of this class, R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ-4 alkyl, -Cχ.4 fluoroalkyl, -O-Cχ-4 alkyl, -O-Cχ_4 fluoroalkyl, -(CH2)l-2~N(RaRb), -SO2Ra, -(CH2)θ-2-CO2R -(CH2)0-2-N(Ra)Cθ2Rb -NO2, or phenyl
A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (II) exactly as defined in the preceding class, except that when R is -Cχ.4 alkyl substituted with -N(RaRb), it is with the proviso that -N(RaRb) is not attached to the carbon atom in the -Cχ-4 alkyl group that is attached to the ring nitrogen (i.e., that the -N(RaRb) group is not attached to the carbon atom alpha to the ring nitrogen).
Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (II), wherein
Q is phenyl;
T is:
(1) -H,
(2) -N(RaRb),
(3) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with 1 or 2 substituents each of which is independently -Cχ_4 alkyl or -C(=O)Ra, or
(4) -N(Ra)-(CH2)l-2-heteroaromatic, wherein the heteroaromatic is a 5- or 6-membered ring containing 1 or 2 N atoms;
R2 is methyl;
R3 is -H; and R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents each of which is independently -F, -CI, -Br, -Cχ_4 alkyl, -CF3, -O-Cχ_4 alkyl, -SO2CH3, -SCH3, -N(CH3)2 or -OCF3;
each Ra and Rb is independently -H, methyl or ethyl; and
s is an integer equal to zero or 1;
or a pharmaceutically acceptable salt thereof. In an aspect of this subclass, R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents each of which is independently -F, -CI, -Br, -Cχ_4 alkyl, -CF3, -O-Cχ-4 alkyl, or -OCF3.
Another class of compounds of the present invention includes any compound of Formula (I) , wherein
Rl is -Rk;
Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen
( atoms and from 1 to 3 nitrogen atoms or (ii) a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen atoms and from 1 to 3 nitrogen atoms; wherein the saturated heterocyclic ring or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently (1) -Cχ_4 alkyl, which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -O-Cχ-4 alkyl, -O-Cχ-4 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra -N(RaRb), -C(=O)-(CH2)θ-2N(RaRb), N(Ra)-C(=O)-(CH2)0-2N(RbRC), -SO2Ra, -N(Ra)SO2Rb -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(2) -OH,
(3) -C(=O)Ra
Figure imgf000031_0001
(5) -C(=O)N(RaRb), (6) -C(=O)-Cχ-6 alkyl-N(RaRb),
(7) -SRa,
(8) -S(=O)Ra,
(9) -SO2Ra (10) -N(RaRb),
(11) -Rm,
(12) -Cχ-4 alkyl-Rm, wherein the alkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -CN, -Cχ_4 haloalkyl, -O-Cχ-4 alkyl, -O-Cχ_4 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa,
-S(=O)Ra, -N(RaRb), -N(Ra)CO2Rb, -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(13) -Co-4 alkyl-N(Ra)-Co-4 alkyl-Rm,
(14) -Co-4 alkyl-O-Co-4 alkyl-Rm, (15) -Co-4 alkyl-S-Co-4 alkyl-Rm,
(16) -Co-4 alkyl-C(=O)-Co-4 alkyl-Rm,
(17) -C(=O)-O-Cθ-4 alkyl-Rm, or
(18) -C(=O)N(Ra)-Co-4 alkyl-Rm;
wherein each Rm is independently -C3-6 cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein any N is optionally oxidized to form an N-oxide; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cχ_4 alkyl, -CF3, -O-Cχ_4 alkyl, -OCF3, or -N(RaRb); the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Cχ_4 alkyl or oxo, and is additionally optionally mono-substituted with phenyl, -(CH2)l-2-phenyl,
-C(=O)-phenyl, -CO2-phenyl, or -CO2-(CH2)l-2-phenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently halogen, -Cχ_4 alkyl, or oxo; and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein
Rl is:
Figure imgf000033_0001
Figure imgf000033_0002
R8 i is:
(1) -H,
(2) -Cχ_4 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -OH, -O-Cχ_4 alkyl, -OCF3, -C(=O)Ra, -CO2Ra, -SRa, -N(RaRb), 0r -C(=O)N(RaRb),
(3) -C(=O)Ra,
(4) -CO2Ra
(5) -C(=O)N(RaRb), (6) -C(=O)-(CH2)l-2-N(RaRb),
(7) -SO2Ra
(8) -(CH2)X-2-R ,
(9) -(CH2)0-2-C(=O)-(CH2)0-2-Rm, (10) -C(=O)-O-(CH2)0-2-Rm, or
(11) -C(=O)N(Ra)-(CH2)0-2-Rm;
RlO is -H, -OH, -Cχ-4 alkyl, -O-Cχ-4 alkyl, -N(RaRb), or -O-(CH2)l-2-Rm ;
Rl is
(1) -H,
(2) -Cχ-4 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -OH, -O-Cχ-4 alkyl, -OCF3, -C(=O)Ra, -CO2Ra, -SRa, -N(RaRb), 0r -C(=O)N(RaRb),
(3) -C(=O)Ra,
Figure imgf000034_0001
(5) -C(=O)-(CH2)l-2-N(RaRb), or
(6) -SO2Ra;
R2 is methyl;
R3 is -H or methyl;
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ-4 alkyl, -O-Cχ.4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)0-2-CO2Ra, -(CH2)0-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) or phenyl; and
each Ra and Rb is independently -H or -Cχ_4 alkyl;
or a pharmaceutically acceptable salt thereof.
In an aspect of this subclass, R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ-4 alkyl, -O-Cχ_4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)θ-2-Cθ2Ra, -(CH2)0-2-N(R )CO2Rb, -NO2, or phenyl.
Another class of the present invention includes any compound of
Formula (Dl):
Figure imgf000035_0001
wherein R2 is:
(1) -Cχ_6 alkyl, (2) -Cχ-6 alkyl substituted with -N(RaRb),
(3) -Cχ_6 alkyl substituted with phenyl which is:
(a) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cχ_4 alkyl, -Cχ_4 haloalkyl, -O-Cχ.4 alkyl, -O-Cχ-4 haloalkyl, or -Co-6 alkyl-N(RaRb); and
(b) optionally mono-substituted with -Cχ_4 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Cχ_6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atom, and 0 or 1 S atom; (4) -Cχ-6 alkyl optionally substituted with -OH and substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently -Cχ_6 alkyl, -O-Cχ-6 alkyl, oxo, or phenyl; or (5) -Cχ-6 alkyl substituted with a 5- or 6-membered heteroaromatic ring which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -Cχ_6 alkyl, -O-Cχ_6 alkyl, oxo, or phenyl;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (III) exactly as defined in the preceding class, except that when R is -Cχ_6 alkyl substituted with -N(RaRb), it is with the proviso that -N(RaRb) is not attached to the carbon atom in the -Cχ_6 alkyl group that is attached to the ring nitrogen (i.e., that the -N(RaRb) group is not attached to the carbon atom alpha to the ring nitrogen).
Another sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (Dl), wherein
R2 is:
(1) -Cχ-4 alkyl, (2) -(CH2)l-3-N(RaRb),
(3) -(CH2)l-3-phenyl, wherein the phenyl is:
(a) optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, -Cχ_4 alkyl, -CF3, -O-Cχ_4 alkyl, -O-CF3, or -(CH2)l-3-N(RaRb); and
(b) optionally mono-substituted with -(CH2)l-3-saturated heterocycle which is a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms, wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Cχ_4 alkyl or pyridyl;
(4) -(CH2) 1 -3-saturated heterocycle, wherein the -(CH2) 1-3- moiety is optionally substituted with an -OH and the saturated heterocycle is a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently a -Cχ_4 alkyl; or
(5) -(CH2)l-3-pyridyl;
R3 is -H or methyl;
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ-4 alkyl, -O-Cχ-4 fluoroalkyl, -(CH2)χ_2-N(RaRb), -SO2Ra, -(CH2)0-2-Cθ2Ra, -(CH2)0-2-N(Ra)CO2R , -NO2, -SRa -N(RaRb) or phenyl; and
each Ra and Rb is independently is H or -Cχ_4 alkyl;
or a pharmaceutically acceptable salt thereof.
In an aspect of this subclass, R4 is ~CH2~phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ-4 alkyl, -O-Cχ-4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra -(CH2)θ-2-Cθ2Ra, -(CH2)0-2-N(Ra)CO2Rb, -NO2, or phenyl.
Another class of compounds of the present invention includes any compound of Formula (I), wherein
Rl is -C(=O)NH-(CH2)l-2-Rk ; and
Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S;
and all other variables are as originally defined above;
or a pharmaceutically acceptable salt thereof.
A sub-class of the preceding class of compounds of the present invention includes any compounds of Formula (I), wherein
Rl is -C(=O)NH-(CH2)l-2-Rk ; and
Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S;
R2 is methyl;
R3 is -H or methyl;
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ_4 alkyl, -O-Cχ.4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)0-2-CO2R -(CH2)θ-2-N(Ra)Cθ2Rb -NO2, -SRa -N(RaRb) or phenyl; and
each Ra and Rb is independently -H or -Cχ_4 alkyl;
or a pharmaceutically acceptable salt thereof. In an aspect of this subclass, R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cχ_4 alkyl, -Cχ_4 fluoroalkyl, -O-Cχ.4 alkyl, -O-Cχ_4 fluoroalkyl, -(CH2)l-2-N(R Rb), -SO2Ra, -(CH2)0-2-CO2Ra, -(CH2)0-2-N(Ra)CO2Rb -NO2, or phenyl. It is to be understood that additional embodiments of the present invention include, but are not limited to, compounds of Formula I wherein each of two or three or more of R1, R2, R3, R4 Ra Rb C ? d Rk and Rm is independently defined in accordance with its definition in one of the embodiments or an aspect 5 thereof as set forth above, or in accordance with its definition in one of the foregoing classes set forth above or a sub-class or feature thereof. Any and all possible combinations of these variables in Formula I are additional embodiments within the scope of the present invention.
10 An aspect of the present invention is a compound selected from the group consisting of
N-(2-ethoxybenzyl)-5-hydroxy- 1 -methyl-2-(4-methylphenyl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide; 15.
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-2-(4-methylphenyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-2-{4-[(dimethylamino)methyl]phenyl}-5-hydroxy-l- 20 methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-{4-[(dimethylamino)methyl]phenyl}-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
25 N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-2-[4-(pyrrolidin-l- ylmethyl)phenyl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[4-(pyrrolidin-l-ylmethyl)phenyl]- 1 ,6-dihydropyrimidine-4-carboxamide; 30
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[4-(piperidin-l-ylmethyl)phenyl]- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4-ylmethyl)phenyl]-6- 35 oxo-l,6-dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- [4-(morpholin-4-ylmethyl)phenyl] -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{4-[(4-methylpiperazin-l- yl)methyl]phenyl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-{4-[(diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2- { 4- [(diethylamino)methyl]phenyl } -N-(4-fluorobenzyl)-5-hydroxy- l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxarnide;
2-[(dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-[(4-formylpiperazin-l-yl)(phenyl)methyl]-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo-2- { phenyl [(pyridin-3 - ylmethyl)amino]methyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
2-benzyl- 1 - [2-(dimethylamino)ethyl] -N-(4-fluorobenzyl)-5-hydroxy-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
l-[2-(dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-2-(2-methylphenyl)-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(4-methylphenyl)-6-oxo- 1,6- dihydropyrimidine-4-carboxamide;
2-benzyl-N-(2,3-dimethoxybenzyl)-l-[2-(dimethylamino)ethyl]-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide ; 2- { 4- [(4-ethylpiperazin- 1 -yl)methyl]phenyl } -N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-{4-[(2-pyridin-3-ylpiperidin-l- yl)methyl]phenyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxamide;
N-[4-fluoro-2-(trifluoromethyl)benzyl]-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(3-chloro-4-methylbenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxamide;
5-hydroxy-N-[(lR,2S)-2-hydroxy-2,3-dihydro-lH-inden-l-yl]-l-methyl-2-{4-[(4- methylpiperazin- 1 -yl)methyl]phenyl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy-2-(4-{[(2R)-2-(methoxymethyl)pyrrolidin-l- yl]methyl}phenyl)-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxaιnide;
N-(4-fluorobenzyl)-5-hydroxy-2-(4-{[(2S)-2-(methoxymethyl)pyrrolidin-l- yl]methyl}phenyl)-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-(4-{[(4-fluorobenzyl)amino]methyl}phenyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-benzyl-N-(4-fluorobenzyl)-5-hydroxy- 1 -(2-morpholin-4-ylethyl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
l-[2-(dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l-(pyridin-3-ylmethyl)-l,6-dihydropyrimidine- 4-carboxamide;
2-benzyl-N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l-(2-pyrrolidin-l-ylethyl)-l,6- dihydropyrimidine-4-carboxamide;
2-benzyl-N-(4-fluorobenzyl)-5 -hydroxy-6-oxo- 1 -(2-piperidin- 1 -ylethyl)- 1,6- dihydropyrimidine-4-carboxamide;
2-( 1 -benzylpiperidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-( 1 -methylpiperidin-2-yl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-( 1 -benzylpiperidin-3-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
l-{3-[(dimethylamino)methyl]benzyl}-N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-l-[2-(dimethylamino)ethyl]-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-6-oxo-l-(pyridin-3-ylmethyl)-l,6- dihydropyrimidine-4-carboxamide;
N4-(4-fluorobenzyl)-5-hydroxy-l-methyl-N2-(2-morpholin-4-ylethyl)-6-oxo-l,6- dihydropyrimidine-2,4-dicarboxamide;
N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l-[3-(pyrrolidin-l-ylmethyl)benzyl]-l,6- dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-l-[3-(morpholin-4-ylmethyl)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 - { 3 - [(4-methylpiperazin- 1 -yl)methyl]benzyl } -6-oxo- l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l-{3-[(4-pyridin-2-ylpiperazin-l- yl)methyl]benzyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-[2-(morpholin-4-ylmethyl)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-6-oxo- 1 - { 2- [(4-pyridin-2-ylpiperazin- 1 - yl)methyl]benzyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-pyrrolidin-2-yl-l,6- dihydropyrimidine-4-carboxamide ;
N4-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-N2-(pyridin-2-ylmethyl)-l,6- dihydropyrimidine-2,4-dicarboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-(2-hydroxy-3-morpholin-4-ylpropyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-[4-(morpholin-4-ylmethyl)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(2-morpholin-4-ylethyl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-(2,2-dimethoxyethyl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide ;
2-(2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide; 2-[2-(4-benzoylpiperazin-l-yl)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[l-(N,N-dimethylglycyl)piperidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-2,3-dihydro-lH-indol-2-yl)-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-(l,2,3,4-tetrahydroquinolin-2-yl)- l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(l -methyl- 1 ,2,3 ,4-tetrahydroquinolin-2-yl)- 6-oxo- l,6-dihydropyrimidine-4-carboxamide;
tert-butyl (2S,4R)-4-(benzyloxy)-2-(4-{ [(4-fluorobenzyl)amino]carbonyl}-5-hydroxy- l-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)pyrrolidine-l-carboxylate;
tert-butyl (2S,4R)-2-(4-{ [(4-fluorobenzyl)amino] carbonyl }-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidin-2-yl)-4-hydroxypyrrolidine- 1 -carboxylate ;
2-[(2S,4R)-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[(2S,4R)-4-hydroxypyrrolidin-2-yl]-l-methyl-6-oxo- l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[(2S,4R)-4-hydroxy-l-methylpyrrolidin-2-yl]-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-4-(benzyloxy)-l-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; 2-[(2S,4R)-l-benzoyl-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrirnidine-4-carboxamide;
2-[l-(N,N-dimethylglycyl)-2,3-dihydro-lH-indol-2-yl]-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)-2,3- dihydro-lH-indol-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidin-2-yl)-4-methylpiperazine- 1 -carboxylate ;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(4-methylmorpholin-3-yl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
(+)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
(-)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(4-methylmorpholin-3-yl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide
2-(l -ethyl-2,3-dihydro- lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-( 1 -benzoylpiperidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyridin-2-ylcarbonyl)piperidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(2-methyl- 1 ,2,3 ,4-tetrahydroisoquinolin-3- yl)-6-oxo-l ,6-dihydropyrirnidine-4-carboxamide; 2-(l-benzoylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)pyrrolidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-( 1 -methylpyrrolidin-2-yl)-6-oxo- 1,6- dihydropyrimidine-4-carboxamide;
2-[(2S ,4R)-4-(benzyloxy)- 1 -(pyridin-2-ylcarbonyl)pyrrolidin-2-yl] -N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[l-(dimethylamino)-2-phenylethyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2- [(2S ,4R)- 1 -benzoyl-4-hydroxypyrrolidin-2-yl] -N-(4-fluorobenzyl)-5 -hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-( 1 -isobutyl-2,3-dihydro- lH-indol-2-yl)- 1 -methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-(l-isopropyl-2,3-dihydro-lH-indol-2-yl)-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-[l-(N,N-dimethylglycyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-{ l-[(6-bromopyridin-2-yl)carbonyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy- l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-( 1 -methylpiperazin-2-yl)-6-oxo- 1,6- dihydropyrimidine-4-carboxamide; 2-( 1 -benzoyl-4-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)-l,2,3,4- tetrahydroquinolin-2-yl] - 1 ,6-dihydropyrimidine-4-carboxamide ;
2-( l-acetylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2- [ 1 -(cyclopropylcarbonyl)pyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- [ 1 -(methylsulf onyl)pyrrolidin-2-yl] -6-oxo- 1 ,6-dihydropyrirnidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{l-[(4-methylmorpholin-3- yl)carbonyl]pyrrolidin-2-yl}-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-(l,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-3-ylcarbonyl)pyrrolidin- 2-yl] - 1 ,6-dihydropyrimidine-4-carboxamide ;
2-[(2S,4R)-l-acetyl-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-(l-isonicotinoylpyrrolidin-2-yl)-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-{ l-[(ethylamino)carbonyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy-l-methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-2- { 1 - [( 1 -methyl- lH-imidazol-2- yl)carbonyl]pyrrolidin-2-yl }-6-oxo-l ,6-dihydropyrimidine-4-carboxamide; 2-[(2S,4R)-l-acetyl-4-hydroxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[l-(anilinocarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(4-ethyl-l-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- { 1 - [( 1 -oxidopyridin-2- yl)carbonyl]pyrrolidin-2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyrazin-2-ylcarbonyl)pyrrolidin- 2-yl]-l ,6-dihydropyrimidine-4-carboxamide;
2-[(4R)-3-acetyl-l,3-thiazolidin-4-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-2- [ 1 -methyl-4-(methylsulf onyl)piperazin-2- yl]-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylthiomorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide ;
N- [4-fluoro-2-(methylsulf onyl)benzyl] -5-hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyrazin-2- ylcarbonyl)pyrrolidin-2-yl] - 1 ,6-dihydropyrimidine-4-carboxamide ;
2-(l-acetylpyrrolidin-2-yl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5-hydroxy-l- methyl-6-oxo-l ,6-dihydropyrimidine-4-carboxamide;
2-(3-acetyl-l,3-thiazolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide; 2-[l-(acetylamino)-l-methylethyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-( 1 -acetylpyrrolidin-2-yl)-N-(2-ethoxybenzyl)-5-hydroxy- l-methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-(4-acetyl- 1 -methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-[l-methyl-4-(pyrazin-2- ylcarbonyl)piperazin-2-yl]-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-5-hydroxy-l-methyl-N-[2-(methylthio)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-{l-[(lH-imidazol-5-ylcarbonyl)amino]-l- methylethyl } - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-[l-benzoyl-4-(pyrazin-2-ylcarbonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy- l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-(4-benzoyl- 1 -methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[4-(benzyloxy)-l-(pyrazin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-( 1 -acetylpyrrolidin-2-yl)-N-(2,3-dimethoxybenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-5-hydroxy-N-(2-methoxybenzyl)-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
Nl-[l-(4-{ [(4-fluorobenzyl)amino]carbonyl }-5-hydroxy-l-methyl-6-oxo-l ,6- dihydropyrimidin-2-yl)- 1 -methylethyl]-N2,N2-dimethylethanediamide; 2-(X-acetylpyrrolidin-2-yl)-N-[2-(dimethylamino)benzyl]-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-l-acetylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[4-hydroxy-l-(pyrazin-2-ylcarbonyl)pyrrolidin-2-yl]- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N- [ 1 -(4-{ [(4-fluorobenzyl)amino]carbonyl } -5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidin-2-yl)-l-methylethyl]imidazo[2,l-b][l,3]thiazole-6-carboxamide;
2-[(2S ,4S)- 1 -acetyl-4-fluoropyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-2- { 1 -methyl-4- [( 1 -methyl- 1 H-imidazol-2- yl)carbonyl]piperazin-2-yl}-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-( 1 -methyl- 1-{ [(5-methyl- 1 ,3 ,4-oxadiazol- 2-yl)carbonyl]amino}ethyl)-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
Nl-{ l-[4-({ [4-fluoro-2-(methylsulf onyl)benzyl] amino } carbonyl)-5-hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidin-2-yl] - 1 -methylethyl } -N2,N2- dimethylethanediamide;
2-(4-acetyl-l,2-dimethylpiρerazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyrimidin-4- ylcarbonyl)pyrrolidin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyrimidin-5- ylcarbonyl)pyrrolidin-2-yl]- 1 ,6-dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ l-methyl-l-[(lH-pyrazol-5- ylcarbonyl)amino]ethyl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2R,4R)-l-acetyl-4-methoxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-{ l-[(dimethylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-{ l-[4-({ [4-fluoro-2-(methylsulfonyl)benzyl]amino}carbonyl)-5-hydroxy-l-methyl- 6-oxo-l,6-dihydropyrimidin-2-yl]-l-methylethyl}imidazo[2,l-b][l,3]thiazole-6- carboxamide;
2- [(2R,4R)- 1 -benzoyl-4-methoxypyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy-2- [4-(isopropylsulf onyl)- 1 -methylpiperazin-2-yl] - 1 - methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[l,2-dimethyl-4-(methylsulfonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[(2S,4R)-4-methoxy-l-methylpyrrolidin-2-yl]-l- methyl-6-oxo- 1 ,6-dihydroρyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{l-[(methylsulfonyl)acetyl]pyrrolidin-2- yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2- [(2S)- 1 -acetyl-4,4-difluoropyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2R,4R)-l-acetyl-4-ethoxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; 2-[(2S)-4,4-difluoro-l-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridazin-3- ylcarbonyl)pyrrolidin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-( 1 -methyl- 1 - { [morpholin-4- yl(oxo)acetyl]amino}ethyl)-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2R,4R)-l-[(dimethylamino)(oxo)acetyl]-4-methoxypyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-(pyrazin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- { (2S ,4S)- 1 -methyl-4-
[(methylsulfonyl)amino]pyrrolidin-2-yl}-6-oxo-l,6-dihydropyrimidine-4- carboxamide;
2-{ l-[(dimethylamino)sulfonyl]pyrrolidin-2-yl }-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2R,4R)-4-ethoxy-l-[(methylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-(pyridazin-3-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-(pyridin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]-4,4-difluoropyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ l-[morpholin-4-yl(oxo)acetyl]pyrrolidin- 2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4-fluoro-2- methoxybenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N 1 - [ 1 -(4- { [(4-fluorobenzyl)amino] carbonyl } -5-hydroxy- 1 -methyl-6-oxo- 1,6- dihydropyrimidin-2-yl)-l-methylethyl]-Nl,N2,N2-trimethylethanediamide;
2-[(2S)-l-acetylpyrrolidin-2-yl]-N-(4-fluoro-2-methoxybenzyl)-5-hydroxy-l-methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-[(2S ,4S)-4-fluoro- 1 -methylpyrrolidin-2-yl]-5-hydroxy- 1 -methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2S,4S)-l-[(dimethylamino)(oxo)acetyl]-4-fluoropyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
Nl-[l-(4-{[(3-chloro-4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6-oxo- l,6-dihydropyrimidin-2-yl)-l-methylethyl]-N2,N2-dimethylethanedi amide;
and pharmaceutically acceptable salts thereof.
Another aspect of the present invention is a compound selected from the group consisting of:
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyrazin-2-ylcarbonyl)pyrrolidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-l-benzoyl-4-hydroxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- { 1 - [( 1 -oxidopyridin-2- yl)carbonyl]pyrrolidin-2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-4-(benzyloxy)-l-(pyridin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide ;
(+)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
(-)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmo holin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)pyrrolidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)-l,2,3,4- tetrahydroquinolin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
2- [(2S ,4R)- 1 -benzoyl-4-(benzyloxy)pyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 - methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2- [(2S ,4R)- 1 -acetyl-4-(benzyloxy)pyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 - methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-3-ylcarbonyl)pyrrolidin- 2-yl] - 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy-2-( l-isonicotinoylpyrrolidin-2-yl)- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide; 2-(X,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- { 1 - [( 1 -methyl- lH-imidazol-2- yl)carbonyl]pyrrolidin-2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(l-benzoylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-2- [ 1 -(methylsulf onyl)pyrrolidin-2-yl] -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(4R)-3-acetyl-l,3-thiazolidin-4-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- l,6-dihydropyrimidine-4-carboxamide;
2-{ l-[(ethylamino)carbonyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy-l-methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-(4-ethyl-l-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-4-(benzyloxy)-l-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyridin-2-ylcarbonyl)-2,3- dihydro-lH-indol-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-l,2,3,4-tetrahydroquinolin-2-yl)- 6-oxo- l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(2-methyl-l,2,3,4-tetrahydroisoquinolin-3- yl)-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; 2- [ 1 -(dimethylamino)-2-phenylethyl] -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- l,6-dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4-ylmethyl)phenyl]-6- oxo-l,6-dihydropyrimidine-4-carboxamide;
and pharmaceutically acceptable salts thereof.
Other embodiments of the present invention include the following:
(a) A pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.
(b) A pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula
(I) and a pharmaceutically acceptable carrier.
(c) The pharmaceutical composition of (a) or (b), further comprising a therapeutically effective amount of an HIN infection/ ADDS treatment agent selected from the group consisting of HIN/ ADDS antiviral agents, immunomodulators, and anti-infective agents.
(d) The pharmaceutical composition of (c), wherein the HTV infection/ ADDS treatment agent is an antiviral selected from the group consisting of HIN protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors. (e) A combination useful for inhibiting HIN integrase, for treating or preventing infection by HTV, or for preventing, treating or delaying the onset of ADDS, which is a therapeutically effective amount of a compound of Formula (I) and a therapeutically effective amount of an HIV infection/ADDS treatment agent selected from the group consisting of HIV/ ADDS antiviral agents, immunomodulators, and anti-infective agents.
(f) The combination of (e), wherein the HIN infection/ADDS treatment agent is an antiviral selected from the group consisting of HTV protease inhibitors, non-nucleoside HTV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors. (g) A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).
(h) A method of preventing or treating infection by HTV in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).
(i) The method of (h), wherein the compound of Formula (I) is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIN protease inhibitors, non- nucleoside HTV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors.
(j) A method of preventing, treating or delaying the onset of ADDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I). (k) The method of (j), wherein the compound is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIN protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse transcriptase inhibitors
(1) A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
(m) A method of preventing or treating infection by HIV in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f). (n) A method of preventing, treating or delaying the onset of ADDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
The present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) inhibiting HTV protease, (b) preventing or treating infection by HIN, or (c) preventing, treating or delaying the onset of ADDS. In these uses, the compounds of the present invention can optionally be employed in combination with one or more EON/ ADDS treatment agents selected from HIN/ ADDS antiviral agents, anti-infective agents, and immunomodulators. Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub- classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt.
As used herein, the term "Cχ_6 alkyl" (or "Cχ-C6 alkyl") means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "Cχ_4 alkyl" means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
The term "Co" as employed in expressions such as "Cθ-6 alkyl" means a direct covalent bond. For example, when Rl in Compound I is -Cθ-6 alkyl-O-Cθ-6 alkyl-Rk, then Rl is -O-Rk when both alkyl groups are Co alkyl. Similarly, when an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond. For
Figure imgf000058_0001
example, the compound of Formula (II) has as a substituent at the 2- position of the pyrimidinone ring, wherein s is an integer equal to zero, 1 or 2. When
s is zero, the substituent has the following structure: T
The term "-Cχ_6 alkyl-" refers to a Cx to C linear or branched alkyl group as just defined which is bivalent. It can alternatively be referred to as "Cχ_6 alkylene" or "Cχ-6 alkanediyl". A class of alkylenes of particular interest with respect to the invention is -(CH2)X-6~, and sub-classes of particular interest include -(CH2)l- 4-, -(CH2)X-3-, -(CH2)X-2-, and -CH -.
The term "C2-5 alkynyl" (or "C2-C5 alkynyl") means linear or branched chain alkynyl groups having from 2 to 5 carbon atoms and includes all of the pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-butynyl, 1-propynyl, 2-propynyl, and ethynyl (or acetylenyl). Similar terms such as "C2-3 alkynyl" have an analogous meaning.
The term "C3.8 cycloalkyl" (or "C3-C8 cycloalkyl") means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl). The terms "C3-7 cycloalkyl", "C3-6 cycloalkyl", "C5-7 cycloalkyl" and the like have analogous meanings.
The term "C3-7 azacycloalkyl" (or "C3-C7 azacycloalkyl") means a saturated cyclic ring consisting of one nitrogen and from three to seven carbon atoms (i.e., azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl).
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
The term "Cχ_6 haloalkyl" (which may alternatively be referred to as "Cχ-C6 haloalkyl" or "halogenated Cχ-C6 alkyl") means a Cx to Cβ linear or branched alkyl group as defined above with one or more halogen substituents. The term "Cχ-4 haloalkyl" has an analogous meaning. The term "Cχ_6 fluoroalkyl" has an analogous meaning except that the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH2)θ-4CF3 (i.e., trifluoromethyl, 2,2,2- trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
The term "carbocycle" (and variations thereof such as "carbocyclic" or "carbocyclyl") as used herein refers to (i) a C3 to C8 monocyclic, saturated or unsaturated ring, (ii) a C7 to Cχ2 bicyclic ring system, or (iii) a Cχ to Cχ6 tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated. The carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound. The fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term "fused bicyclic carbocycle" generally refers to a C7 to Cχo bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system. Fused tricyclic carbocycles have an analogous meaning. A subset of the fused bicyclic carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following:
Figure imgf000059_0001
Figure imgf000060_0001
The term "aryl" refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenylenyl.
The term "heterocycle" (and variations thereof such as "heterocyclic" or "heterocyclyl") broadly refers to (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16- membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring, bicyclic ring system, or tricyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocylic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally be oxidized, and any one or more of the nitrogen heteroatoms is optionally quatemized. The heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. When the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
Saturated heterocyclics form a subset of the heterocycles; i.e., the term "saturated heterocyclic" generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated. The term "saturated heterocyclic ring" refers to a 4- to 8-membered saturated monocyclic ring which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazoUdinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl).
Heteroaromatics form another subset of the heterocycles; i.e., the term "heteroaromatic" (alternatively "heteroaryl") generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system. The term "heteroaromatic ring" refers a 5- or 6-membered monocyclic aromatic ring which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples of heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
Representative examples of bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-
Figure imgf000061_0001
alternatively referred to as phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms.
Representative examples of tricyclic heterocycles include phenothiazinyl, carbazolyl, beta-carbolinyl, tetrahydro-beta-carbolinyl, acridinyl, phenazinyl, and phenoxazinyl.
Unless expressly stated to the contrary, an "unsaturated" ring is a partially or fully unsaturated ring. For example, an "unsaturated monocyclic Cβ carbocycle" refers to cyclohexene, cyclohexadiene, and benzene.
Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocycle described as containing from "1 to 4 heteroatoms" means the heterocycle can contain 1, 2, 3 or 4 heteroatoms. When any variable (e.g., Ra, Rb, Re, Rk etc.) occurs more than one time in any constituent or in Formula I or in any other formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
The term "substituted" (e.g., as in "aryl which is optionally substituted with one or more substituents ...") includes mono- and poly-substitution by a named substituent to the extent such single and multiple substitution (including multiple substitution at the same site) is chemically allowed.
The compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.
The N-substituted hydroxypyrimidinone compounds of the present invention may also occur as tautomers thereof. It is understood that the present invention includes all tautomers of the hydroxypyrimidinone compounds of Formula I, both singly and in mixtures.
The compounds of the present invention are useful in the inhibition of HTV integrase, the prevention or treatment of infection by human immunodeficiency virus (HTV) and the prevention, treatment or the delay in the onset of consequent pathological conditions such as ADDS. Preventing ADDS, treating ADDS, delaying the onset of ADDS, or preventing or treating infection by HTV is defined as including, but not limited to, treatment of a wide range of states of HTV infection: ADDS, ARC (ADDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HTV. For example, the compounds of this invention are useful in treating infection by HTV after suspected past exposure to HIV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV integrase, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these purposes.
Compounds representative of the present invention have been tested for inhibition in an assay for the strand transfer activity of integrase. The assay is conducted in accordance with Wolfe, A.L. et al., J. Virol. 1996, 70: 1424-1432, for recombinant integrase, except that: (i) the assay uses preassembled integrase strand transfer complexes; (ii) the strand transfer reaction is performed in the presence of inhibitor in 2.5 mM MgCl2 using 0.5 to 5 nM of a 3' FTTC labeled target DNA substrate as described in WO 02/30930 and (iii) strand transfer products are detected using an alkaline phosphatase conjugated anti-FTTC antibody and a chemiluminescent alkaline phosphatase substrate. Representative compounds (e.g., the compounds set forth in Table 1 below) tested in the integrase assay demonstrated ICso's of about 5 micromolar or less. Further description on conducting the assay using preassembled complexes is found in Hazuda et al., J. Virol. 1997, 71: 7005-7011; Hazuda et al, Drug Design and Discovery 1997, 15: 17-24; and Hazuda et al., Science 2000, 287: 646-650.
Certain compounds representative of the present invention have also been tested in an assay for inhibition of acute HIN infection of T-lymphoid cells, conducted in accordance with Vacca, J.P. et al., Proc. Natl. Acad. Sci. USA 1994, 91: 4096. These compounds demonstrated IC95's of about 20 micromolar or less.
The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. When the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
For the purpose of preventing or treating HIN infection or preventing, treating or delaying the onset of ADDS, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing a therapeutically effective amount of the compound and conventional non-toxic pharmaceutically-acceptabie carriers, adjuvants and vehicles.
The term "administration" and variants thereof (e.g., "administering" a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment. When a compound of the invention or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating EQN infection or AIDS), "administration" and its variants are each understood to include concurrent and sequential provision of the compound or prodrug and other agents. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combining the specified ingredients in the specified amounts. By "pharmaceutically acceptable" is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
The term "subject" (alternatively referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "therapeutically effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated. When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.
The pharmaceutical compositions may be in the form of orally- administrable suspensions or tablets or capsules, nasal sprays, sterile injectible preparations, for example, as sterile injectible aqueous or oleagenous suspensions or suppositories. These compositions can be prepared by methods and contain excipients which are well known in the art. Suitable methods and ingredients are described in Remington's Pharmaceutical Sciences, 18th edition, edited by A. R. Gennaro, Mack Publishing Co., 1990, which is herein incorporated by reference in its entirety.
The compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses. One preferred dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses. Another preferred dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
As noted above, the present invention is also directed to use of the HIV integrase inhibitor compounds of the present invention with one or more agents useful in the treatment of HTV infection or ADDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more of the HTV/ ADDS antivirals, imunomodulators, antiinfectives, or vaccines useful for treating HIN infection or AIDS. Suitable antiviral agents include those listed in the following Table:
ANTIVIRALS
Drug Name Manufacturer Indication (Activity) (Tradename and/or Location) abacavir Glaxo Welcome HTV infection, AIDS, ARC GW 1592 (ZIAGEN®) (nRTI) 1592U89 abacavir + lamivudine + GlaxoSmithKline HTV infection, AIDS, ARC zidovudine (TRIZIVIR®) (nnRTI) acemannan Carrington Labs ARC (Irving, TX) ACH 126443 Achillion Pharm. HTV infections, AIDS, ARC (nucleoside reverse transcriptase inhibitor) acyclovir Burroughs Wellcome HTV infection, AIDS, ARC, in combination with AZT AD-439 Tanox Biosystems HTV infection, AIDS, ARC
AD-519 Tanox Biosystems HIV infection, AIDS, ARC adefovir dipivoxil Gilead HTV infection, AIDS, ARC GS 840 (RTI)
AL-721 Ethigen ARC, PGL, HIV positive,
(Los Angeles, CA) ADDS alpha interferon Glaxo Wellcome Kaposi's sarcoma, HTV, in combination w/Retrovir
AMD3100 AnorMed HIV infection, ADDS,
ARC
(CXCR4 antagonist) amprenavir Glaxo Wellcome HIV infection, ADDS, 141 W94 (AGENERASE®) ARC (PI) GW 141
VX478 (Vertex) ansamycin Adria Laboratories ARC
LM 427 (Dublin, OH) Erbamont (Stamford, CT) antibody which neutralizes Advanced Biotherapy ADDS, ARC pH labile alpha aberrant Concepts (Rockville, Interferon MD)
AR177 Aronex Pharm HTV infection, AIDS, ARC atazanavir (BMS 232632) Bristol-Myers-Squibb HTV infection, ADDS, ARC (ZRTVADA®) (PD beta-fluoro-ddA Nat'l Cancer Institute AIDS-associated diseases
BMS-232623 Bristol-Myers Squibb/ HTV infection, ADDS, (CGP-73547) Novartis ARC (PI)
BMS-234475 Bristol-Myers Squibb/ HTV infection, ADDS, (CGP-61755) Novartis ARC (PI) capravirine Pfizer HTV infection, ADDS, (AG-1549. S-1153) ARC (nnRTI)
CI-1012 Warner-Lambert HTV-1 infection cidofovir Gilead Science CMV retinitis, herpes, papillomavirus curdlan sulfate AJI Pharma USA HIV infection cytomegalovirus immune Medlmmune CMV retinitis globin cytovene Syntex sight threatening CMV ganciclovir peripheral CMV retinitis delavirdine Pharmacia-Upj ohn EHV infection, AIDS, (RESCRIPTOR®) ARC (nnRTI) dextran Sulfate Ueno Fine Chem. Ind. ADDS, ARC, HIV Ltd. (Osaka, Japan) positive asymptomatic ddC Hoffman-La Roche HTV infection, ADDS, ARC
(zalcitabine, (fflVDD®) (nRTI) dideoxycytidine) ddl Bristol-Myers Squibb HTV infection, ADDS, ARC; Dideoxyinosine (VDDEX®) combination with AZT/d4T (nRTI)
DPC 681 & DPC 684 DuPont HTV infection, ADDS, ARC (PI)
DPC 961 & DPC 083 DuPont HIV infection ADDS, ARC (nnRTRI) emvirine Triangle Pharmaceuticals HTV infection, AIDS, ARC (COACTINON®) (non-nucleoside reverse transcriptase inhibitor)
EL10 Elan Corp, PLC HIV infection (Gainesville, GA) efavirenz DuPont HIV infection, AIDS, (DMP 266) (SUSTΓVA®) ARC (nnRTI)
Merck (STOCRIN®) famciclovir Smith Kline herpes zoster, herpes simplex emtricitabine Triangle Pharmaceuticals HTV infection, ADDS, ARC FTC (COVIRACIL®) (nRTI) Emory University emvirine Triangle Pharmaceuticals HIV infection, AIDS, ARC (COACTINON®) (non-nucleoside reverse transcriptase inhibitor)
HBY097 Hoechst Marion Roussel HIV infection, AIDS, ARC (nnRTI) hypericin VIMRx Pharm. HTV infection, ADDS, ARC recombinant human Triton Biosciences ADDS, Kaposi's sarcoma, interferon beta (Almeda, CA) ARC interferon alfa-n3 Interferon Sciences ARC, AIDS indinavir Merck (CRDOVAN®) EON infection, ADDS, ARC, asymptomatic HIV positive, also in combination with
AZT/ddl/ddC
(PI)
ISIS 2922 ISIS Pharmaceuticals CMV retinitis JE2147/AG1776 Agouron HIN infection, ADDS, ARC
(PI)
KNI-272 Nat'l Cancer Institute HlV-assoc. diseases lamivudine, 3TC Glaxo Wellcome HTV infection, AIDS, (EP IR®) ARC; also with AZT (nRTI) lobucavir Bristol-Myers Squibb CMV infection lopinavir (ABT-378) Abbott HTV infection, ADDS, ARC
(PI) lopinavir + ritonavir Abbott (KALETRA®) HTV infection, AIDS, ARC (ABT-378/r) (PI) mozenavir AVID (Camden, NJ) HIN infection, AIDS, ARC (DMP-450) (PI) nelfinavir Agouron HIN infection, ADDS, (VIRACEPT®) ARC (PI) nevirapine Boeheringer HIN infection, ADDS, Ingleheim ARC (nnRTI)
(VIRAMUNE®) novapren Novaferon Labs, Inc. HIN inhibitor (Akron, OH) pentafusaide Trimeris HIN infection, AIDS, ARC T-20 (fusion inhibitor) peptide T Peninsula Labs AIDS octapeptide (Belmont, CA) sequence
PRO 542 Progenies HIN infection, AIDS, ARC (attachment inhibitor) PRO 140 Progenies HTV infection, AIDS, ARC (CCR5 co-receptor inhibitor) trisodium Astra Pharm. Products, CMV retinitis, HIV infection, phosphonoformate Inc other CMV infections
PNU-140690 Pharmacia Upjohn HTV infection, ADDS, ARC (PI) probucol Vyrex HTV infection, ADDS
RBC-CD4 Sheffield Med. Tech HTV infection, AIDS, (Houston TX) ARC ritonavir Abbott HTV infection, AIDS,
(RΓΓONAVIR®) ARC (PI) (ABT-538) saquinavir Hoffmann-LaRoche HTV infection, AIDS, (FORTOVASE®) ARC (PI) stavudine; d4T Bristol-Myers Squibb HTV infection, AIDS, ARC didehydrodeoxy- (ZERΓΓ®) (nRTI) thymidine
T-1249 Trimeris HTV infection, ADDS, ARC (fusion inhibitor)
TAK-779 Takeda HTV infection, ADDS, ARC (injectable CCR5 receptor antagonist) tenofovir Gilead (VIREAD®) HTV infection, A DS, ARC (nRTI) tipranavir (PNU-140690) Boehringer Ingelheim HIV infection, ADDS, ARC ' (PD
TMC-120 & TMC-125 Tibotec HTV infections, AIDS, ARC (nnRTI)
TMC-126 Tibotec HTV infection, ADDS, ARC (PD valaciclovir Glaxo Wellcome genital HSV & CMV infections virazole Viratek/ICN (Costa asymptomatic HTV positive, ribavirin Mesa, CA) LAS, ARC zidovudine; AZT Glaxo Wellcome HTV infection, AIDS, ARC, (RETROVIR®) Kaposi's sarcoma in combination with other therapies (nRTI) PI = protease inhibitor nnRTI = non-nucleoside reverse transcriptase inhibitor nRTI = nucleoside reverse transcriptase inhibitor
A compound of the present invention can also be administered in combination with another HTV integrase inhibitor such as a compound described in WO 99/62513,WO 99/62520, or WO 99/62897. A compound of the present invention can also be administered in combination with a CCR5 receptor antagonist, such as a compound described in WO 99/04794, WO 99/09984, WO 99/38514, WO 00/59497, WO 00/59498, WO 00/59502, WO 00/59503, WO 00/76511,
WO 00/76512, WO 00/76513, WO 00/76514 , WO 00/76792, or WO 00/76793. The compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more HTV/ ADDS antivirals, immunomodulators, antiinfectives, or vaccines useful for treating HIV infection or ADDS disclosed in the Table in WO 01/38332, which is herein incorporated by reference in its entirety.
It will be understood that the scope of combinations of the compounds of this invention with HIV/ ADDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to those listed above or listed in the above-referenced Table in WO 01/38332, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS. The HIN/ADDS antivirals and other agents will typically be employed in these combinations in their conventional dosage ranges and regimens as reported in the art, including the dosages described in the Physicians' Desk Reference, 54th edition, Medical Economics Company, 2000. The dosage ranges for a compound of the invention in these combinations are the same as those set forth above.
Abbreviations used in the instant specification, particularly the Schemes and Examples, include the following:
ADDS = acquired immunodeficiency syndrome ARC = AIDS related complex
BOC or Boc = t-butyloxycarbonyl Bn = benzyl Bz = benzoyl
CBZ or Cbz = carbobenzoxy (alternatively, benzyloxycarbonyl) DMAD = dimethylacetylenedicarboxylate DMAP = dimethylaminopyridine DMF = N,N-dimethylformamide Et = ethyl
EtOAc = ethyl acetate FIA-MS = flow injection analysis mass spectrometry
HIV = human immunodeficiency virus HPLC = high performance liquid chromatography m-CPBA = meta-chloroperbenzoic acid Me = methyl NMP = N-methyl pyrrolidinone
NMR = nuclear magnetic resonance Ph = phenyl
TFA = trifluoroacetic acid THF = tetrahydrofuran The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials and reagents. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above.
The compounds of the present invention can be prepared by coupling suitable substituted alkyl l-alkyl-l,6-dihydro-5-hydroxy-6-oxopyrimidine-4- carboxylates (or carboxylic acids or halides) with the appropriate amines, as represented by Scheme 1. In the scheme, P is H or a protective group, typically an ester (e.g., benzoate or pivalate) that is normally removed under the conditions employed to convert the the methyl ester to the amide. The ester protective group is typically used to purify the 2-substituted-5,6 dihydroxypyrimidine-4-carboxylates after their synthesis when the unprotected product cannot be crystallized from the reaction crude and/or for synthetic reasons. Scheme 1
Figure imgf000072_0001
Compound I
Methods for coupling carboxylic acid derivatives with amines to form carboxamides are well known in the art. Suitable methods are described, for example, in Jerry March, Advanced Organic Chemistry, 3rd edition, John Wiley & Sons, 1985, pp. 370-376. Amines of formula 1-1 can be prepared using the methods described in Richard Larock, Comprehensive Organic Transformations, VCH Publishers Inc, 1989, pp 385-438, or routine variations thereof.
Methyl 1 -alkyl- 1 ,6-dihydro-5-hydroxy-6-oxopyrimidine-4-carboxylates of formula 1-2 can be prepared as shown in Scheme 2, wherein amidoxime 2-1 can be reacted with DMAD in an appropriate solvent and at a suitable temperature to give the intermediate dihydroxypyrimidine 2-2, followed by protection of the 5-hydroxy group in 2-2 with a suitable protecting agent such as benzoate or pivalate to give 2-3, and then alkylation of nitrogen- 1 to afford 1-2. This procedure is described in the literature [Culbertson et al., JHeterocycl. Chem. 1979, 16 (7): 1423-24].
Dihydroxypyrimidine 2-2 can be isolated or directly protected to give 2-3. The alkyl group can be introduced on NΪ by reaction of 2-3 with an alkylating agent in the presence of an inorganic base (e.g., cesium carbonate). If a mixture of N- and O- alkylated derivatives results, the desired N-alkylated product 1-2 can be separated by flash chromatography. Scheme 2 is exemplified in Example 1.
Scheme 2
protection
P* = protective group
Figure imgf000073_0001
Figure imgf000073_0002
Methyl 1 -alkyl- 1 ,6-dihydro-5 -hydroxy-6-oxopyrimidine-4-carboxylates of formula 1-2 can be prepared as shown in Scheme 3, wherein an N-alkylamidoxime 3-1 can be reacted with dimethylacetylenedicarboxylate to give the unprotected 1-2 (P=H). The unprotected compound can be isolated as such or it can be converted to 1-2 by reaction with a suitable protecting group. Scheme 3 is exemplified in Example 2.
Scheme 3
protective group
Figure imgf000073_0003
Amidoximes 2-1 and 3-1 are prepared from the corresponding nitriles by chemistry described herein (see Example 1, Step 1 and Example 2, Step 2). Nitriles can be prepared from carboxylic acids by various procedures known in the art, including, for example, conversion to carboxamides by the procedure of of Pozdnev (Tetrahedron Lett. 1989, 30: 5193) (see also, Example 6, Step 2), and dehydration of the amide by the procedure of Waldmann (Tetrahedron 1994, 50: 11865) (see also, Example 6, Step 3).
Compounds of the present invention of general formula 3-3 or 3-6 can be prepared in accordance with Scheme 3, Parts 1 and 2, wherein haloderivative 3-1 or 3-4 can be synthesized by the bromination or chlorination of a suitable substrate affording a -CH2Br, -CH2CI, -CHBr-, or -CHCl- group, followed by displacement of the halogen with a nucleophile ("Nu") such as an amine, thiol, or alcoholate to obtain the nucleophile-substituted methyl ester intermediate 3-2 or 3-5, which need not be isolated. Elaboration of the methyl ester functionality into the carboxamide will afford the final product 3-3 or 3-6. Scheme 3 is exemplified in Example 5.
Scheme 3 - Part 1
Figure imgf000074_0001
Scheme 3 - Part 2
R4
Figure imgf000075_0001
Scheme 4 depicts the preparation of compounds of the invention that contain an alkylated aliphatic amine in the substituent at the 2 position. Nitrogen alkylation is achieved via a reductive amination or alkylation. The nitrogen alkylation can be performed before formation of the amide (via 4-3) or after formation of the amide (via 4-2) depending on the substrate, with suitable deprotection as necessary. Scheme 4 is exemplified in Examples 6 to 8 below.
Scheme 4
Figure imgf000076_0001
Compounds of the present invention with general formula 5-3 containing an acylated nitrogen or sulfonylated nitrogen in the substituent at the 2- position, can be prepared following Scheme 5. Acylation or sulfonylation of the nitrogen in the 2-substituent of the pyrimidine core provides compound 5-2, which can be elaborated into the final amide 5-3 by reaction of a suitable amine in a polar solvent. Scheme 5 is exemplified in Examples 9 to 12 below. Scheme 5
Figure imgf000077_0001
The preparation of compounds that feature a carboxamide at the 2 position of the pyrimidine core can be achieved as shown in Scheme 6, wherein a starting material bearing a 2-ethyl- and a 4-methylcarboxylate functionality (6-1) is employed. This strategy will allow the regioselective elaboration of the 4-methyl ester into the carboxamide by reaction with a suitable amine. The other ester bond in the 2 position can then be further elaborated. Scheme 6 is exemplified in Example 13 below. Scheme 6
Figure imgf000078_0001
Compounds of the present invention of formula 7-2 can be prepared by reaction of aldehydes or ketones 7-1 with suitable amines under reductive alkylation conditions, as shown in Scheme 7. Scheme 7 is exemplifed in Example 14 below.
Scheme 7
Figure imgf000079_0001
Θ = absent, alkyl, or aryl
P = H or protective group
Rw = H, alkyl, or aryl
Rx = H, alkyl, or aryl
Ry = alkyl or aryl, or Rx and Ry together with the N to which they are attached form an N-containing heterocycle
In the processes for preparing compounds of the present invention set forth in the foregoing schemes and exemplified in the examples below, functional groups in various moieties and substituents may be sensitive or reactive under the reaction conditions employed and/or in the presence of the reagents employed. Such sensitivity/reactivity can interfere with the progress of the desired reaction to reduce the yield of the desired product, or possibly even preclude its formation. Accordingly, it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. Protection can be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 and in T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups can be removed at a convenient subsequent stage using methods known in the art. For example, in preparing the compounds of the invention it is sometimes necessary to protect one or more amino groups (e.g., amino groups present in substituents at the 2-position of the pyrimidinone ring) with, for example, a Boc or Cbz group or to protect hydroxy (e.g., the 5-hydroxy group on the pyrimidinone ring) with, for example, a benzoyl or benzyl group. The Boc group can be removed by acid treatment (e.g., TFA) either before or after formation of the final amide at C-6 of the pyrimidinone nucleus. The Cbz and benzyl groups are typically removed by catalytic hydrogenation or under strong acid conditions, either prior to or following formation of the final amide. The benzoyl group can be removed concurrently with the formation of the final amide. Examples 6 and 12 below illustrate the use of a Boc protective group and of Boc, benzoyl and benzyl protective groups in the preparation of compounds of the invention.
Scheme 8
Figure imgf000080_0001
The preparation of compounds that feature a bis oxalamide at the 2 position of the pyrimidine core can be achieved as shown in Scheme 8, wherein a starting material bearing a basic nitrogen at the 2- position of the pyrimidine carboxyamide (8-1) is employed. This strategy will allow to obtain the final compound (8-3) following two possible procedures: by simple coupling of monoamide oxalic acid to the amine (8-1) or by the acylation of the basic nitrogen of (8-1) with dimethyl oxalate to give the ester intermediate (8-2) that is converted to the final compound by heating in presence of amine in appropriate solvent. Scheme 8 is exemplified in Examples 17, 18, and 20 below.
The following examples serve only to illustrate the invention and its practice. The examples are not to be construed as limitations on the scope or spirit of the invention.
EXAMPLE 1 Methyl 5-(benzoyloxy)-2-[l-(tert-butoxycarbonyl)pyrrolidin-2-yl]-l-methyl-6-oxo- l,6-dihydropyrimidine-4-carboxylate
Figure imgf000081_0001
Step 1: Tert-butyl-2-[amino(hydroxyimino)methyl]pyrrolidine-l-carboxylate
Figure imgf000081_0002
A solution of hydroxylamine hydrochloride (1.0 eq.) in MeOH was added at 0 °C to a solution of KOH (1.0 eq.) in MeOH. The resulting reaction mixture was filtered and added to a solution of tert-butyl-2-cyanopyrrolidine-l-carboxylate (1.0 eq.) in methanol and stirred at 40 °C for 2 h.The solvent was removed in vacuo and the residue treated with water; the solid was filtered and washed with a mixture of Et2O: Petroleum Ether 1:1 to afford the title compound as a white solid as a mixture of rotamers by NMR.
1H-NMR (DMSO-dβ, 400 MHz) 6 8.92 (s, 1 H), 5.35 (s,l H), 5.15 (s, 1 H), 4.25 (bs, 0.5 H), 4.10 (s, 0.5 H), 3.40-3.30 (m, 1 H), 2.10-1-70 (m, 4 H), 1.40 (s, 4.5 H),1.35 (s, 4.5 H), one signal is obscured by water.
Step 2: Methyl 5-(benzoyloxy)-2-[l-(tert-butoxycarbonyl)pyrrolidin-2-yl]-6- hydroxypyrimidine-4-carboxylate
Figure imgf000082_0001
A solution of the product of Step 1 (1.0 eq.) and dimethyl acetylenedicarboxylate (1.05 eq.) in CHC13 was refluxed for 3 h. The reaction mixture was concentrated and the crude product was used directly in the next step without further purification. The crude product was dissolved in xylene and refluxed for 24 h. The solvent was removed in vacuo and the crude was dissolved in pyridine. Benzoic anhydride was added (1.5 eq.). The reaction mixture was stirred at room temperature until the starting material was consumed as determined by MS analysis. The reaction mixture was concentrated, and the resulting oil was diluted with ethyl acetate and washed with IN HCl solution, saturated NaHCO3 solution, saturated NaCl solution. The crude oil obtained after organic solvent evaporation was purified by flash chromatography to obtain the title compound as a yellow solid.
1H-NMR (CDC13, 400 MHz) 5 12.08 (bs, 1 H), 8.18 (d, J = 7.6 Hz, 2 H), 7.64 (t, / = 7.4 Hz, 1 H), 7.50 (t, /= 7.6 Hz, 2 H), 4.80-4.60 (m, 1 H), 3.82 (s, 3 H), 3.60-3.50 (m, 1 H), 3.40-3.20 (m, 1 H), 2.50-2.10 (m, 2 H). 2.00-1.70 (m, 2 H), 1.50 (s, 9 H). MS m z 444 (M+H)+.
Step 3: Methyl 5-(benzoyloxy)-2-[ 1 -(tert-butoxycarbonyl)pyrrolidin-2-yl]- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate To a stirred solution of the product of Step 2 (1.0 eq.) in THF, Cs2CO3 was added (1.2 eq.) followed by the addition of CH3I (2.0 eq.). The reaction was stirred at 40°C until the starting material was consumed as determined by MS analysis. The reaction was concentrated and the residue taken up with EtOAc, washed with 1 N HCl, saturated solution of NaHCO3 and brine. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. Reaction crude showed 3.4:1 ratio N (desired product) versus O methylation. The title product was purified by flash column chromatography (EtOAc: Petroleum Ether = 1:1) and obtained as a 1:1 mixture of rotamers by NMR.
1H-NMR (CDCI3, 400 MHz) 5 8.12 (d, J = 7 Hz, 2 H), 7.58 (t, / = 7 Hz, 1 H), 7.46 (t, J = 7 Hz, 2 H), 4.97-4.95 (m, 0.5 H), 4.87-4.83 (m, 0.5 H), 3.74 (s, 1.5 H), 3.72 (s, 1.5 H), 3.63 (s, 1.5 H), 3.59 (s, 1.5 H), 3.56-3.42 (m,l H), 2.40-2.25 (m, 5 H), 1.41 (s, 4.5 H), 1.25 (s, 4.5 H). MS m/z 458 (M+H)+.
Also obtained was the O-methylated compound of formula:
Figure imgf000083_0001
as a mixture of rotamers by NMR. 1H-NMR (CDC13, 400 MHz) δ 8.21 (d, J = 7.6 Hz, 2H), 7.72 (t, /= 7.6 Hz, IH), 7.56 (t, J = 7.6 Hz, 2H), 5.10-5.05 (m, 0.3H), 5.00-4.95 (m, 0.7H), 4.01 (s, 3H), 3.87 (s, 3H), 3.80-3.60 (m, 2H), 2.50-2.40 (m, IH), 2.15-2.00 (m, 2H), 2.00-1.85 (m, IH), 1.61 (s, 2.7H), 1.40 (s, 6.3H). MS m/z 458 (M+H)+.
EXAMPLE 2 Benzyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-l-methyl-6-oxo-l,6- dihydropyrimidin-2-yl]indoline-l-carboxylate
Figure imgf000083_0002
Step 1: Benzyl 2-[[hydroxy(methyl)amino](imino)methyl]indoline-l- carboxylate
Figure imgf000084_0001
l-Benzyloxycarbonyl-2-cyanoindoline was added to a solution of triethylamine (2 eq.) and MeNHOH.HCl (2 eq.) in EtOH. After stirring overnight the reaction mixture was evaporated, dissolved in EtOAc, washed with water, dried over Na2SO4 and evaporated to afford the title compound.
1H NMR (DMSO-d6, 340K, 300 MHz) δ 7.68 (d, J= 8.0 Hz, 1 H), 7.41-7.30 (m, 5 H), 7.19 (t, J= 7.5 Hz, 2 H), 6.99 (t, J= 7.6 Hz, 1 H), 5.53 (dd, J= 5.5, 10.9 Hz, 1 H), 5.22 (s, 2 H), 3.62 (dd, /= 11.0, 16.6 Hz, 1 H), 3.33 (s, 3 H), 3.01 (dd, /= 5.5 Hz, 16.6 Hz, 1 H). MS m/z 326 (M+H)+.
Step 2: Benzyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-l-methyl-6-oxo-l ,6- dihydropyrimidi-2-yl]indoline- 1 -carboxylate
The product of Step 1 was dissolved in CHC13 and dimethylacetylenedicarboxylate was added dropwise (1.2 eq.) at room temperature. After 4 h the mixture was evaporated, and the residue was dissolved in xylene and stirred at 160 °C for 2 days. The solvent was then evaporated, and the residue was dissolved in pyridine, after which (PhCO) O (2 eq.) was added and the reaction mixture was stirred for 2 days. After evaporation, the resulting crude oil was diluted with EtOAc, washed with HCl IN, dried over Na2SO4 and evaporated. The product was purified by flash chromatography on silica gel (EtOAc/ petroleum ether, 1 :4) to afford the title product. 1H NMR (DMSO-d6, 340 K, 400 MHz) δ 8.08 (d, J = 7.3 Hz, 2 H), 7.77 (t, J = 7.4 Hz, 2 H), 7.62 (t, J = 7.6 Hz, 2 H), 7.31-7.20 (m, 7 H), 7.00 (t, J = 13 Hz, IH), 5.83 (dd, /= 4.6 Hz, 11.0 Hz, 1 H), 5.23-5.13 (m, 2 H), 3.76 (dd, J= 11.1,16.6 Hz, 1 H), 3.65 (s, 3 H), 3.56 (s, 3 H), 3.27 (dd, J= 4.4 Hz, 16.6 Hz, 1 H). MS m/z 540 (M+H)+. EXAMPLE 3 N-(4-Fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylphenyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000085_0001
To a stirred solution of methyl 5-[(2,2-dimethylpropanoyl)oxy]-l- methyl-2-(4-methylphenyl)-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate (prepared from 4-methylbenzonitrile by procedures similar to those set forth in Examples 2 or 3) in DMF 3 equivalents of 4-fluorobenzylamine were added and mixture was stirred at 90 °C for 2 h. The title product precipitated from the cooled reaction mixture after the addition of 2 Ν HCl, and was collected by filtration and washed with diethyl ether. 1H ΝMR (DMSO-d6, 400 MHz) δ 12.45 (s, 1 H), 9.31 (bt, J= 6.0 Hz, 1 H), 7.62 (m, 2 H), 7.40-7.32 (m, 4 H), 7.14 (t, J= 8.8 Hz, 2 H), 4.45 (d, J= 6.0 Hz, 2 H), 3.35 (s, 3 H), 2.48 (s, 3 H). MS m z 368 (M+ H)+.
EXAMPLE 4 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxarnide
Figure imgf000085_0002
Step 1: 4,5-Dihydroxy-6-(methoxycarbonyl)pyrimidine-2-carboxylic acid
Figure imgf000086_0001
2-Ethoxycarbonyl-4,5-Dihydroxy-6-(methoxycarbonyl)pyrimidine [obtained from ethyl amino(hydroxyimino)ethanoate (Branco, P.S. et al, Tetrahedron 1992, 40: 6335) by procedures similar to those set forth in Example 1] was suspended in dioxane/THF 2: 1 and IN NaOH was added. After 20 min the mixture was acidified with IN HCl solution, concentrated and filtered to give the title product. 1H-NMR (DMSO-d, 400 MHz) δ 13.10 (bs, 1 H), 11.11 (bs, 1 H), 3.82 (s, 3 H). MS m/z 213 (M-H)".
Step 2: Methyl 5,6-dihydroxypyrimidine-4-carboxylate
Figure imgf000086_0002
A solution of the product of Step 1 in HCl IN solution was stirred for 6 hours at 90°C. Reaction mixture was filtered and the solid washed with HCl IN. Evaporation of the filtrate afforded the title product as a solid. 1H NMR (DMSO-d6, 300 K, 400 MHz) δ 7.75 (s, 1 H), 3.82 (s, 3 H). 13C NMR (DMSO-d6, 300 K, 400 MHz) δ 165.66, 158.20, 147.14, 139.00, 127.85, 52.16.
Step 3: Methyl 5-[(2,2-dimethylpropanoyl)oxy]-6-hydroxypyrimidine-4- carboxylate
Figure imgf000086_0003
Pivaloyl chloride 1.1 eq. was added to a solution of the product of Step 2 in pyridine, and the mixture was heated to 40°C for 10 minutes. HPLC showed the complete conversion of starting material. The reaction mixture was concentrated, the resulting oil was diluted with ethyl acetate and washed with 1 N HCl solution. The title product was obtained as a brown solid after evaporation of the organic phase and trituration with diethyl ether.
1H NMR (DMSO-d6, 400 MHz) δ 13.35 (s,l H), 8.18 (s,l H), 3.85 (s, 3 H),1.28 (s, 9 H).
Step 4: Methyl 5-[(2,2-dimethylpropanoyl)oxy]-l-methyl-6-oxo-l, 6- dihydropyrimidine-4-carboxylate
Figure imgf000087_0001
Dimethyl sulfate (1.5 eq.) was added to a solution of the product of
Step 3 (1 eq.) in THF containing cesium carbonate (1.5 eq.). The reaction was carried out at 50°C for thirty minutes. The solvent was evaporated and the resulting oil was dissolved in ethyl acetate, washed with IN HCl solution. The crude title compound was recovered as yellow solid and used in the next step without purification.
1H NMR (DMSO-d6, 400 MHz) δ 8.43 (s,l H), 3.81 (s, 3 H), 3.45 (s, 3 H),1.30 (s, 9
H).
Step 5: N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-
4-carboxamide 4-Fluorobenzylamine (3 eq.) was added to a solution of the crude product of Step 4 in DMF and the reaction mixture was heated to 90°C for one hour. The title compound was obtained by RP-HPLC (C18, eluting with water and acetonitrile containing 0.1 % TFA).
1H ΝMR (DMSO-d6, 400 MHz) δ 12.5 (s,l H), 9.54 (t, J = 6.2 Hz, 1 H), 8.05 (s,l H),
7.36 (dd, /= 6.2, 8.4 Hz, 2 H), 7.14 (t, J= 8.4 Hz, 2 H), 4.45 (d, / = 6.2 Hz, 2 H), 3.44
(s,3 H). MS m/z 276 (M-H)".
EXAMPLE 5 N-(4-Fluorobenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4-ylmethyl)phenyl]-6-oxo- 1 ,6-dihydropyrimidine-4-carboxarrιide
Figure imgf000088_0001
Step 1: Methyl 2-[4-(bromomethyl)phenyl]-5-[(2,2-dimethylpropanoyl)oxy]-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
Figure imgf000088_0002
To a vigorously boiling solution of methyl 5-[(2,2- dimethylpropanoyl)oxy]-l-methyl-2-(4-methylphenyl)-6-oxo-l,6-dihydropyrimidine- 4-carboxylate in carbon tetrachloride N-bromosuccinimide (1 eq.) and benzoyl peroxide (0.05 eq.) were added as dry powders. After 4 hr the mixture was allowed to reach room temperature and the precipitated succinimide was filtered off. The filtrate was evaporated under vacuum and the solid residue was used as such.
1H NMR (DMSO-d6, 400 MHz) δ 7.68-7.57 (m, 4 H), 4.77 (s, 2 H), 3.80 (s, 3 H), 3.27 (s, 3 H), 1.30 (s, 9 H). Step 2: N-(4-Fluorobenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4- ylmethyl)phenyl]-6-oxo-l,6-dihydropyrimidine-4-carboxamide A THF solution of methyl 2-[4-(bromomethyl)ρhenyl]-5-[(2,2- dimethylpropanoyl)oxy] - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate was reacted with 4 eq. of morpholine for 0.5 h at room temperature. After evaporation of volatiles, the oily residue was taken into DMF and treated with 3 eq. of 4- fluorobenzylamine at 90°C for 2 h. Title product was isolated as its trifluoroacetate salt by RP-HPLC (C18,water/acetonitrile with 1% of TFA as eluant). 1H-NMR (DMSO-d6,400 MHz) δ 12.45 (s, 1 H), 10 (bs, 1 H), 9.31 (bt, 1 H), 7.74 (m, 2 H), 7.62 (m, 2 H), 7.35 (m, 2 H), 7.14 (t, 7=8.8 Hz, 2 H), 4.54-4.38 (m, 4 H), 4.1- 3.9 (m, 2 H), 3.9-3.7 (m, 2 H), 3.68-3.51 (m, 2 H), 3.31 (s, 3 H), 3.2-3.1 (m, 2 H). MS: m/z 453 (M+Hf.
EXAMPLE 6 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000089_0001
Step 1: 4-(tert-Butoxycarbonyl)morpholine-3-carboxylic acid
Figure imgf000089_0002
To a vigorously stirred solution of 3-morpholinecarboxylic acid and triethylamine (1.11 eq.) in MeOH (1.4 M) at 50 °C was added di-t-butyl dicarbonate (2 eq.). Stirring was continued at 50 °C for 5 min and at room temperature overnight. The reaction mixture was then concentrated to obtain an oily residue and suspended between EtOAc (500 ml) and saturated NaHCO3 (500 ml). The organic layer was extracted with saturated NaHCO3 (2x250 ml) and H2O (250 ml). Combined aqueous layers were brought to pH = 2.0 with 3 M HCl and immediately extracted with EtOAc (2x500 ml). The combined organic layers were washed with dilute HCl, dried, filtered and evaporated to give the title compound as a pale yellow oil, a 1 : 1 mixture of rotamers by NMR. δ 1H NMR (400 MHz, DMSO-d6) 12.93 (bs, 1 H), 4.32 (s, 0.5 H), 4.29 (s, 0.5 H), 4.2- 4.1 (m, 1 H), 3.83-3.74 (m, 1 H), 3.58-3.52 (m, 2 H), 3.36-3.31 (m, 1 H), 3.16 (t, J=11.4 Hz, 0.5 H), 3.00 (t, J=11.4 Hz, 0.5 H), 1.40 (s, 4.5 H), 1.36 (s, 4.5 H). MS m/z 232 (M+H)+.
Step 2: tert-Butyl 3-(aminocarbonyl)morpholine-4-carboxylate
Figure imgf000090_0001
To a stirred solution of the compound prepared in Step 1 (1 eq.), pyridine (0.6 eq.) and di-t-butyl dicarbonate (1.3 eq.) in dioxane (0.6 M), NHUHCO3
(1.26 eq.) was added and the mixture was stirred at room temperature for 20 hours.
Mixture was concentrated, taken up in EtOAc and washed with water and brine.
Organics were dried over Na2SO4 and evaporated giving the title product as an oil which crystallized at room temperature. 1H-NMR (DMSO-d6, 300 MHz) δ 7.35 (bs, 1 H), 7.06 (bs, 1 H), 4.15 (bs, 2 H), 3.76
(bs, 1 H), 3.57-3.51 (m, 2 H), 3.28 (m, 1 H), 3.18 (m, 1 H), 1.36 (s, 9 H).
MS rn/z 231 (M+H)+.
Step 3: tert-Butyl 3-cyanomorpholine-4-carboxylate
Figure imgf000090_0002
A solution of the product of Step 2 (1 eq.) and triethylamine (2.1 eq.) in CH2C12 (0.1 M) was cooled to 0 °C and trifluoroacetic anhydride (1.1 eq.) added dropwise under nitrogen. Stirring was continued 3.5 hours more at room temperature and volatiles removed in vacuo. Residues taken in EtOAc were washed with water, brine and dried over Na2SO4. Evaporation gave the title compound as a brown solid. 1H NMR (DMSO~d6, 400 MHz) 6 5.04 (d, J = 2.7 Hz, 1 H), 3.96 (d, /=12.2 Hz, 1 H), 3.86 (dd, /= 11.5, 2.6 Hz, 1 H), 3.69 (d, J=12.4 Hz, 1 H), 3.56 (dd, J= 12.2, 3.2 Hz, 1 H), 3.40 (td, J= 11.9, 2.89 Hz, 1 H), 2.97 (m, 1 H), 1.43 (s, 9 H). MS m/z 213 (M+H)+.
Step 4: tert-Butyl 3-[(Z)-amino(hydroxyimino)methyl]mo holine-4- carboxylate
Figure imgf000091_0001
A solution of of the product of Step 3 (1 eq.), hydroxylamine hydrochloride (1.4 eq.) and triethylamine (1.7 eq.) in EtOH (0.5 M) was refluxed under nitrogen for 5 hours. Mixture was concentrated and residues taken up in EtOAc and washed with water and brine. Combined organics were dried over Na2SO4 and evaporated giving the title compound as a yellow solid.
1H NMR (DMSO-de, 400 MHz) δ 9.16 (bs, 1 H), 5.32 (bs, 2 H), 4.30 (bs, 1 H), 4.08 (d, 7=11.6 Hz, 1 H), 3.75 (d, 7 = 6.8 Hz, 1 H), 3.50-3.33 (m, 4 H), 1.38 (s, 9 H).
MS: m z 246 (M+H)+.
Step 5: Dimethyl-2-({ 2-amino-2-[4-(tert-butoxycaι-bonyl)morpholin-3- yl]ethenyl } oxy)but-2-enedioate
Figure imgf000092_0001
A solution of the product of Step 4 (1 eq.) and dimethylacetylenedicarboxylate (1.2 eq.) in CHC13 was refluxed for 1 hour under nitrogen and solution concentrated. Residue was purified by flash chromatography on silica gel, eluents petroleum ether/EtOAc 7:3 -> 1:1, to give the desired product as a mixture of two isomers E/Z (76:14).
1H NMR (DMSO-d6, 400 MHz, 300K) δ 6.60 and 6.20 (2 bs, 2 H), 5.58 and 5.41 (2s, 1 H), 4.36 (bs, 1 H), 4.04 (bs, 1 H), 3.8 (bs, 1 H), 3.76 and 3.72 (2 s, 3 H), 3.63 and 3.58 (2 s, 3 H), 3.53 (td, 7= 13.6, 3.7 Hz, 1 H), 3.44 (t, 7= 10.4 Hz, 1 H), 3.31 (m, 2 H), (s, 9 H). MS m/z 388 (M+H)+.
Step 6: tert-Butyl-3-[4,5-dihydroxy-6-(methoxycarbonyl)pyrimidin-2- yl]morpholine-4-carboxylate
Figure imgf000092_0002
The adducts of Step 5 were refluxed in xylenes for 24 hours. Then the reaction was cooled down and concentrated in vacuo. Ethyl ether was added until precipitation of a solid that was filtered, washed with ethyl ether and dried to give the title pyrimidine as an orange solid. 1H NMR (DMSO-dβ, 400 MHz, 340 K) δ 4.62 (s, IH), 4.15 (d, J =12 Hz, IH), 3.84 (bs, IH), 3.82 (s, 3H), 3.70 (dd, J = 12.3, 4 Hz, IH), 3.61 (dd, J= 12.2, 3.8 Hz, IH), 3.56 (t, J= 13 Hz, IH), 3.43 (td, J= 11.5, 3.4 Hz, IH), 1.35 (s, 9H). MS m/z 356 (M + H)+.
Step 7: tert-Butyl-3-[5-(benzoyloxy)-4-hydroxy-6-
(methoxycarbonyl)pyrimidin-2-yl]moφholine-4-carboxylate
Figure imgf000093_0001
The pyrimidine from Step 6 in dry pyridine (0.2 M), was treated with benzoic anhydride (2 eq.) overnight at room temperature. The mixture was evaporated, taken in EtOAc and washed with HCl IN, NaHCO3 and brine. Organics were dried over Na2SO4, and filtered, evaporated and purified by flash chromatography on silica gel, eluents EtO Ac/Petroleum Ether: 7/3.
1H NMR (DMSO-d6, 300 MHz, 340K) δ 13.3 (bs, 1 H), 8.07 (d, 7 = 7.5 Hz, 2 H), 7.76 (t, 7 = 7.5 Hz, 1 H), 7.61 (t, 7 = 7.5 Hz, 2 H), 4.73 (s, 1 H), 4.22 (d, 7 = 12.4 Hz, 1 H), 3.86 (d, 7= 11.0 Hz, IH), 3.78 (dd, 7= 12.4, 3.9 Hz, 1 H), 3.73 (s, 3 H), 3.58 (t, 7= 13.9 Hz, 2 H), 3.47 (td, J = 10.7, 3.6, 1 H), 1.36 (s, 9 H). MS /z 600 (M + H)+.
Step 8: Alkylated derivatives 8 A and 8B.
Figure imgf000093_0002
The pyrimidine product of Step 7 in dry THF (0.6 M) was treated with cesium carbonate (1.5 eq.) and dimethyl sulfate (1.5 eq.) at 50 °C for 1 hour. Solvent was removed in vacuo and residue taken in EtOAc, washed with HCl IN and brine. Organics were dried over Na2SO4, filtered and evaporated to obtain a crude which was purified by flash chromatography on silica gel, (eluents EtO Ac/Petroleum Ether: 3/7) to separate the two compounds 8A and 8B (ratio 8A 8B 1/0.85). An alternative route was also employed as follows: The pyrimidine product of Step 7 was added to a suspension of LiH (1.1 eq) in dioxane at room temperature. The mixture was aged 45 min at 38 °C and was then cooled to room temperature. Dimethylsulfate (1.3 eq) was added and the mixture was warmed to 38 °C (4h) and 56 °C (4h). The reaction mixture was cooled to 16 °C and glacial acetic acid (0.1 eq) was added, followed by water and EtOAc. The aqueous layer was separated and extracted with EtOAc. The combined organic layer was dried (Na2SO4) and concentrated to an oil, which was chromatographed through silica gel, eluting with 50-55% EtOAc/hexanes to separated compound 8A from 8B. The fractions were evaporated to a foamy solid. This solid was dissolved in ether and re-evaporated to foamy solid that could be scraped out easily. This solid was dried in a vacuum oven overnight at 40 °C to afford 8B as a pale yellow solid. The ratio of 8A/8B is variable with this route, from 1:4 to 1:12.
tert-Butyl-3-[5-(benzoyloxy)-4-methoxy-6-(methoxycarbonyl)pyrimidin-2-yl] morpholine-4-carboxylate (8A).
1H NMR (300 MHz, DMSO-d6+TFA, 330K) δ 8.10 (d, J=7.9 Hz, 2 H), 7.77 (t, J=7.3 Hz, 1 H), 7.61 (t, J=7.4 Hz, 2 H), 4.94 (bs, IH), 4.50 (d, J=11.6 Hz, IH), 4.0 (s, 3H), 3.85-3.81 (m, 2 H), 3.76 (s, 3 H), 3.66 (d, J=10.4 Hz, IH), 3.49-3.45 (m, 2 H), 1.35 (bs, 9 H). MS m/z 474 (M + H)+.
tert-Butyl-3-[5-(benzoyloxy)-4-(methoxycarbonyl)-l-methyl-6-oxo-l,6- dihydropyrimidin-2-yl]morpholine-4-carboxylate (8B).
1H NMR (DMSO-d6, 400 MHz, 330K,) δ 8.09 (d, 7 = 7.3 Hz, 2 H), 7.77 (t, 7 = 7.5 Hz, 1 H), 7.62 (t, 7 = 7.8 Hz, 2 H), 5.08 (d, 7 = 3.4 Hz, 1 H), 4.21 (d, 7 = 12.3 Hz, 1 H), 3.95-3.85 (m, 3 H), 3.76 (s, 3 H), 3.58 (s, 3 H), 3.55-3.50 (m, 2 H), 1.34 (s, 9 H). MS m/z 474 (M + H)+.
Step 9: tert-Butyl-3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidin-2-yl]-morpholine-4-carboxylate
Figure imgf000095_0001
The methyl ester 8B in dry MeOH was treated with 4- fluorobenzylamine (2.5 eq.) at reflux for 2 hours. Solvent was removed in vacuo and residue triturated with Et2O to obtain the title product.
1H NMR (300 MHz, DMSO-d6, 320K) δ 11.95 (bs, 1 H), 8.32 (t, 7= 6.0 Hz, 1 H), 7.39-7.35 (m, 2 H), 7.19-7.13 (m, 2 H), 4.96 (dd, 7= 4.25, 2.42 Hz, 1 H), 4.62 (dd, J= 14.9, 6.95 Hz, IH), 4.49 (dd, J=14.9, 5.83 Hz, IH), 4.16 (dd, J= 12.2, 2.0 Hz, IH), 3.87-3.79 (m, 2H), 3.70-3.64 (m, IH), 3.55-3.45 (m, 5H), 1.23 (s, 9H). MS /z 463 (M+H) +.
Step 10: N-(4-fluorobenζyl)-5-hydroxy-l-methyl-2-morpholin-3-yl-6-oxo-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000095_0002
The compound from Step 9 was treated with a mixture of dichloromethane/TFA (2/1) for 1 hour at room temperature. Organics were removed in vacuo to give the title compound as a solid.
1H NMR (300 MHz, DMSO-d6, 300 K) δ 9.45 (bs, 1 H), 7.39-7.36 (m, 2 H), 7.19- 7.15 (m, 2 H), 4.93 (d, 7= 9.2 Hz, 1 H), 4.64 (dd, 7= 15.4, 6.7 Hz, 1 H), 4.55 (dd, 7=15.4, 6.2 Hz, 1 H), 4.35 (d, 7= 12.8 Hz, 1 H), 4.08 (d, 7= 12.6 Hz, 1 H), 3.77 (t, 7 = 12.4 Hz, 1 H), 3.55 (s, 3 H), 3.55-3.46 (m, 2 H), 3.40-3.34 (m, 1 H). MS rn z 363 (M + H)+. Step 11: N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-
6-oxo-l,6-dihydropyrimidine-4-carboxamide
The compound from Step 10 was dissolved in MeOH and treated with triethylamine (1 eq.), sodium acetate (1.6 eq.), formaldehyde 37% w/w aq. soln. (3 eq.), and sodium cyanoborohydride (1.43 eq.). The mixture was left stirring at room temperature for 1 hour. The reaction mixture was concentrated and the title compound was obtained by RP-HPLC purification (C18, eluting with water and acetonitrile containing 0.1 % TFA), as its trifluoroacetate salt.
1H NMR (400 MHz, DMSO-d6+TFA) δ 12.33 (bs, 1 H), 10.05 (bs, 1 H), 9.48 (t, 7 = 6.4 Hz, 1 H), 7.35-7.33 (m, 2 H), 7.15-7.12 (m, 2 H), 4.98 (d, 7= 8.8 Hz, 1 H), 4.57 (d, 7= 6.4 Hz, 2 H), 4.36 (d, 7= 12.7 Hz, 1 H), 4.13 (d, 7= 12.4 Hz, 1 H), 3.77 (t, 7 = 12.5 Hz, 1 H), 3.69 (d, 7= 12.8 Hz, 1 H), 3.54 (s, 3 H), 3.48-3.41 (m, 2 H), 2.83 (s, 3 H).
MS m z 377 (M + H) +.
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylrnorpholin-3-yl)- 6-oxo- l,6-dihydropyrimidine-4-carboxamide has been resolved into its enantiomers by semi preparative chiral HPLC using the following conditions:
Solvents: a mixture of 1 : 1 0.2%TFA in Hexanes : EtOH Column: chiralpak AS column, 250 x 46 mm at l.Oml/min, collected by absorbtion at 260 nM The first eluate is the (+) enatiomer (MeOH, c = 0.24, 25C): [α]D=(+) 55.42. The second eluate is the (-) enantiomer (MeOH, c=0.215, 25C) [α]D= (-) 51.63.
EXAMPLE 7
2-(4-ethyl- 1 -methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000096_0001
Step 1: Methyl l-methyl-2-(4-tert-butoxycarbonylpiperazin-2-yl))-5- benzoyloxy-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
Figure imgf000097_0001
Methyl l-methyl-2-(4-tert-butoxycarbonyl-l-benzyloxycarbonylpiperazin-2-yl))-5- benzoyloxy-6-oxo-l,6-dihydropyrimidine-4-carboxylate (prepared from 1- [(benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid (Bigge et al, Tetrahedron Lett. 1989, 30: 5193) by procedures similar to those set forth in Examples 2 or 3 in combination with a deprotection step) was dissolved in MeOH and hydrogenated at atm pressure on 10% Pd/C for 1 hour. The crude title product was obtained after filtration and evaporation.
Step 2: N-(4-fluorobenzyl) 1 -methyl-2-(4-tert-butoxycarbonylpiperazin-2-yl))-
5-hydroxy-6-oxo-l,6-dihydropyrimidine-4-carboxamide
Figure imgf000097_0002
The crude product from Step 1 was dissolved in MeOH and 4- fluorobenzylamine (3.5 eq.) added. After being refluxed overnight, the precipitate was filtered and washed with Et2O to afford the title product.
Step 3: N-(4-fluorobenzyl) l-methyl-2-(4-tert-butoxycarbonyl-l- methylpiperazin-2-yl))-5-hydroxy-6-oxo-l,6-dihydropyrimidine-4-carboxamide
Figure imgf000098_0001
The solid product from Step 2 was dissolved in MeOH and NaCNBH3 (1.4 eq.), AcONa (1.6 eq.), HCHO 37 % (1 eq.) were added. The reaction mixture was stirred at room temperature for 2 days, and then evaporated to afford the crude title product.
1H NMR (DMSOd6 + TFA, 340K, 400MHz) δ 7.40-7.35 (m, 2H), 7.18-7.10 (m, 2H), 4.83 (d, J = 7.3 Hz, IH), 4.59 (d, J = 6.3 Hz, 2H), 4.41 (d, J = 14.9 Hz, IH), 4.20-4.10 (m, IH), 3.75-3.60 (m, IH), 3.54 (s, 3H), 3.38-3.25 (m, 2H), 3.15-3.05 (m, IH), 2.85 (s, 3H), 1.45 (s, 9H). MS (EI+) m/z = 476 (M+H)+.
Step 4: N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methylpiperazin-2-yl)-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000098_0002
The crude product from Step 3 was stirred in CH2C12/TFA (1 : 1) for 2 hours to remove the Boc protective group from the piperazinyl nitrogen.
1H ΝMR (DMSOde, 340K, 400MHz) δ 12.25 (bs, IH), 9.03 (bs, IH), 7.42-7.35 (m, 2H), 7.20-7.10 (m, 2H), 4.62-4.45 (m, 2H), 4.14-4.09 (m, IH), 3.62 (s, 3H), 3.62-3.52 (m, IH), 3.48-3.32 (m, IH), 3.25-3.15 (m, IH), 3.15-3.05 (m, 2H), 2.44-2.32 (m, IH), 2.34 (s, 3H).
MS (EI+) m/z = 376 (M+H)+.
Step 5 : 2-(4-ethyl-l-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide Triethylamine (2 eq.), NaCNBH3 (1.4 eq.), AcONa (1.6 eq.) and CH3CHO (1 eq.) were added to a methanolic solution of the crude product obtained in step 4. The reaction was stirred at room temperature for 1 hour. The title product was obtained as its trifluroacetate salt by preparative RP-HPLC purification (C18, gradient of CH3CN/H2O + 0.01 %TFA).
1H NMR (DMSO-d6 + TFA, 300 MHz) δ 9.40 (t, 7 = 5.9 Hz, 1 H), 7.34 (t, 7 = 8.02 Hz, 2 H), 7.14 (t, 7= 8.7 Hz, 2 H), 5.00 (d, 7= 9.9 Hz, 1 H), 4.54 (d, 7= 6.1 Hz, 2 H), 4.04-3.82 (m, 3 H), 3.55-3.43 (m, 4 H), 3.30-3.22 (m, 4 H), 2.87 (s, 3 H), 1.21 (t, 7 = 7.14 Hz, 3 H). MS m/z 404 (M+H)+.
EXAMPLE 7B Step 1: N-(4-fluorobenζyl)-5-hydroxy-2-[4-(isopropylsulfonyl)-l- methylpiperazin-2-yl] - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4- carboxamide
Figure imgf000099_0001
4-fluorobenzyl 2-(l,2-dimethylpiperazin-2-yl) -5-hydroxy- 1-methyl -6-oxo- 1,6- dihydropyrimidine-4-carboxylate , obtained during the preparation of the compound in example 7 step 4, was dissolved in THF/ΝaOH 2Ν (1:1) followed by the addition of iPrSO2Cl (4 eq). After being stirred at room temperature overnight, further addition of iPrSO2Cl (2.4 eq) and NaOH 2N (2.4 eq) were made to complete the reaction. After 3 hours NaOH 2N (10 eq) was added and the reaction mixture was stirred for 10 minutes at room temperature. The title product was isolated by preparative HPLC (Column C18, gradient of CH3CN/H2O + 0.01 %TFA).
1H NMR (DMSOd6 + TFA, 300K, 300MHz) δ 9.48 (bt, J = 6.5 Hz,lH), 7.39-7.35 (m, 2H), 7.7.22-7.12 (m„ 2H), 4.96 (d, J = 8.4 Hz, IH), 4.57 (d, J = 6.3 Hz, 2H), 4.23 (d, J = 14.4 Hz, IH), 3.96 (d, J = 10.8 Hz, IH), 3.76 (d, J = 10.2 Hz, IH), 3.53 (s, 3H), 3.50-3.35 (m, 3H), 3.23-3.15 (m, IH), 2.87 (s, 3H), 1.25 (d, J = 6.9 Hz, 6H). MS: m/z 482 (M+H)
EXAMPLE 8 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methylpiperidin-2-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000100_0001
Methyl 5-(benzoyloxy)-l-methyl-6-oxo-2-piperidin-2-yl-l,6- dihydropyrimidine-4-carboxylate (prepared from l-(benzyloxycarbonyl)piperidine-2- carboxylic acid by procedures similar to those set forth in Examples 1 or 2 in combination with a deprotection step) was suspended in THF and treated with 3 eq. of triethylamine and 3 eq. of methyl iodide at 40 °C. After stirring for 5 h, THF was evaporated and residue poured into EtOAc and washed with brine. Organic phase was dried (Νa2SO4), filtered and concentrated under reduced pressure. The oily residue was taken into EtOAc and treated with 3 eq. of 4-fluorobenzylamine at 90 °C for 0.5 h. The title product was isolated as its trifluoroacetic salt by preparative RP-HPLC (C18, 5 μM, acetonitrile/water containing 0.1% TFA as eluant). 1H NMR (DMSO-d6, 400 MHz) δ 12.28 (bs, 1 H), 9.50 (bt, 1 H), 9.31 (bs, 1 H), 7.37 (dd, 7 = 5.6 Hz, 8.4 Hz, 2 H), 7.18 (t, 7 = 8.8 Hz, 2 H), 4.8-4.6 (m, 1 H), 4.57 (d, 7 = 6.4 Hz, 2 H), 3.70-3.60 (m, 1 H), 3.50 (s, 3 H), 3.4-3.3 (m, 1 H), 2.78 (bs, 3 H), 2.4- 2.3 (m, 1 H), 1.92-1.46 (m, 5 H). MS m/z 375 (M+H)+.
EXAMPLE 9 2-(l-Acetylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000101_0001
Step 1: Methyl 5-(benzoyloxy)-l-methyl-6-oxo-2-pyrrolidin-2-yl-l,6- dihydropyrimidine-4-carboxylate
5 Methyl-5-(benzoyloxy)-2-[l-(tert-butoxycarbonyl)pyrrolidin-2-yl]-6- hydroxypyrimidine -4-carboxylate was treated with TFA:CH2C12 (3:7) at 0 °C. The solution was warmed to room temperature and the progress of the reaction was monitored by MS analysis. After lh the reaction was complete and the solvent was removed under reduced pressure using a rotatory evaporator. The title product was
10 precipitated with Et2O and collected by filtration.
1H-NMR (CDC13, 400 MHz) δ 8.17 (d, 7 = 7.4 Hz, 2 H), 7.67 (t, 7 = 7.6 Hz, 1 H), 7.52 (t, 7 = 7.6 Hz, 2 H), 5.45 (dd, 7 = 7.6, 6.7 Hz, 1 H), 3.82 (s, 3 H), 3.66 (s, 3 H), 3.61 (t, 7 = 7.0 Hz, 2 H), 2.78-2.69 (m, 1 H), 2.40-2.00 (m, 3 H). MS m/z 358 (M+H)+. i5
Step 2: 2-(l-Acetylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide To a stirred solution of the product of Step 1 (1.0 eq.) in CHC13, triethylamine (3.0 eq.) was added followed by the addition of acetyl chloride (1.5 eq.).
20 The reaction was stirred at room temperature until the starting material was consumed as determined by MS analysis. The reaction mixture was concentrated and the crade product was used directly in the subsequent step without further purification. A solution of the crude product from above (1.0 eq.) in NMP was treated with 4- fluorobenzylamine (2.0 eq.). The solution was stirred at reflux until the reactants were consumed as determined by MS analysis. The title compound was obtained by RP- HPLC purification (C18, eluting with water and acetonitrile containing 0.1 % trifluoroacetic acid) as a 4: 1 mixture of rotamers by NMR.
1H-NMR (DMSO-d6, 400 MHz) δ 12.11 (bs, 1 H), 8.49 (t, 7=6.2 Hz, 0.8 H), 8.30 (t, 7=6.2 Hz, 0.2 H), 7.4-7.3 (m, 2 H), 7.15 (t, 7= 8.8 Hz, 2 H), 5.22 (dd, 7=8.0, 3.2 Hz, 0.2 H), 5.02 (dd, 7=8.0, 3.2 Hz, 0.8 H), 4.60-4.47 (m, 2 H), 3.95-3.85 (m, 0.8 H), 3.80-3.70 (m, 0.2 H), 3.59-3.57 (m, 0.8 H), 3.55 (s, 2.4 H), 3.52 (s, 0.6 H), 3.43-3.37 (m, 0.2 H), 2.40-1.7 (m, 4 H), 2.5 (s, 2.4 H), 1.75 (s, 0.8 H). MS m/z 389 (M+H)+.
EXAMPLE 10
2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000102_0001
Step 1: Methyl 2-(2,3-dihydro- lH-indol-2-yl)- 1 -methyl-5-benzoyloxy-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
Figure imgf000102_0002
Benzyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-l-methyl-6-oxo-l,6- dihydropyrimidi-2-yl]indoline-l-carboxylate was dissolved in EtOAc and hydrogenated at atmospheric pressure on 10% Pd/C overnight. The crude title product was obtained after filtration and evaporation
Step 2: Methyl 2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-5-benzoyloxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
Figure imgf000103_0001
TΗF was added to the crude product of Step 1, followed by pyridine (2 eq.) and PhCOCl (1 eq.). After being stirred at room temperature overnight, the reaction mixture was evaporated to give the crude title product.
Step 3: 2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide The crude product of Step 2 was dissolved in MeOΗ and 4- fluorobenzylamine (3.5 eq.) added. The solution was stirred at 60 °C over night. The title product was obtained by preparative RP-ΗPLC (C18, gradient of CΗ3CΝ/Η2O +
0.01 %TFA).
1H NMR (DMSO-d6 + TFA, 340 K, 400 MHz) δ 7.75-7.80 (m, 1 H), 7.45-6.97 (m, 13
H), 5.77 (dd, 7= 10, 3.6 Hz, 1 H), 4.35-4.50 (m, 2 H), 3.72 (dd, 7= 16, 10 Hz, 1 H),
3.35 (s, 3 H), 3.16 (dd, 7= 16, 3.6 Hz, 1 H). MS m/z 499 (M+H)+.
EXAMPLE 11 N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)-l,2,3,4- tetrahydroquinolin-2-yl]-l,6-dihydropyrimidine-4-carboxamide
Figure imgf000104_0001
Step 1: Methyl 2-(l,2,3,4-tetrahydroquinolin-2-yl)-l-methyl-5-benzoyloxy-6- oxo- 1 ,6-dihydropyrimidine-4-carboxylate
Figure imgf000104_0002
Benzyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-l-methyl-6-oxo-l,6- dihydropyrimidi-2-yl] - 1 ,2,3 ,4-tetrahydroquinoline- 1 -carboxylate (prepared from tetrahydroquinoline-2-carboxylic acid (Robl et al, Tetrahedron Letters 1995, 36: 1593) by protection of the nitrogen and following procedures similar to those set forth in Examples 1 or 2 in combination with a deprotection step) was dissolved in EtOAc and hydrogenated at atmospheric pressure on 10% Pd C at room temperature overnight. The title product was obtained as the residue after filtration and evaporation of the organic solvent.
Step 2: Methyl 5-benzoyloxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)- l,2,3,4-tetrahydroquinolin-2-yl]-l,6-dihydropyrimidine-4-carboxylate
Figure imgf000105_0001
The residue of Step 1 was dissolved in dichloromethane. Pyridine, picolinoyl chloride hydrochloride and a catalytic amount of DMAP were added. A further addition of the reactants was made after two hours. After evaporation of the solvent, the residue was diluted with EtOAc, the organic phase washed with water, dried (Na2SO ) and evaporated to afford the title product.
Step 3: N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2- ylcarbonyl)- 1 ,2,3 ,4-tetrahydroquinolin-2-yl]- 1 ,6-dihydropyrimidine-4- carboxamide
The residue of Step 2 was dissolved in DMF and 4-fluorobenzylamine (3 eq.) was added. The reaction mixture was stirred at 90°C for 1 h. The title compound was purified by preparative HPLC and isolated as its trifluoroacetic salt (C18, gradient of CH3CΝ/H2O + 0.01% TFA). 1H-NMR (DMSO-d6 +TFA, 400 MHz, 340 K) δ 8.35 (d, 7 = 4.2 Hz, 1 H), 7.81 (t, 7 = 7.4 Hz, 1 H), 7.54 (bt, 1 H), 7.49 (d, 7 = 7.7 Hz, 1 H), 7.37 (dd, 7 = 5.2 Hz, 7.0 Hz, 1 H), 7.25-7.22 (m, 2 H), 7.17-7.09 (m, 3 H), 6.90 (t, 7= 7.3 Hz, 1 H), 6.62 (t, 7 = 7.3 Hz, 1 H), 6.43 (bs, 1 H), 5.74 (t, 7= 7.6 Hz, 1 H), 4.42 (dd, 7=6.4 Hz, 14.8 Hz,lH), 4.32 (dd, 7=6.4 Hz, 14.8 Hz, 1 H), 3.65 (s, 3 H), 2.80-2.70 (m, 3 H), 1.85-1.75 (m, 1 H).
MS m/z 514 (M+H)+.
EXAMPLE 12
2- [(2S,4R)- 1 -benzoyl-4-hydroxypyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000106_0001
Step 1: Methyl 2-[(2S,4R)-l-benzoyl-4-(benzyloxy)ρyrrolidin-2-yl]-5-
(benzoyloxy)- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate
Figure imgf000106_0002
Methyl 2-[(2S,4R)-l-tert-butyloxycarbonyl-4-(benzyloxy)pyrrolidin-2- yl]-5-(benzoyloxy)-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxylate [obtained from N-Boc-O-benzyl-L-hydroxyproline using chemistry similar to those set forth in Examples 1 or 2; the stereochemistry of products of Steps 1 to 3 is based on that of starting material] was dissolved in dichloromethane (0.03 M), followed by addition of an excess of TFA. The mixture was stirred at room temperature for 1 hour. The solvent was evaporated in vacuo. To the residue dissolved in pyridine, benzoic anhydride (2 eq.) was added. The mixture was stirred at room temperature for 5 hours. Pyridine was evaporated in vacuo and the residue dissolved in EtOAc was washed with HCl (1M), saturated aqueous NaHCO3 and brine, dried on Na2SO4, filtered and evaporated in vacuo to give the title product as a yellow solid.
1H NMR (DMSO-d6, 400 MHz, 330 K) δ 8.07 (d, 7= 7.6 Hz, 2 H), 7.77 (t, 7=7.3 Hz, H), 7.62 (t, 7=7.74 Hz, 2 H), 7.52-7.49 (m, 5 H), 7.33-7.30 (m, 5 H), 5.47 (bt, 1 H), 4.53 (d, 7= 12.1 Hz, 1 H), 4.44 (d, 7=12.0 Hz, 1 H), 4.36 (bs, 1 H), 3.87-3.84 (m, 1 H), 3.76 (s, 3 H), 3.73 (s, 3 H), 3.57 (d, 7=11.2 Hz, 1 H) 2.70 (t, 7=12.2 Hz, 1 H), 2.31-2.28 (m, 1 H).
Step 2: 2-[(2S,4R)-l-benzoyl-4-(benzyloxy)ρyrrolidin-2-yl]-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxamide
Figure imgf000107_0001
The compound of Step 1 was dissolved in methanol and 4- fluorobenzylamine (5 eq.) was added. The mixture was refluxed overnight. After cooling, the reaction mixture was filtered and washed with ethyl ether to obtain the title product as a white solid.
1H ΝMR (DMSO-dθ, 400 MHz, 300 K) δ 12.15 (s, 1 H), 9.00 (br t, IH), 7.48 (d, 7=7.6 Hz, 2 H) 7.41-7.20 (m, 10 H), 7.12 (t, 7= 8.8 Hz, 2H), 5.27 (t, 7= 8Hz, 1 H), 4.63 (dd, 7= 14.9, 7.3 Hz, 1 H), 4.56-4.38 (m, 2 H), 4.26 (bs, 1 H) 4.25 (d, 7=11.4 Hz, 2 H) 3.68 (s, 3 H), 3.52 (d, 7= 11.2 Hz, 1 H), 2.66-2.63 (m, 1 H), 2.26-2.20 (m, 1 H). MS m/z 557 (M+H)+.
Step 3: 2-[(2S,4R)-l-benzoyl-4-hydroxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide The title compound of Step 2 was dissolved in AcOH and 10% Pd/C
(10% weight) was added. The mixture was stirred under H2 at atmosphere overnight.
Pd C was filtered, AcOH evaporated in vacuo, and the resulting title compound was washed with methanol.
1H ΝMR (DMSO-d6, 400 MHz) δ 12.1 (s, 1 H), 9 (bt, 1 H), 7.51-7.47 (m, 3 H), 7.41- 7.33 (m, 4 H) 7.11 (t, 7= 8.8 Hz, 2 H), 5.27 (t, 7= 8 Hz, 1 H), 5.08 (d, 7=3.2 Hz, 1 H), 4.63 (dd, 7=14.8 Hz, 7.3 Hz, 1 H), 4.43-4.39 (m, 2 H), 4.20 (d, J= 7.4 Hz, 1 H), 3.67 (s, 3 H), 2.41-2.36 (m, 1 H), 2.2-2.1 (m, 1 H). MS m/z 467 (M+H)+.
EXAMPLE 13
N^-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-N2-(ρyridin-2-ylmethyl)-l,6- dihydropyrimidine-2,4-dicarboxamide
Figure imgf000108_0001
2-Ethyl 4-methyl 5-[(2,2-dimethylpropanoyl)oxy]-l-methyl-6-oxo-l,6- dihydropyrimidine-2,4-dicarboxylate (made by protection and alkylation of the starting material of Example 4, Step 1 using procedures similar to those set forth in Examples 1 or 2) was dissolved in DMF, 4-fluorobenzylamine (3.1 eq.) was added and the mixture was stirred at 90 °C overnight. After concentration of the solvent, the residue was taken into EtOAc, washed with 1 Ν HCl, dried over Νa2S04 and evaporated to obtain crade N-(4-fluorobenzyl)-2-ethoxycarbonyl- 1 -methyl-5-hydroxy- 6-oxo-l,6-dihydropyrimidine-4-carboxamide. To this crude product was added 2- picolylamine (8 eq.), and the reaction was stirred at 90 °C overnight. The title product was obtained as its trifluoroacetic salt by preparative RP-HPLC purification (C18 gradient of CH3CΝ/H2O + 0.01% TFA). 1H NMR (DMSO-d6, 300K, 400 MHz) δ 12.70 (bs, 1 H), 9.75-9.65 (m, 2 H), 8.56 (d, 7 = 4.4 Hz, 1 H), 7.90-7.80 (m, 1 H), 7.44 (d, 7= 8.0 Hz, 1 H), 7.40-7.35 (m, 3 H), 7.17 (t, 7 = 9.2, 2 H), 4.60 (d, 7= 6.0 Hz, 2 H), 4.54 (d, 7= 6.0 Hz, 2 H), 3.67 (s, 3H). MS rn/z 412 (M+H)+.
EXAMPLE 14
2-[2-(4-benzoylpiperazin-l-yl)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000109_0001
Step 1: 2-(2,2-dimethoxyethyl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000109_0002
Methyl 2-(2,2-dimethoxyethyl)-5-benzoyloxy-l-methyl-6-oxo-l ,6- dihydropyrimidine-4-carboxylate (1.0 eq.) (prepared from 3,3-dimethoxypropionitrile by procedure similar to those set forth in Examples 1 or 2) in dry MeOH was treated with 4-fluorobenzyl amine (2.5 eq.) at reflux for 2 hours. Solvent was removed in vacuo and residue triturated with Et2O to obtain the title product. 1H ΝMR (DMSO-dβ, 300K, 400 MHz) δ: 9.80 (br s, IH), 7.41-7.38 (m, 2H), 7.15 (t, J = 8.7 Hz, 2H), 5.04 (br s, IH), 4.47 (d, J = 6.2 Hz, 2H), 3.46 (s, 3H), 3.28 (s, 6H), 3.01 (d, J = 5.5 Hz, 2H). MS: m/z 366 (M-H)+
Step 2: Ν-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-(2-oxoethyl)-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000110_0001
The product of Step 1 was treated with a mixture HCl 1N/THF for 1 hour at 40 °C. Organics were removed in vacuo and residue extracted in DCM, dried over Na2SO4 and concentrated to give the title compound as a foam which was immediately reacted in the following reductive amination. MS: m/z 320 (M + H)+.
Step 3: 2-[2-(4-benzoylpiperazin-l-yl)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide The product of Step 2 was dissolved in MeOH and treated with sodium acetate (1.6 eq.), 1-benzoylpiperazine (2 eq.), and sodium cyanoborohydride (1.43 eq.). The mixture was left stirring at room temperature for lhour. The reaction mixture was concentrated and the title compound was obtained by RP-HPLC purification ( C18, eluting with water and acetonitrile containing 0.1 % TFA). 1H ΝMR (CDC13+TFA, 273 K, 600 MHz) δ: 10.431 (br s, IH), 8.38 (t, J = 5.7 Hz, IH), 7.61 (t, J = 6.4 Hz, IH), 7.52 (t, J = 7.7 Hz, 2H), 7.41 (d, J = 7.4 Hz, 2H), 7.28 (2H, overlapped by CHC13), 7.07 (t, J = 8.5 Hz, 2H), 4.97 (d, J = 14 Hz, IH), 4.63 (d, J = 5.7 Hz, 2H), 4.10 (d, J = 14 Hz, IH), 3.93 (d, J = 11.9 Hz, IH), 3.82-3.74 (m, 4H), 3.61 (s, 3H), 3.47 (t, J = 12.6 Hz, IH), 3.41 (br s, 2H), 3.29-3-26 (m, IH), 3.15-3.14 (m, IH).
MS: m/z 494 (M + H)+.
EXAMPLE 15 N-(4-fluorobenζyl)-5-hydroxy-l-(2-hydroxy-3-morpholin-4-ylpropyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
Figure imgf000111_0001
Step 1: Methyl l-allyl-5-[(2,2-dimethylpropanoyl)oxy]-6-oxo-l,6- dihydropyrimidine-4-carboxylate
Figure imgf000111_0002
Methyl 5-[(2,2-dimethylpropanoyl)oxy]-6-hydroxy-l ,6- dihydropyrimidine-4-carboxylate (see Example 4, Step 3) was dissolved in THF, then allyl bromide (2 eq.) and Cs2CO3 (2 eq.) were added. The reaction mixture was refluxed for 2h, then evaporated. The residue was diluted with EtOAc, washed with IN HCl, dried (Na2SO4) and the solvent evaporated. The product was purified by flash chromatography on silica gel eluting with a gradient of petroleum ether/EtOAc. 1H-NMR (DMSO-d6, 400 MHz, 300K) δ 8.47 (s, IH), 5.99-5.92 (m, IH), 5.25-5.14 (m, 2H), 4.58 (d, J = 5.5 Hz, 2H), 3.82 (s, 3H), 1.28 (s, 9H).
Step 2: N-(4-fluorobenzyl)-5-hydroxy- 1 -(2-hydroxy-3-morpholin-4-ylpropyl)- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
2a. The compound of Step 1 was dissolved in dichloroethane and m-CPBA was added (5 eq.). The reaction mixture was refluxed until the starting material was completely consumed, then evaporated. MS m/z 311 (M+H)+.
2b. Crude material from step 2a was dissolved in MeOH and morpholine (6 eq.) was added. The reaction mixture was refluxed for 3h, then evaporated. MS (EI+) m z 398 (M+H)+.
2c. Crade material from step 2b was dissolved in DMF and 4- fluorobenzylamine (3 eq.) was added. The reaction mixture was stirred at 90 °C for 3h. The title compound was obtained as its trifluoroacetate salt by RP-HPLC purification (gradient of CH3CN/H2O + 0.01% TFA).
1H-NMR (DMSO-d6 +TFA, 400 MHz, 340K) δ 9.27 (bt, IH), 7.94 (s, IH), 7.40-7.36
(m, 2H), 7.15-7.11 (m, 2H), 4.48 (d, J= 6.4 Hz, 2H), 4.30-4.36, (m, IH), 4.09 (dd, J=
13.6, 4.0 Hz, IH), 3.91-3.86 (m, 5H), 3.34-3.30 (m, 5H), 3.18 (dd, J= 13.6 ,4.0 Hz,
IH).
MS rn/z 407 (M+H)+.
EXAMPLE 16
2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000112_0001
Stepl: 1 -Benzyl-2-methyl-(2S ,4S)-4-fluoropyrrolidine- 1 ,2-dicarboxylate
Figure imgf000112_0002
l-benzyl-2-methyl(2S,4R) 4-hydroxypyrrolidine-l,2 dicarboxylate in dichloromethane was added dropwise to a solution, precooled to -78 °C, of N,N- diethylaminosulfur trifluoride (1.0 eq.) in dichloromethane. The reaction was stirred while the temperature was allowed to increase to 25 °C. The solvent was concentrated under vacuum and the crude was purified by flash chromatography (eluent: petroleum ether: EtOAc = 1:1) to give the title compound.
1H NMR (CDC13, 300 MHz, 300 K) δ 7.42-7.30 (m, 5H), 5.35-5.10 (m, 3H), 4.65 (d, J=9.6 Hz, 0.5H), 4.57 (d, J= 9.4Hz, 0.5H), 3.99-3.62 (m, 2H), 3.79 (s, 1.5H), 3.68 (s,
1.5H), 2.62-2.29 (m, 2H).
MS: m/z 282 (M+H)+.
Ill Step 2: (4S)- 1 - [(Benzyloxy)carbonyl] -4-fluoro-L-proline
Figure imgf000113_0001
l-Benzyl-2-methyl-(2S,4S)-4-fluoropyrrolidine-l,2-dicarboxylate dissolved in methanol was treated with NaOH IN (2 eq.) and the reaction mixture was stirred at 50 °C for 3 hours. After concentration of the solvent, HCl IN was added until pH=l and the aqueous layer was extracted three times with dichloromethane. The organic phase was washed with brine, dried over Na2SO4 and filtered to give, after concentration, title compound.
1HNMR (CDC13, 400 MHz, 300 K) δ 7.45-7.30 (m, 5H), 5.33-5.18 (m, 3H), 4.70-4.60 (bm, IH), 4.00-3.65 (m, 2H), 2.85-2.25 (m, 2H). MS: m/z 268 (M+H)+.
Step 3: Benzyl-(2S ,4S)-2-aminocarbonyl-4-fluoropyrrolidine- 1 -carboxylate
Figure imgf000113_0002
A stirred solution of (4S)-l-[(Benzyloxy)carbonyl]-4-fluoro-L-proline in dioxane was treated with pyridine (0.7 eq.) and Boc2O (1.3 eq.), then ammonium bicarbonate (1.26 eq.) was added and the mixture was stirred at room temperature for 15 hours.
Dioxane was concentrated and the residue was taken up in ethyl acetate, washed with
1 N HCl and brine, dried over Na2SO4 to give, after filtration and concentration, title compound.
1H NMR (DMSO-d6, 400 MHz, 340 K) δ 7.40-7.28 (m, 5H), 5.25 (dt, JH-F= 53.6 Hz, J = 4.5 Hz, IH), 5.13-5.06 (m, 2H), 4.28 (d, J= 9.6Hz, IH), 3.80-3.63 (m, 2H), 2.45-
2.21 (m, 2H).
MS: m/z 267 (M+H)+. Step 4: Benzyl-(2S,4S)-2-cyano-4-fluoropyrrolidine-l-carboxylate
Figure imgf000114_0001
B enzyl-(2S ,4S)-2-aminocarbonyl-4-fluoropyrrolidine- 1 -carboxylate in dichloromethane was treated at 0 °C with Et3N (2.1 eq.) and trifluoroacetic anhydride was added dropwise.
The reaction mixture was stirred at 0 °C for 0.5 hour and 10 minutes at room temperature. Then, it was diluted with dichloromethane, washed with HCl IN and brine, dried over Na2SO4 and filtered to give, after concentration, title compound. 1H NMR (DMSO-d6, 400 MHz, 340 K) δ 7.42-7.30 (m, 5H), 5.40 (dbt, JH-F= 52.3 Hz, IH), 5.20 (d, J=12.7 Hz, IH), 5.16 (d, J= 12.7 Hz, IH), 4.94 (d, J= 8.4Hz, IH), 3.68- 3.56 (m, 2H), 2.63-2.41(m, 2H). MS: m z 249 (M+H)+.
Step 5: Benzyl-(2S,4S)-2-[amino(hydroxyimino)methyl]-4-fluoropyrrolidine-
1 -carboxylate
Benzyl-(2S,4S)-2-cyano-4-fluoropyrrolidine-l-carboxylate dissolved in absolute ethanol was treated with triethyl amine (1.5eq.) and hydroxylamine hydrochloride (1.3 eq.).
The reaction mixture was stirred at 50 °C for 3 hours and then the solvent was removed under reduced pressure. The residue was partitioned between water and dichloromethane and the aqueous layer was extracted with dichloromethane three times. The organic phase was dried over Na2SO4 and filtered. The solid obtained by concentration was then recrystallized from MeOH to give title compound. 1H NMR (DMSO-d6, 400 MHz, 300 K) δ 9.10 (bs, IH), 7.40-7.25 (m, 5H), 5.35-5.15 (m, 3H), 5.07 (m, 2H), 4.43 (d, J= 9.1 Hz, IH), 3.72-3.56 (m, 2H), 2.45-2.20 (m, 2H). MS: m z 282 (M+H)+.
Step 6: Dimethyl-2-{[(amino-{(2S,4S)-l-[(benzyloxy)carbonyl]-4- fluoropyrrolidin-2-yl } methylidene)amino] oxy } but-2-enedioate
Figure imgf000115_0001
Benzyl-(2S,4S)-2-[amino(hydroxyimino)methyl]-4-fluoropyrrolidine-l-carboxylate in chloroform was treated with dimethylacetylene dicarboxylate for 3 hours at 60 °C.
The chloroform was then concentrated to give the title compound as a 8:2 mixture of isomers.
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 7.45-7.25 (m, 5H), 6.51 (bs, 1.6 H), 6.14
(bs, 0.4 H), 5.64 (s, 0.8H), 5.61 (s, 0.2 H), 5.30 (dt, JH-F = 53.9 Hz, J= 4.6 Hz, IH), 5.15-5.04 (m, 2H), 4.51 (t, J=8.8 Hz, 0.8H), 4.44 (bt, 0.4H), 3.85-3.48 (m, 8H), 2.67-
2.23 (m, 2H).
MS: m/z 424 (M+H)+.
Step 7: Methyl-2-{(2S,4S)-l-[(benzyloxy)carbonyl]-4-fluoropyrrolidin-2-yl}-
5,6-dihydroxypyrimidine-4-carboxylate
Figure imgf000115_0002
Dimethyl-2-{[(amino-{(2S,4S)-l-[(benzyloxy)carbonyl]-4-fluoropyrrolidin-2- yl}methylidene)amino]oxy}but-2-enedioate was refluxed for 6 hours in ortho-xylene. The reaction mixture was then cooled down to room temperature and petroleum ether was added. A light brown solid precipitated to give after filtration title compound, that was not purified furthermore, but used as such in the following reaction.
Step 8: Methyl-5-(benzoyloxy)-2-{ (2S,4S)-l-[(benzyloxy)carbonyl]-4- fluoropyrrolidin-2-yl } -6-hydroxypyrimidine-4-carboxylate
Figure imgf000116_0001
Methyl-2-{(2S,4S)-l-[(benzyloxy)carbonyl]-4-fluoropyrrolidin-2-yl}-5,6- dihydroxypyrimidine-4-carboxylate in pyridine was treated with benzoic anhydride (1.3 eq.) and the reaction mixture was stirred at room temperature overnight. Pyridine was concentrated and the residue was taken up in ethyl acetate and washed with HCl IN and brine. The organic phase was dried over Na SO4 and filtered to give after concentration a crude that was purified by flash chromatography , (eluent: petroleum ether: ethyl acetate= 1:1) to give title compound.
1H NMR (DMSO-dβ, 400 MHz, 300 K) δ 13.50 (bs, IH), 8.09 (d, J=7.7Hz, 2H), 7.80 (t, J= 7.35 Hz, IH), 7.64 (t, J=7.8 Hz, 2H), 7.45-7.15 (m, 5H), 5.36 (dbt, JH-F=54 HZ, IH), 5.14 (m, 2H),5.02-4.93 (m, IH), 3.95-3.60 (m, 2H), 3.76 (s, 3H), 2.80-2.36 (m, 2H). MS: m z 496 (M+H)+.
Step 9 : Methyl-5-(benzoyloxy)-2- { (2S ,4S)- l-[(benzyloxy)carbonyl] -4- fluoropyrrolidin-2-yl } - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4- carboxylate .
Figure imgf000117_0001
Methyl-5-(benzoyloxy)-2-{(2S,4S)-l-[(benzyloxy)carbonyl]-4-fluoropyrrolidin-2-yl}- 6-hydroxypyrimidine-4-carboxylate, dissolved in dry dioxane, was added to a suspension of lithium hydride (1.2 eq.) in dry dioxane. The reaction mixture was stirred at 38 °C for 45 minutes and then cooled down to room temperature. Dimethyl sulfate (1.3 eq.) was added and the mixture was heated to 58 °C and stirred at this temperature for 3 hours. The reaction mixture was then cooled down and glacial acetic acid (0.2 eq.) was added, followed by water and ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate; the organic phase was dried over Na2SO4 and filtered to give, after concentration, a crade that was purified by flash chromatography (eluent petroleum ether: ethyl acetate from 4:6 to 2:8) to give the title compound as a 4.6:5.4 mixture of rotamers by NMR.
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 8.08 (d, J=7.5 Hz, 2H), 7.79 (t, J= 7.3 Hz, IH), 7.63 (t, J=7.5 Hz, 2H), 7.37-7.11 (m, 5H), 5.48-5.38 (m, 2H), 5.20 (d, J= 12.8 Hz, 0.46H), 5.12 (d, J=11.8 Hz, 0.54H), 5.10 (d, J=12.5 Hz, 0.54H), 4.92 (d, J=12.8 Hz, 0.46H), 4.00-3.75 (m, 2H), 3.72 (s, 3H), 3.59 (s, 1.6H), 3.52 (s, 1.4H), 2.90-2.65 (m, 2H). MS: m/z 510 (M+H)+.
Step 10: Methyl-2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-5-(benzoyloxy)-6- hydroxypyrimidine-4-carboxylate.
Figure imgf000118_0001
Methyl-5-(benzoyloxy)-2-{(2S,4S)-l-[(benzyloxy)carbonyl]-4-fluoropyrrolidin-2-yl}- l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxylate, dissolved in ethyl acetate was treated with Pd/C 10% (10%w/w) and acetic anhydride (1 eq.) and submitted under H2 atmosphere at room temperature. The reaction mixture was stirred at room temperature for 18 hours and then the suspension was filtered over celite to give the title compound as a 7:3 mixture of rotamers by NMR.
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 8.07 (m, 2H), 7.78 (m, IH), 7.62 (m, 2H), 5.75-5.26 (m, 2H), 4.13-3.60 (m, 2H), 3.72 (s, 3H), 3.59 (s, 3H), 2.79-2.36 (m, 2H), 2.03 (s, 2.1H), 1.87 (s, 0.9H). MS: m/z 418 (M+H)+.
Step 11: 2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide.
Methyl-2-[(2S,4S)-l-acetyl-4-fluoropyrrolidin-2-yl]-5-(benzoyloxy)-6- hydroxypyrimidine-4-carboxylate was dissolved in MeOH (0.12 N) and treated with 4-F-benzylamine (3 eq.) in a sealed tube. The reaction mixture was stirred at 65 °C for 18 hours, then it was cooled down. The solvent was evaporated and the residue was washed with ethyl ether several times to obtain a solid that was recrystallized from ethanol and washed again with ethyl ether to give the title compound as a 7.3:2.7 mixture of rotamers by NMR.
1H NMR (DMSO-dβ, 500 MHz, 300 K) δ 12.01 (bs, IH), 8.52 (t, J = 6.3 Hz, 0.7H), 8.34 (t, J = 6.3 Hz, 0.3H), 7.34-7.29 (m, 2H), 7.18-7.12 (m, 2H), 5.39 (dbt, JH-F=54.3 Hz, 0.7H), 5.29 (dt, JH-F=54.2 Hz, J=4.4 Hz, 0.3 H), 5.38 (d, J=8.9 Hz, 0.3H), 5.18 (dd, J=9.2 and 1.6 Hz, 0.7H), 4.55-4.47 (m, 2H), 4.20-3.78 (m, 2H), 3.51 (s, 2.1H), 3.50 (s, 0.9H), 2.75-2.54 (m, IH), 2.47-2.27 (m, IH), 2.00 (s, 2.1H), 1.81 (s, 0.9H). MS: m z 407 (M+H)+.
EXAMPLE 17
2-{(2S,4R)-l-[(dimethylamino)(oxo)acetyl]-4-methoxypyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide
Figure imgf000119_0001
Step 1: (4R)- 1 - [(Benzyloxy)carbonyl] -4-methoxy-L-proline
Figure imgf000119_0002
Synthesized following the procedure reported on Journal of Medicinal Chemistry
1988, 31, 875-885.
Step 2: Benzyl-(2S,4R)-2-cyano-4-methoxypyrrolidine-l-carboxylate
Figure imgf000119_0003
To compound (4R)-l-[(Benzyloxy)carbonyl]-4-methoxy-L-proline dissolved in dioxane, Boc anhydride (1.3 eq), ΝHφHCOs (1.26 eq.) and pyridine were added. The mixture was stirred overnight at room temperature. Dioxane was removed in vacuo and the residue, dissolved in ethyl acetate, was washed with HCl IN, saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated in vacuo to get the primary amide. The crude product was dissolved in dichloromethane and triethylamine (2.1 eq.) was added. The mixture was cooled down to 0° C and trifluoroacetic anhydride (1.1 eq.) was added. After 1 hour the dichloromethane solution was diluted and washed with HCl IN, saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and evaporated in vacuo. The compound was purified by flash chromatography on silica gel (eluent ethyl acetate: petroleum ether = 20%: 80%) as a 4:6 mixture of rotamers by NMR. 1H NMR (DMSO-de, 400 MHz, 300 K) δ 7.45-7.3 (m, 5H), 5.20 (d, J=12 Hz, 0.4H), 5.14 (s, 1.2H), 5.12 (d, J= 12 Hz, 0.4H), 4.75 (t, J= 7 Hz, 0.4H), 4.64 (t, J= 7.8 Hz, 0.6H), 4.02 (bs, IH), 3.6-3.45 (m, 2H), 3.21 (s, 3H), 2.45-2.40 (partially under DMSO) (m, IH), 2.40-2.25 (m, lH).
Step 3: Benzyl-(2S,4R)-2-[amino(hydroxyimino)methyl]-4methoxypyrrolidine
-1 -carboxylate
Figure imgf000120_0001
To benzyl-(2S,4R)-2-cyano-4-methoxypyrrolidine-l-carboxylate, dissolved in ethanol (0.4 M), hydroxylamine hydrochloride (1.3 eq.) and triethylamine (1.5 eq.) were added. The mixture was stirred at 40°C for 4 hours then at room temperature overnight. The mixture was concentrated in vacuo and the residue dissolved in ethyl acetate washed with brine, dried over Na2SO4, filtered and concentrated to give title compound. 1H NMR (DMSO-d6, 400 MHz, 300 K) δ 9.05 (bs, IH), 7.45-7.25 (m, 5H), 5.4 (bs,
2H), 5.10 (d, J= 13 Hz, IH), 5.03 (d, J=13 Hz, IH), 4.26 (t, J= 7.4 Hz, IH), 3.97 (bs,
IH), 3.63-3.45 (m, 2H), 3.22 (s, 3H) 2.3-2.03 (m, 2H). Step 4: Dimethyl-2-{ [(amino-{ (2S,4R)-l-[(benzyloxy)carbonyl]-4- methoxypyrrolidin-2-yl}methylidene)amino]oxy}but-2-enedioate
Figure imgf000121_0001
To benzyl-(2S,4R)-2-[amino(hydroxyimino)methyl]-4methoxypyrrolidine -1- carboxylate, dissolved in chloroform, dimethyl acetylendicarboxylate (1.1 eq.) was added. The mixture was refluxed for 1 hour and left stirring at 40° C overnight. The chloroform was removed in vacuo and the crade product purified by flash chromatography on silica gel (eluent ethyl acetate: petroleum ether = 40: 60). Two isomers were present in ratio 7:3.
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 7.40-7.23 (m, 5H), 6.7-6.55 (2bs, 1.4 H), 6.35-6.2 (bs, 0.6H), 5.61 (s, 0.7H), 5.59 (s, 0.3H), 5.10 (d, J=13 Hz, 0.7H), 5.08 (s, 0.6H), 5.02 (d, J=13 Hz, 0.7H), 4.30-4.20 (m, IH), 3.97 (bs, IH), 3.78 (s, 2.1H), 3.73 (s, 0.9H), 3.62 (s, 0.9H), 3.59 (s, 2.1H), 3.65-3.50 (m, 2H), 3.22 (s, 3H), 2.37-2.23 (m, IH), 2.10-1.95 (m, IH).
Step 5: Methyl 5-(benzoyloxy)-2-{(2S,4R)-l-[(benzyloxy)carbonyl]-4- methoxypyrrolidin-2-yl } -6-hydroxypyrimidine-4-carboxylate
Figure imgf000121_0002
Dimethyl-2- { [(amino- { (2S,4R)- 1 - [(benzyloxy)carbonyl] -4-methoxypyrrolidin-2- yl}methylidene)amino]oxy}but-2-enedioate were dissolved in xylene and the solution stirred at 150°C for 3 hours and at room temperature overnight. Xylene was concentrated in vacuo. To the crade compound, dissolved in pyridine, benzoic anhydride (1.3 eq.) was added and the reaction mixture was stirred at room temperature overnight. The solution was concentrated in vacuo and the crade dissolved in ethyl acetate washed with 1 N HCl, saturated aqueous NaHCO3 and brine, dried on Na2SO4, filtered and evaporated in vacuo. The crade product was purified by flash chromatography on silica gel (eluent ethyl acetate: petroleum ether = 10:90) and showed a 1:1 mixture of rotamers by NMR.
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 13.5 (s, IH), 8.09 (t, J= 7.0 Hz, 2H), 7.82- 7.75 (m, IH), 7.66-7.61 (m, 2H), 7.40-7.25 (m, 4 H), 7.12-7.06 (m, IH), 5.10 (s, IH), 5.09 (d, J= 12.5 Hz, 0.5H), 4.88 (d, J= 12.5 Hz, 0.5H), 4.66 (dd, J= 16.2 and 8.0 Hz, IH), 4.10-4.00 (m, IH), 3.74 (s, 3H), 3.75-3.60 (m, 2H), 3.25 (s, 3H), 2.45-2.40 (partially under DMSO) (m, IH), 2.13-2.03 (m, IH).
Step 6: Methyl-5-(benzoyloxy)-2-{ (2S,4R)-l-[(benzyloxy)carbonyl]-4- methoxypyrrolidin-2-yl } - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4- carboxylate
Figure imgf000122_0001
To methyl 5-(benzoyloxy)-2-{ (2S,4R)-l-[(benzyloxy)carbonyl]-4-methoxypyrrolidin- 2-yl}-6-hydroxypyrimidine-4-carboxylate, dissolved in dioxane, LiH (1.4 eq.) was added and the reaction mixture stirred at 38° C for 40 minutes. The temperature was raised to 60°C and dimethyl sulphate (1.3 eq.) was added dropwise. After two hours the reaction mixture was cooled down to 0°C and HCl 1 N was added to quench the reaction. The reaction mixture was extracted with ethyl acetate and the organic phase washed with HCl IN, saturated aqueous NaHCO3 and brine, dried on Na2SO4, filtered and concentrated in vacuo. The desired product was isolated by flash chromatography on silica gel (eluent ethyl acetate: petroleum ether = 30:70) as a 1:1 mixture of rotamers by NMR:
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 8.08 (t, J= 6.8, 2H), 7.82-7.75 (m, IH),
7.66-7.61 (m, 2H), 7.38-7.22 (m, 4H), 7.08-7.02 (m, IH), 5.18-5.12 (m, IH), 5.13 (d,
J= 13.1 Hz, 0.5H), 5.07 (d, J= 13.1 Hz, 0.5H), 5.06 (d, J= 12.4 Hz, 0.5H), 4.84 (d, J=
12.4 Hz, 0.5H), 4.08-4.17 (m, IH), 3.73 (s, 3H), 3.75-3.55 (m, 2H), 3.65 (s, 1.5H),
3.44 (s, 1.5H), 3.26 (s, 3H), 2.62-2.52 (partially under DMSO) (m, IH), 2.30-2.15 (m,
IH).
MS: m/z 522 (M+H)+
Step 7: Benzyl-(2S,4R)-2-(4-{ [(4-fluorobenzyl)amino]carbonyl}-5~hydroxy~l- methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-4-methoxypyrrolidine-l- carboxylate
Figure imgf000123_0001
To methyl-5-(benzoyloxy)-2-{(2S,4R)-l-[(benzyloxy)carbonyl]-4-methoxypyrrolidin- 2-yl}-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxylate,dissolved in methanol, 4- F-benzylamine (3 eq.) was added. The reaction mixture was stirred at reflux overnight. Methanol was removed in vacuo and the residue triturated with ethyl ether to give the title product as a 4:6 mixture of rotamers by NMR:
1H NMR (DMSO-d6 + TFA, 400 MHz, 300 K) δ 14.0 (bs, IH), 8.92 (t, J = 6.4 Hz, 0.4H), 8.73 (t, J = 5.9 Hz, 0.6H), 7.35-7.25 (m, 4H), 7.20-7.05 (m, 4H), 6.93 (d, J=
7.5 Hz, IH), 5.09-4.95 (m, IH), 5.09 (d, J= 12.3 Hz, 0.6H), 4.75 (d, J= 12.3 Hz, 0.6H), 5.05 (d, J= 13 Hz, 0.4H), 4.98 (d, J= 13 Hz, 0.4H), 4.52-4.43 (m, 2H), 4.12-
4.06 (bm, 0.4H), 4.06-4.02 (bm, 0.6H), 3.87 (dd, J = 11.5 and 4.5Hz, 0.4H), 3.84 (dd, J= 12 and 2.7Hz, 0.6H), 3.65-3.55 (m, IH), 3.59 (s, 1.2H), 3.41 (s, 1.8H), 3.25 (s, 3H), 2.45-2.40 (partially under DMSO) (m, IH), 2.30-2.15 (m, IH). MS: m/z 511 (M+H)+ Step 8: N-(4-fluorobenzyl)-5-hydroxy-2-[(2S,4R)-4-methoxypyrrolidin-2-yl]-
1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000124_0001
Benzyl-(2S,4R)-2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6-oxo- l,6-dihydropyrimidin-2-yl)-4-methoxypyrrolidine-l-carboxylate was dissolved in methanol and Pd/C 10%wt (14%w/w) was added. The mixture was stirred under H2 atmosphere at room temperature. After 2 hours the reaction mixture was filtered and methanol was removed in vacuo to give title compound.
1H NMR (DMSO-d6+TFA, 400 MHz, 300 K) δ 12.58 (bs, IH), 10.16 (bs, IH), 9.74 (t, J= 6.3 Hz, IH), 8.90 (bs, IH), 7.36 (dd, J = 8.5 and 5.7 Hz, 2H), 7,19 (t, J= 8.8 Hz, 2H), 5.01 (bs, IH), 4.50-4.60 (m, 2H), 4.19 (bs, IH), 3.55-3.45 (m, IH), 3.47 (s, 3H), 3.45-3.35 (m, IH), 3.32 (s, 3H), 2.74 (dd, J= 13.9 and 7.5 Hz, IH), 2.17-2.10 (m, IH). MS: m/z 377 (M+H)+
Step 9: 2-{(2S,4R)-l-[(dimethylamino)(oxo)acetyl]-4-methoxypyrrolidin-2- yl } -N-(4-fluorobenzyl)-5-hydroxy- l-methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide
To N-(4-fluorobenzyl)-5-hydroxy-2-[(2S,4R)-4-methoxypyrrolidin-2-yl]-l-methyl-6- oxo-l,6-dihydropyrimidine-4-carboxamide, triethylamine (1 eq.) was added. The reaction mixture was cooled down to 0°C and methyl chlorooxoacetate (3 eq.) was added. After 1 hour the reaction mixture was concentrated and a big excess of dimethylamine 2M in THF (30 eq.) was added The reaction mixture was concentrated and the desired compound was isolated by HPLC purification (Waters, Symmetry C18, 5um, 19x50mm eluting with water and acetonitrile containing 0.1% trifluoroacetic acid) as a 2:8 mixture of rotamers by NMR:
1H NMR (DMSO-d6, 400 MHz, 340 K) δ 11.9 (bs, IH), 8.99 (bs, 0.8H), 8.85 (bs,
0.2H), 7.40-7.30 (m, 2H), 7.14 (t, J= 8.8 Hz, 2H), 5.21 (t, J= 7.5 Hz, IH), 4.54 (dd, J=
14.9 and 6.7 Hz, IH), 4.45 (dd, J = 14.9 and 6.4 Hz, IH), 4.10 (bs, IH), 3.91 (dd, J =
11.6 and 4.6 Hz, 0.2H), 3.79 (dd, J= 11.2 and 4.4 Hz, 0.8H), 3.60-3.50 (m, IH), 3.58
(s, 2.4H), 3.48 (s, 0.6H), 3.29 (s, 0.6H), 3.27 (s, 2.4H), 2.87 (s, 2.4H), 2.81 (s, 2.4H),
2.64 (s, 0.6H), 2.57 (s, 0.6H), 2.70-2.50 (m, IH), 2.30-2.20 (m, 0.8H), 2.20-2.10 (m,
0.2H).
MS: m/z 476 (M+H)+
EXAMPLE 18
N1-[l-(4-{ [(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidin-2-yl)- 1 -methylethyl] -N2,N2-dimethylethanediamide (11).
Figure imgf000125_0001
Stepl: 2-Amino-2-methylpropanenitrile
Figure imgf000125_0002
Organic Synthesis Coll. Nol.D pg 29
Acetone cyanohydrin was diluted with MeOH (approx. 3 mmol/mL). The solution was cooled and saturated with ammonia gas, and the reaction mixture was allowed to stand for one day. The excess of ammonia and methyl alcohol were evaporated by rotary evaporation. Residue consisted in the title product.
Step 2: Benzyl 1 -cyano- 1-methylethylcarbamate
Figure imgf000126_0001
To a suspension of 2-amino-2-methylpropanenitrile in water an equimolar amount of Na2CO3 and a slight excess (1.1 eq) of benzylchloroformate were added, with an external cooling. Reaction mixture was stirred o/n at room temperature, extracted in EtOAc and the organic phase was washed with NaHCO3ss, dried (Na2SO4), filtered and concentrated. Product was obtained as a white solid.
1H-NMR (CDC13) δ 7.48-7.33 (bs, 5 H), 5.15 (s, 2 H), 4.98 (bs, 1 H), 1.68 (s, 6 H); 13C-NMR (CDCI3) δ 153.33, 13.81, 127.81, 127.63, 127.55, 120.64, 66.56, 46.19, 26.67; MS (M+l) m/z 219.
Step 3: Benzyl 2-amino-2-(hydroxyimino)- 1 , 1 -dimethylethylcarbamate.
Figure imgf000126_0002
Hydroxylamine hydrochloride in methanol was added to an equimolar stirred solution of potassium hydroxide in methanol. The mixture was stirred for 15 min and the precipitated potassium chloride was removed by filtration. The filtrate was added to an equimolar amount of the nitrile and the solution stirred overnight at 40 °C, then cooled to room temperature and concentrated. The resulting residue was triturated with water and the white solid, after drying under vacuum, consists mainly in the title product.
1H-NMR (DMSO) δ 9.12 (bs, 1 H), 7.48 (bs, 5 H), 7.08 (bs, 1 H), 5.33 (bs, 2 H), 4.98 (s, 2 H), 1.39 (s, 6 H); MS (M+l) m/z 252. Step 4: Methyl 2-(l-{ [(benzyloxy)carbonyl] amino }-l-methylethyl)-5,6- dihydroxypyrimidine-4-carboxylate.
Figure imgf000127_0001
Benzyl 2-amino-2-(hydroxyimino)-l,l-dimethylethylcarbamate was suspended in chloroform and treated with 1.2 eq of dimethylacetylenedicarboxylate and reaction was refluxed overnight. After cooling at room temperature, volatiles were evaporated and the residue was taken into xylene and heated at 145 °C for 48 h. The reaction mixture was stirred at room temperature overnight to allow the precipitation of the product (5) as a light brown solid. This solid was collected by filtration and washed with diethyl ether.
1H-NMR (DMSO) δ 12.54 (s, 1 H), 10.21 (s, 1 H), 7.44 (bs, 1 H), 7.30 (bs, 5 H), 4.95 (s, 2 H), 3.80 (s, 3 H), 1.47 (s, 6 H); MS (M+l) m/z 362.
Step 5: Methyl 5-(benzoyloxy)-2-(l-{ [(benzyloxy)carbonyl] amino }-l- methylethyl)-6-hydroxypyrimidine-4-carboxylate.
Figure imgf000127_0002
To a stirred solution of methyl 2-(l-{[(benzyloxy)carbonyl]amino}-l-methylethyl)- 5,6-dihydroxypyrimidine-4-carboxylate in pyridine, 1.1 eq of benzoic anhydride were added and stirring prolonged at room temperature over night. Pyridine was evaporated and residue was taken in ethyl acetate and washed with 1 N HCl and brine. Organic layer was separated, dried (Na2SO4), filtered and concentrated by rotary evaporation and residue was purified by flash column chromatography (SiO2, petroleum ether/ethyl acetate 60/40 v/v as eluant). Collection and evaporation of appropriate fractions afforded title product. 1H-NMR (CDCI3) δ 12.2 (bs, 1 H), 8.15 (d, 7 = 7.4 Hz, 2 H), 7.65 (t, 7 = 7.4 Hz, 1 H), 7.50 (t, 7 = 7.5 Hz, 2 H), 7.32 (bs, 5 H), 5.54 (bs, 1 H), 5.05 (s, 2 H), 3.82 (s, 3 H), 1.67 (s, 6 H); MS (M+l) m/z 466.
Step 6: Methyl 5-(benζoyloxy)-2-(l-{[(benζyloxy)carbonyl]amino}-l- methylethyl)-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxylate
Figure imgf000128_0001
To a stirred solution of LiH (1.1 eq) in dioxane, methyl 5-(benzoyloxy)-2-(l-
{ [(benzyloxy)carbonyl] amino } - 1 -methylethyl)-6-hydroxypyrimidine-4-carboxylate was added and the mixture was stirred at 38 °C for 45 min. After cooling down to room temperature, dimethylsulfate (1.3 eq) was added and reaction mixture was heated at 60 °C for 2 h. Mixture was then cooled to room temperature, dioxane evaporated and residue was purified by flash chromatography, eluting with 65/55 v/v petroleum ether/ethyl acetate. Collection and evaporation of appropriate fractions afforded the title product.
1H-NMR (CDC13) δ 8.19 (d, 7= 7.3 Hz, 2 H), 7.65 (t, 7 = 7.3 Hz, 1 H), 7.51 (t, 7 = 7.6 Hz, 2 H), 7.33 (bs, 5 H), 5.63 (bs, 1 H), 5.03 (s, 2 H), 3.80 (s, 3 H), 3.63 (bs, 3 H), 1.72 (s, 6 H); MS (M+l) m/z 480.
Step 8: Benzyl l-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-
6-oxo-l,6-dihydropyrimidin-2-yl)-l-methylethylcarbamate.
Figure imgf000128_0002
To a methanolic solution of methyl 5-(benzoyloxy)~2-(l-
{ [(benzyloxy)carbonyl] amino } - 1 -methylethyl)- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxylate, p-fluoro benzylamine (3 eq) was added and mixture was refluxed over night. After evaporation of methanol, residue was taken in EtOAc, washed with IN HCl and brine, dried (Na2SO4), filtered and evaporated to obtain the title product. 1H-NMR (CDC13) δ 11.9 (bs, 1 H), 7.79 (bt, 1 H), 7.35-7.29 (m, 7 H), 7.07 (t, 7 = 8.6 Hz, 2 H), 5.27 (bs, 1 H), 5.02 (bs, 2 H), 4.58 (d, 7 = 6.2 Hz, 2 H), 3.67 (s, 3 H), 1.70 (s, 6 H); MS (M+l) m/z 469.
Step 9: 2-(l-amino-l-methylethyl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo-l,6-dihydropyrimidine-4-carboxamide.
Figure imgf000129_0001
A methanolic solution of Benzyl l-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy- l-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-l-methylethylcarbamate was stirred over night under a hydrogen atmosphere in the presence of catalytic 10% Pd/C. Catalyst was then filtered off through celite, and the filtrate was concentrated. Product was obtained after trituration with ethyl ether.
1H-ΝMR (DMSO) δ 12.31 (bs, 1 H), 9.68 (bt, 7 = 6.6 Hz, 1 H), 8.60 (bs, 2 H), 7.43 (dd, 7= 8.4 Hz, 7 = 5.7 Hz, 2 H), 7.20 (t, 7 = 8.8 Hz, 2 H), 4.54 (d, 7= 6.6 Hz, 2 H),
3.56 (s, 3 H), 1.73 (s, 6 H); MS (M+l) m/z 335.
Step 10: Methyl {[l-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidin-2-yl)-l- methylethyl] amino } (oxo)acetate.
Figure imgf000130_0001
To a stirred mixture of 2-(l-amino-l-methylethyl)-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide (4) and triethyl amine (3 eq) in chloroform, methyl chlorooxoacetate (1.5 eq) was added with an external cooling.
Finished the addition, the ice bath was removed and the mixture was stirred at room temperature for 3h. Reaction mixture was then partitioned between chloroform and
IN HCl. Organic layer was separated, washed with brine, dried (Νa2SO ), filtered and concentrated to obtain title product.
1H-NMR (DMSO) δ 12.2 (bs, 1 H), 9.47 (s, 1 H), 9.04 (t, 7 = 6.3 Hz, 1 H), 7.38 (dd,
7= 8.4 Hz, 7 = 5.7 Hz, 2 H), 7.16 (t, 7 = 8.8 Hz, 2 H), 4.50 (d, 7 = 6.3 Hz, 2 H), 3.78
(s, 3 H), 3.45 (s, 3 H), 1.67 (s, 6 H); MS (M+l) m/z 421.
Stepl 1 : N1-[l-(4-{ [(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6- ooxxoo--11 ,,66--ddiihhyyddrrooppyyririmmiiddiinn--22--yl)- 1 -methylethyl] -N2,N2- dimethylethanediamide (11).
Methyl { [l-(4-{ [(4-fluorobenzyl)amino]carbonyl } -5 -hydroxy- l-methyl-6-oxo-l ,6- dihydropyrimidin-2-yl)-l -methylethyl] amino }(oxo)acetate was refluxed in an excess of 2 M solution of dimethylamine in THF for 2 h. Reaction mixture was cooled to room temperature, evaporated and residue was purified by RP HPLC (C18, water/acetonitrile containing 0.1% of trifluoroacetic acid as eluant). Collection and lyophilization of appropriate fractions afforded the title product. 1H-ΝMR (DMSO) δ 12.19 (s, 1 H), 9.32 (s, 1 H), 9.06 (t, 7 = 6.4 Hz, 1 H), 7.40 (dd, 7 =8.5 Hz, 7 = 5.7 Hz, 2 H), 7.18 (t, 7 = 8.8 Hz, 2 H), 4.51 (d, 7 = 6.4 Hz, 2 H), 3.55 (s, 3 H), 2.93 (s, 3 H), 2.87 (s, 3 H), 1.68 (s, 6 H); 13C-NMR (DMSO) δ 168.23, 163.76, 163.09, 161.20 (d, 7 = 96.4 Hz), 158.46, 151.90, 145.49, 134.77, 129.40 (d, 7 = 3.2 Hz), 124.29, 115.05 (d, 7 = 8.5 Hz), 56.50, 41.51, 35.46, 33.42, 32.68, 26.85; MS (M+l) m/z 434; MS (M+l) m/z 434. EXAMPLE 19
Stepl : N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-l-{ [(5-methyl-
1 ,3 ,4-oxadiazol-2-yl)carbonyl] amino } ethyl)-6-oxo- 1,6- dihydropyrimidine-4-carboxamide
Figure imgf000131_0001
A solution of 5-methyl-l,3,4-oxadiazole-2-carboxylic acid was treated with 1.9 equivalents of oxalyl chloride and a few drops of anhydrous N,N-dimethylformamide. After 1 h, mixture was concentrated, residue was triturated with ra-hexane and directly added to an equimolar solution of 2-(l-amino-l-methylethyl)-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide (described in step 9, example 18) in acetonitrile. Triethyl amine (3 eq) was added to the mixture and the reaction was stirred overnight at room temperature. Title product was isolated by prep RP HPLC (C18, acetonitrile/water containing 0.1% of trifluoroacetic acid as eluant). 1H-ΝMR (DMSO) δ 12.2 (bs, 1 H), 9.84 (s, 1 H), 9.05 (t, 7= 6.5 Hz , 1 H), 7.38 (dd, 7 = 8.4 Hz, 7 = 5.6 Hz, 2 H), 7.17 (t, 7 = 8.8 Hz, 2 H), 4.50 (d, 7 = 6.5 Hz, 2 H), 2.56 (s, 3 H), 1.74 (s, 6 H), one methyl signal obscured by water, MS (M+l) m/z 445.
EXAMPLE 20
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]-4,4-difluoropyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide
Figure imgf000132_0001
Stepl: 1 -Benzyl -2-methyl-(2S)-4-oxopyrrolidine-l ,2-dicarboxylate
Figure imgf000132_0002
A solution of dimethyl sulfoxide (2.1 eq) in dry dichloromethane was added dropwise to a stirred solution of oxalyl chloride (1.01 eq) in dry dichloromethane (1.25 N) at - 78 °C under N2 atmosphere. After 15 min, a solution of the commercially available 1- benzyl-2-methyl-(2S,4R)-4-hydroxypyrrolidine-l,2-dicarboxylate in dry dichloromethane was added slowly, and stirring was continued for 30 min at -78 °C. After addition of triethylamine (5 eq), the mixture was gradually warmed up to room temperature. The mixture was quenched with water and aqueous layer was separated and extracted with dichloromethane. The extract was washed with brine and dried over Na2SO4. Concentration of the solvent in vacuo gave a residue, which was purified by flash cromatography (ethyl acetate:petroleum ether = 3:7) to give title product as a yellow oil.
1H NMR (DMSO-d6+TFA, 400 MHz, 330 K) δ 7.40-7.32 (m, 5H), 5.20-5.09 (m, 2H), 4.79 (d, J = 9.7 Hz, IH), 3.95 (d, J = 17.9 Hz, IH), 3.78 (d, J = 17.9 Hz, IH), 3.64 (s, 3H), 3.13 (dd, J = 18.7 and 10.6, IH), 2.62 (dd, J = 18.7 and 2.7 Hz, IH). MS: m/z 278 (M+H)+
Step 2: 1-Benzyl 2-methyl (2S)-4,4-difluoropyrrolidine-l,2-dicarboxylate
Figure imgf000133_0001
A solution of l-benzyl-2-methyl-(2S)-4-oxopyrrolidine-l,2-dicarboxylate in dichloromethane was slowly added to a solution of diethylaminosulfur fluoride in dichloromethane precooled to - 78 °C. The reaction mixture was warmed to room temperature and mixed with cold water. The organic layer was separated, washed with water, dried over Na2SO and evaporated to give title compound as a yellow oil. 1H NMR (DMSO-d6, 400 MHz, 330K) δ 7.40-7.32 (m, 5H), 5.16-5.12 (m, 2H), 4.63 (br s, IH), 3.96-3.80 (m, 2H), 3.65 (s, 3H), 3.15-2.86 ( , IH), 2.56-2.45 (partially under DMSO) (m, IH). 19F NMR 1H-19F dec (DMSO-de, 400 MHz, 330 K) δ - 98.13 (d, J = 223.7 Hz) + -98.72 (d, J = 223.6 Hz) (rotamer a), -101.38 (d, J = 190.7 Hz) + -102.00 (d, J = 191.3 Hz) (rotamer b) (2F). MS m/z 300 (M + H)+.
Step 3: l-[(Benzyloxy)carbonyl]-4,4-difluoro-L-proline
Figure imgf000133_0002
A solution of 1 -benzyl 2-methyl (2S)-4,4-difluoropyrrolidine-l,2-dicarboxylate in methanol was refluxed with 2N NaOH (2 eq) for 2 hours. Methanol was removed and pH adjusted to 1 with 3 N HCl obtaining a suspension which was extracted several times with ethyl acetate. Combined organics were dried over Na2SO4 and evaporated to give title product as a dark brown oil.
1H NMR (DMSO-d6, 400 MHz, 330K) δ 12.96 (br s, IH), 7.36-7.31 (m, 5H), 5.11 (s, 2H), 4.50 (bs, IH), 3.91-3.80 (m, 2H), 3.01-2.82 (m, IH), 2.56-2.41 (partially under DMSO) (m, IH). MS: m/z 284 (M-H)+.
Step 4: Benzyl-(2S)-2-aminocarbonyl-4,4-difluoropyrrolidine-l-carboxylate
Figure imgf000134_0001
To a stirred solution of l-[(benzyloxy)carbonyl]-4,4-difluoro-L-proline, pyridine (0.6 eq.) and di-t-butyl dicarbonate (1.3 eq) in dioxane, ammonium bicarbonate (1.26 eq) was added and the mixture was stirred at room temperature for 20 hours. Dioxane was concentrated and the residue dissolved in ethyl acetate and washed with HCl 1 N, saturated aqueous NaHCO3 and brine, dried over Na2SO , filtered and evaporated in vacuo to obtain a yellow oil.
Two sets of signals, two conformers (ratio 1:1) were present. 1H NMR (DMSO-d6,400 MHz, 300 K) δ 7.56 (d, J = 15.4 Hz, IH), 7.39-7.34 (m, 5H), 7.17 (d, J = 19.3 Hz, IH), 5.10-5.08 (m, 2H), 4.42 (dd, J = 9.3 and 4.7, 0.5 H), 4.34 (dd, J = 9.2 and 4.6 Hz, 0.5 H), 3.92-3.73 (m, 2H), 2.90-2.72 (m, IH), 2.43-2.30 (m, IH). MS: m/z 285 (M+H)+.
Step 5: Benzyl-(2S)-2-cyano-4,4-difluoroρyrrolidine-l -carboxylate
Figure imgf000134_0002
A solution of benzyl-(2S)-2-aminocarbonyl-4,4-difluoropyrrolidine-l -carboxylate and triethylamine (2.1 eq.) in dichloromethane was cooled to 0°C and trifluoroacetic anhydride (1.1 eq.) was added dropwise under nitrogen. Stirring was continued for 1 hour allowing the mixture to reach room temperature. Nolatiles removed in vacuo and residue taken up in ethyl acetate, washed with HCl IN, brine and dried over Νa2SO4. Evaporation gave title compound as brown oil.
1H NMR (DMSO-d6, 400 MHz, 300 K) δ 7.40-7.34 (m, 5H), 5.20-5.03 (m, 3H), 3.99-3.72 (m, 2H), 3.06-2.69 (m, 2H).
Step 6: Benzyl-(2S)-2-[amino(hydroxyimino)methyl]-4,4-difluoropyrrolidine-
1 -carboxylate
Figure imgf000135_0001
A solution of benzyl-(2S)-2-cyano-4,4-difluoropyrrolidine-l-carboxylate, hydroxylamine hydrochloride (1.4 eq.) and triethylamine (1.7 eq.) in ethanol was refluxed under nitrogen for 5 hours. Mixture was concentrated and residues taken up 5 in ethyl acetate and washed with water and brine. Combined organics were dried over Na2SO4 and evaporated to give title compound as a foam.
1H NMR (DMSO-d6, 300 MHz, 330 K) δ 9.12 (bs, IH), 7.38-7.34 (m, 5H), 5.36 (bs, 2H), 5.13 (d, J = 14.4 Hz, IH) + 5.09 (d, J = 14.4 Hz, IH), 4.56 (dd, J = 8.6 and 4.9 Hz, IH), 4.07-3.76 (m, 2H), 2.80-2.71 (m IH), 2.60-2.51 (partially under DMSO) (m, 10 IH).
MS: m/z 300 (M+H)+.
Step 7: Dimethyl-2-{ [(amino-{ (2S)-l-[(benzyloxy)carbonyl]-4,4- difluoropyrrolidin-2-yl}methylidene)amino]oxy}but-2-enedioate
Figure imgf000135_0002
A solution of benzyl-(2S)-2-[amino(hydroxyimino)methyl]-4,4-difluoropyrrolidine-l- carboxylate and dimethylacetylendicarboxylate (1.2 eq.) in chloroform was refluxed for 1 hour under nitrogen and the solution was concentrated. Residue was purified by flash chromatography on silica gel, (eluent: petroleum ether:ethyl acetate = 7.5:2.5), to
20 give the desired product as a 3: 1 mixture of two isomers by 1H NMR.
1H NMR (DMSO-d6, 300 MHz, 330 K) δ 7.45 -7.25 (m, 5H), 6.63 (bs, 1.5H), 6.30 (bs, 0.5H), 5.62 (s, 0.75H), 5.60 (s, 0.25H), 5.13 (s, 2H), 4.58 (dd, J = 9.1 and 4.9 Hz) + 4.57 (dd, partially overlapped) (IH), 3.96-3.86 (m, 2H), 3.79 (s, 2.2H), 3.74 (s, 0.8H), 3.66 (s, 0.8H), 3.61(s, 2.2H), 2.93-2.81(m, IH), 2.56-2.43 (partially under
25 DMSO)(m, IH).
MS: m/z 442 (M+H)+. Step 8: Methyl-2-{(2S)-l-[(benzyloxy)carbonyl]-4,4-difluoropyrrolidin-2-yl}-
Figure imgf000136_0001
A solution of dimethyl-2-{ [(amino-{(2S)-l-[(benzyloxy)carbonyl]-4,4- difluoropyrrolidin-2-yl } methylidene)amino] oxy } but-2-enedioate in o-xylene was refluxed for 6 hours. Then the reaction was cooled down and concentrated at rotavapor. Ethyl ether was added until precipitation of a solid that was filtered, washed with other ethyl ether and dried to give the title pyrimidine as a brown solid. Two sets of signals, two rotamers (ratio 1:1) were present. 1H NMR (DMSO-d6, 400 MHz, 300 K) δ 12.97 (s, IH), 10.38 (s, IH), 7.40-7.29 (m, 3H), 7.22-7.15 (m, IH); 7.10-7.05 (m, IH), 5.12 (d, J = 12.6 Hz, 0.5H) 5.10 (s, IH), 4.89 (d, J = 12.6 Hz, 0.5H), 4.86-4.72 (m, IH), 4.10-3.86 (m, 2H), 3.81 (s, 3H), 2.90-2.85 (m, IH), 2.64-2.53 (partially under DMSO) (m, IH). MS: m/z 410 (M+H)+.
Step 9: Methyl 5-(benzoyloxy)-2-{(2S)-l-[(benzyloxy)carbonyl]-4,4-
Figure imgf000136_0002
Methyl-2-{(2S)-l-[(benzyloxy)carbonyl]-4,4-difluoropyrrolidin-2-yl}-5,6- dihydroxypyrimidine-4-carboxylate in dry pyridine was treated with benzoic anhydride (2 eq.) overnight at room temperature.
The mixture was evaporated, taken up in ethyl acetate and washed with HCl IN and brine. Organics were dried over Na2SO4, filtered and evaporated to obtain an oil which was purified by flash chromatography on silica gel (eluent: ethyl acetate:petroleum ether = 7:3). 1H NMR (DMSO-d6) 300 MHz, 330 K) δ 13.51 (bs, IH), 8.10 (d, J = 7.6 Hz, 2H), 7.79 (t, J = 7.1 Hz, IH), 7.64 (t, J = 7.6 Hz, 2H), 7.33-7.17 (m, 5H), 5.13 (s, 2H), 4.99 (t, J = 7.3 Hz, IH), 4.09-3.97 ( , 2H), 3.77 (s, 3H), 3.02-2.99 ( , 2H). MS: m z 514 (M+H)+.
Step 10: Methyl-5-(benzoyloxy)-2-{ (2S)-l-[(benzyloxy)carbonyl]-4,4- difluoroρyrrolidin-2-yl } - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4- carboxylate
Figure imgf000137_0001
Methyl 5-(benzoyloxy)-2-{ (2S)-l-[(benzyloxy)carbonyl]-4,4-difluoropyrrolidin-2-yl}- 6-hydroxypyrimidine-4-carboxylate dissolved in dry 1,4-dioxane was added to a suspension of LiH (1.4 eq.) in dioxane. The mixture was stirred at 38° C for 45 minutes and then cooled down to room temperature. Dimethyl sulphate (1.3 eq.) was added and the mixture was warmed to 58 °C for 1 hour. The reaction mixture was cooled down to 16 °C and glacial acetic acid (0.1 eq) was added, followed by water and ethyl acetate. The combined organic layers were dried (Na2SO ), filtered and concentrated to an oil which was cromatographed through silica gel (eluent: ethyl acetate:petroleum ether=3:7) to give the desired compound as a 1:1 mixture of two rotamers by 1H NMR 1H NMR (DMSO-de, 300 MHz, 300 K) δ 8.11-8.08 (m, 2H), 7.80 (t, J= 7.7 Hz, IH), 7.67 - 7.65 (m, 2H), 7.36-7.10 (m, 5H), 5.50 (dd, J = 9.2 and 4.7 Hz, IH), 5.22 (d, J = 12.9 Hz, 0.5H), 5.14-4.95 (m, IH), 4.93 (d, J = 12.3 Hz, 0.5H), 4.16-3.79 (m, 2H), 3.74 (s, 3H), 3.61 (s,1.5H), 3.45 (s,1.5H), 3.25-3.11 (m, IH), 2.89-2.74 (m, IH). MS: m/z 528 (M+H)+.
Step 11: Benzyl-(2S)-4,4-difluoro-2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidin-2-yl)pyrrolidine- 1 - carboxylate
Figure imgf000138_0001
Methyl-5~(benzoyloxy)-2- { (2S)- 1 - [(benzyloxy)carbonyl] -4,4-difluoropyrrolidin-2-yl } - l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxylate in dry MeOH was treated with 4-fluorobenzyl amine (2.5 eq.) at reflux for 2 hours. Solvent was removed in vacuo and the residue was taken up in ethyl acetate, washed with HCl IN, brine, dried over Na2SO4. The filtrate was concentrated in vacuo and triturated with ethyl ether to obtain the title compound as a 1.5:1 mixture of two rotamers by NMR. 1H NMR (DMSO-d6+TFA, 300 MHz, 300 K) δ 8.92 (bt, 0.4H), 8.69 (bt, 0.6H), 7.36- 7.31 (m, 4H), 7.20-7.09 (m, 4H), 6.97 (d, J = 7.2 Hz, IH), 5.34-5.25 (m, IH), 5.14 (d, J = 12.4 Hz, 0.4H ), 5.07-4.99 (m, 1.2H), 4.81 (d, J = 12.2 Hz, 0.4H), 4.51-4.48 (m, 2H), 4.38-4.21 (m, IH), 4.07-3.96 (m, IH), 3.59 (s, 1.2H),3.48 (s, 1.8H), 3.05- 2.95 (m, IH), 2.78-2.68 (m, IH). MS: m/z 517 (M+H)+.
• Step 12: (2S)-4,4-difluoro-2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-
1 -methyl-6-oxo- 1 ,6-dihydropyrimidin-2-yl)pyrrolidinium trifluoroacetate
Figure imgf000138_0002
A solution of benzyl-(2S)-4,4-difluoro-2-(4-{ [(4-fluorobenzyl)amino]carbonyl}-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidin-2-yl)pyrrolidine- 1-carboxylate in MeOH was treated with Pd/C 10%wt (10% w/w) for 3 hours at room temperature under H2 atmosphere. The mixture was filtrated over a celite pad, concentrated in vacuo and treated with trifluoroacetic acid (10 eq.). The acid in excess was removed in vacuo to obtain title product as a pale yellow solid after trituration with ethyl ether. 1H NMR (DMSO-de+TFA, 300 MHz, 340K) δ 9.60 (bt, IH), 7.39 (t, J = 8 Hz, 2H), 7.17 (t, J = 8,8 Hz, 2H), 5.35 (t, J = 8.4 Hz, IH), 4.62 (dd, J = 15.3 and 6.6 Hz, IH), 4.55 (dd, J = 15.2 and 6.3 Hz, IH), 4.05-3.87 (m, 2H), 3.48 (s, 3H), 3.30-3.14 (m, IH), 2.96- 2.78 (m, IH). MS: m/z 383 (M+H)+.
Step 13: 2-{ (2S)-l-[(dimethylamino)(oxo)acetyl]-4,4-difluoropyrrolidin-2-yl }-
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-
4-carboxamide
A solution of (2S)-4,4-difluoro-2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidin-2-yl)pyrrolidinium trifluoroacetate in chloroform and triethylamine (1.01 eq.) was treated with methyl chlorooxacetate (2 eq.) at 0 °C.
The mixture was allowed to reach room temperature for 2 hours. Dimethylamine (30 eq.) was added at room temperature and the mixture left stirring over night. The mixture was concentrated in vacuo and purified by preparative HPLC (Column: C18, eluent: acetonitrile and water containing 0.1 % trifluoroacetic acid). To obtain the title product two rotamers (ratio 4:1) were found in 1H ΝMR. 1H ΝMR (DMSO-d6+TFA, 300 MHz, 300 K) δ 9.23 (t, J = 6.5 Hz, 0.8H), 9.10 (bt, 0.2H), 7.34 - 7.31 (m, 2H), 7.11 (t, J = 8.8 Hz, 2H), 5.48 (dd, J = 8.9 and 5.7 Hz, IH), 4.53 (dd, J = 15.0 and 6.7 Hz, IH), 4.42 (dd, J = 15.0 and 6.2 Hz, IH), 4.24-4.16 (m, IH), 4.05-4.02 (t, J = 11.8 Hz, IH), 3.52 (s, 2.4H), 3.45 (s, 0.6H), 3.15-3.04 (m, 1.6H), 2.84 (s, 2.4H), 2.80 (s, 2.4H), 2.79 - 2.65 (m, 0.4H), 2.63 (s, 0.6H), 2.57 (s, 0.6H). MS: m/z 482 (M+H)+.
EXAMPLE 21 2- [ 1 ,2-dimethyl-4-(methylsulf onyl)piperazin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide
Figure imgf000140_0001
Stepl: 1 -benzyl 4-tert-butyl 2-cyano-2-methylpiperazine-l,4-dicarboxylate
Boc
Figure imgf000140_0002
Cbz
To a cooled (-75 °C) solution of LDA 2M in heptane/THF (1.5 eq) in THF, a solution of l-[(benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid
(Bigge et al, Tetrahedron Lett. 1989, 30: 5193) in THF was added dropwise at -75°C.
After being stirred for 1 hour at -75 °C, Mel (1.5 eq) was added. After 2 hours at -75 °C the reaction mixture was left warming to r.t., evaporated, diluted with AcOEt, washed with NaHCO3, water, brine and dried over Na2SO4.. The crade was purified by flash chromatography on silica gel (petroleum ether/ AcOEt, 85:15) to obtain the title compound .
1H NMR (DMSOd6, 340K, 300MHz) δ 7.45-7.30 (m, 5H), 5.19 (AA' system, J = 13 Hz, 2H), 4.05 (d, J = 14 Hz, IH), 3.87-3.78 (m, IH), 3.66 (d, J = 14 Hz, IH), 3.62-
3.35 (m, 3H), 1.66 (s, 3H), 1.45 (s, 9H).
MS: m/z 360 (M+H)+.
Step 2: 1-benζyl 4-tert-butyl 2-[(Z)-amino({ [(l£)-3-methoxy-l- (methoxycarbonyl)-3-oxoprop-l-enyl]oxy}imino)methyl]-2-methyl piperazine- 1 ,4-dicarboxylate. Boc
Figure imgf000141_0001
A solution of 1 -benzyl 4-terf-butyl 2-cyano-2-methylpiperazine-l,4-dicarboxylate in EtOH was added to a solution of Et3N (3.2 eq) and NH2OH HCl (3 eq) in EtOH. The mixture was stirred 2 hr at 40 °C. After evaporation of the solvent, the residue was diluted with AcOEt, washed with water, dried over Na2SO4, filtered and concentrated. The residue was further dissolved in chloroform and dimethylacetylenedicarboxylate (1.5 eq) added to the stirred solution. Reaction was refluxed over night. The mixture was evaporated and the residue was purified by flash chromatography on silica gel (petroleum ether/ AcOEt, 65:35) affording the title compound as mixuture of isomers in 3.5:1 ratio.
1H NMR (DMSOd6, 340K, 300MHz). Two sets of signals were observed due to the presence of the geometric isomers: δ 7.48-7.25 (m, 5H), 6.31( bs, 1.56 H), 6.01 (bs, 0.44 H), 5.63 ( s,0.78 H), 5.55 (s, 0.22 H), 5.12-5.02 (m, 2H), 3.85-3.60 (m, 9H), 3.60-3.45 (m, 2H), 3.45-3.31 (m, IH), 1.51 (s, 2.4H) , 1.45 (s, 0.66 H), 1.41 (s, 9H). MS: m/z 535 (M+H)+.
Step3: 1-benzyl 4-tert-butyl 2-[5-(benzoyloxy)-4-hydroxy-6-
(methoxycarbonyl) pyrimidin-2-yl]-2-methylpiperazine- 1 ,4-dicarboxylate
Figure imgf000141_0002
1-benzyl 4-tert-butyl 2-[(Z)-amino({ [(lE)-3-methoxy-l-(methoxycarbonyl)-3- oxoprop-l-enyl]oxy}imino)methyl]-2-methylpiperazine-l,4-dicarboxylate was dissolved in xylene and stirred at 155 °C for 8h. After evaporation of the solvent, the residue was dissolved in pyridine and benzoic anhydride (1.5 eq) was added. The reaction mixture was stirred at room temperature over night, then pyridine was evaporated. The residue was diluted with AcOEt, the organic phase washed with HCl IN, dried (Na2SO4) and evaporated. The title product was obtained by flash chromatography (eluent: petroleum ether/ AcOEt 70/30).
1H-NMR (DMSOde, 340K, 400MHz) δ 12.96 (bs, IH), 8.07 (d, 7=7.2 Hz, 2 H), 7.76 (t, 7=7.6 Hz, IH), 7.62 (t, 7=7.6 Hz, 2H), 7.37-7.22 (m, 5H), 5.03 (s, 2H), 3.96 (dt Hz, 72=5.8 Hz, IH), 3.80-3.52 (m, 7H), 3.47-3.40 (m, IH), 1.65 (s, 3H), 1.35 (s, 9H).
MS: m/z 607 (M+H)+.
Step 4: 1-benzyl 4-tert-butyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-l- methyl-6-oxo- 1 ,6-dihydropyrimidin-2-yl] -2-methylpiperazine- 1 ,4- dicarboxylate.
Figure imgf000142_0001
A B
1-Benzyl 4-tert-butyl 2-[5-(benzoyloxy)-4-hydroxy-6-(methoxycarbonyl) pyrimidin- 2-yl]-2-methylpiperazine-l,4-dicarboxylate was added to a suspension of LiH (1.1 eq) in dioxane (7 ml/mmol) at room temperature. The mixture was stirred at 40 °C for 45 min, then dimethylsulfate (1.3 eq) was added and the temperature was raised to 60 °C. After 1 h glacial acetic acid (0.1 eq) was added to the reaction mixture, followed by water (7 ml/mmol) and EtOAc (7 ml/mmol). The aqueous layer was separated and extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated. The crude was purified by flash chromatography on silica gel (AcOEt/petroleum ether, 1:4) to separate the title compound A from B (ratio A/B
1.3/1).
A: 1H NMR (CD3CN, 320K, 300MHz) δ 8.18 (d, 7=7.2 Hz, 2H), 7.80 (t, 7=7.5 Hz,
IH), 7.63 (t, 7=7.8 Hz, 2H), 7.45-7.22 (m, 5H), 5.08 (AA' system, J = 12 Hz, 2H),
4.18-3.88 (m, 3H), 3.81 (s, 3H), 3.68-3.46 (m, 5H, at 3.58 (s)), 3.40-3.22 (m, IH),
1.75 (s, 3H), 1.49 (s, 9H) .
MS: m/z 621 (M+H)+.
Step 5: Methyl 5-(benzoyloxy)-2-[4-(tert-butoxycarbonyl)-2-methylpiperazin-
Figure imgf000143_0001
1 -Benzyl 4-tert-butyl 2- [5 -(benzoyloxy)-4-(methoxycarbonyl)- 1 -methyl-6-oxo- 1,6- dihydropyrimidin-2-yl]-2-methylpiperazine-l,4-dicarboxylate was dissolved in AcOEt (20 ml/mmol) and hydrogenated at atm pressure on 10% (w/w) Pd/C over night. After filtration of the catalyst, solvent was evaporated to give crade product.
1H NMR (DMSOd6 + TFA, 340K, 400MHz) δ 8.08 (d, J = 7.1 Hz, 2H), 7.787 (t, J = 7.4 Hz, IH), 7.63 (t, J =7.8 Hz, 2H), 4.30 (d, J = 15.2 Hz, IH), 3.90-3.50 (m, lOH), 3.35-3.25 (m, IH), 1.81(s, 3H), 1.37 (s, 9H) . MS (EI+) m/z 487 (M+H)+.
Step 6: 2-[l,2-dimethyl-4-(methylsulfonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-
5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide .
Crude methyl 5-(benzoyloxy)-2-[4-(tert-butoxycarbonyl)-2-methylpiperazin-2-yl]-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxylate was dissolved in MeOH, p- fluorobenzylamine (3.0 eq) was added and the mixture was refluxed over night. Evaporation of the solvent afforded crude product. MS: m/z 476 (M+H)+. Crude obtained in the previous step was dissolved in MeOH (20 ml/mmol) and NaCNBHj (2.8 eq), AcONa (3.2 eq) and HCHO 37 % in H2O (4eq) were added. The reaction mixture was stirred at room temperature over night, evaporated and the crude solid (4-fluorobenzyl 2-[4-(?ert-butoxycarbonyl)- 1 ,2-dimethylpiperazin-2-yl]-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxylate) obtained washed with Et2O.
MS (EI+) m/z 490 (M+H)+.
Deprotection of Boc group was carried out in DCM/TFA (1:1, 10 ml/mmol) for 1 hour. MS (EI+) m/z 390 (M+H)+. The crude product was dissolved in DCM , Et3N (3.3 eq) and MeSO2Cl (2.6 eq) were added and the reaction was stirred at room temperature over night. The reaction mixture was evaporated and the crude residue purified by preparative HPLC (C18, gradient of CH3CN/H2O + 0.01% TFA) to obtain the title product. 1H NMR (CD3CN + TFA, 320K, 400MHz) δ 8.51 (bs, IH), 7.46-7.36 (m, 2H), 7.15- 7.10 (m, 2H), 4.64 (d, J = 6.4 Hz, 2H), 4.04 (dd, Jj = 14.4 Hz, J2 = 2.2 Hz, IH), 3.88- 3.80 (m, IH), 3.68 (dt, JΪ = 13.6 Hz, J2 = 3.3 Hz, IH), 3.61 (s, 3H), 3.60-3.50 (m, IH) 3.42-3.31(m, 2H), 2.94 (s, 3H), 2.81 (s, 3H), 1.92 (s, 3H). MS: m/z 468 (M+H)+. Tables 1 and 2 below list compounds of the present invention which have been prepared. The tables provide the structure and name of each compound, the mass of its molecular ion plus 1 (M+) or molecular ion minus 1 (M-) as determined via FIA-MS, and the synthetic scheme employed to prepare the compound. When the compound was prepared as a salt, the identity of the salt is included with the compound name. The synthetic scheme identified as "1*" in Table 1 is identical to Scheme 1 above, except for an additional deprotection step to remove Boc, Cbz, or benzyl present in the 2-substituent in the pyrimidinone ring. Table 1
Exp Structure Name M+ Scheme
N-(2-ethoxybεnzyl)-5-hydroxy- 394 l-methyl-2-(4-methylρhenyl)-6- oxo- 1 ,6-dihydropyrimidme-4- carboxamide
N-(2,3-diιnethoxybenzyI)-5- 410 hy droxy- 1 -methyl-2- (4- methylphenyl)-6-oxo-l,6- dihydropyrimidine-4- carboxamide
N-(2,3-dimethoxybenzyl)-2-{4- 453 [(dimethylamino)methyl]phenyl } -5-hy droxy-1 - ethy 1-6-oxo- l,6-dihydropyrimidine-4-
Figure imgf000145_0001
carboxaπύde (TFA salt)
N-(4-fluorobenzyl)-2-{4- 411 [(dimethylamino)methyl]phenyI }-5-hydroxy-l-methyl-6-oxo- 1 ,6-di ydropyrimidine-4- carboxamide (TFA salt)
N-(2,3-dimethoxybenzyl)-5- 479 hy droxy- 1 -methy l-6-oxo-2- [4- (pyrrolidin- l-ylmethyl)ρhenyl]- 1 ,6-dihydropyrimidine-4- carboxamide (TFA salt)
N-(4-fluorobenzy l)-5 -hydroxy- 1 437 methyl-6-oxo-2-[4-(pyrrolidin-l ylmethyl)pheπyl]- 1 ,6- dihydropyrimidme-4- carboxamide (TFA salt)
N-(4-fluorobenzyl)-5-hydroxy-l 451 methyl-6-oxo-2- [4-(piρeridin- 1 ylmethyl)ρhenyl] -1,6- dihydropyrimidine-4- carboxamide (TFA salt)
N-(2,3-dimethoxybenzyl)-5- 495 hydroxy- l-methyl-2- [4- (morpholin-4-ylmethyl)pbeny 1] ■ 6-oxo- 1 ,6-dihydropyrimidine-4-
Figure imgf000145_0002
carboxamide (TFA salt)
Figure imgf000146_0001
l-[2-(dimethylamino)ethyl]-N- 425 (4-fluorobenzyl)-5-hydroxy-2- (2-methylphenyl)-6-oxo- 1,6- dihydropyrimidine-4- carboxamide (TFA salt)
N-(4-fluorobenzyl)-5-hydroxy-l 368 methyl-2-(4-methylphenyl)-6- oxo- l,6-dihydropyrimidine-4- carboxamide
2-benzyl-N-(2,3- 467 dimethoxybenzyl)-l-[2- (dimethylamino)ethyl]-5- hydroxy-6-oxo- 1 ,6- dihydropyrimidine-4- carboxamide (TFA salt)
2- { 4- [(4-ethylpiperazin- 1- 480 yl)methyl]phenyl}-N-(4- fluorobenzyl)-5 -hydroxy- 1 - metlιyl-6-oxo-l,6-
Figure imgf000147_0001
dihydropyrimidine-4- carboxamide (TFA salt)
N-(4-fluorobenzyl)-5-hydroxy- 528 methy 1-6-0X0-2- {4- [(2-pyridin- 3-ylpiperidin-l- yl)methyl]phenyl } - 1 ,6- dihydropyrimidine-4- carboxamide (TFA salt)
N-(4-fluorobenzyl)-5-hydroxy-l 276 (M-) methyl-6-oxo-l,6- dihydropyriπ-idine-4- carboxamide
N-(2,3-dimethoxybenzyl)-5- 320 hydroxy- 1-methy 1-6-oxo- 1 ,6- dihydropyrimidine-4- carboxamide
N-[4-fluoro-2- (M-) 344 (trifluoromethyl)benzyl]-5- hydroxy- l-methyl-6-oxo- 1 ,6- dihydropyriπ-idine-4- carboxamide
Figure imgf000147_0002
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
96 N-(4-fluorobenzyl)-5-hydroxy-2 452 ( 1 -isonicotinoylpyrrolidin-2-y 1)- l-methyl-6-oxo-l,6- dihydropyrimidine-4- carboxamide (TFA salt)
97 2-{ l-[(ethylamino)carbonyl]- 418 pyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1,6- dihydropyrimidine-4- carboxamide
98 N-(4-fluorobenzyl)-5-hydroxy-l 455 methyl-2-{ 1 -[(1-methyl- lH- imidazol-2- yl)carbonyl]pyrrolidin-2-yl}-6 oxo- 1 ,6-dihydropyrimidine-4- carboxamide (TFA salt)
99 2-[(2S,4R)-l-acetyl-4- 405 1* hydroxypyrrolidin-2-yl]-N-(4- fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6- dihydropyrimidine-4- carboxamide
100 2- [ 1 -(anilinocarbony l)pyrrolidin 466 2-yl]-N-(4-fluorobenzyl)-5- hy droxy- 1 -methy 1-6-oxo- 1 , 6- dihydropyrimidine-4- carboxamide
101 2-(4-ethyl-l-methylpiperazin-2- 404 yl)-N-(4-fluorobenzyl)-5- hydroxy- l-methyl-6-oxo- 1 ,6- dihydropyrimidine-4- carboxamide (TFA salt)
102 N-(4-fluorobenzyl)-5-hydroxy-l 468 methyl-2- { l-[(l-oxidopyridin-2- yl)carbonyl]pyrrolidin-2-yl } -6- oxo- 1 , 6-dihydropyrimidine-4- carboxamide
103 N-(4-fluorobenzyl)-5-hydroxy- 1 453 methyl-6-oxo-2-[l-(pyrazin-2- ylcarbonyl)pyrrolidin-2-yl]- 1 ,6 dihydropyrimidine-4- carboxamide (TFA salt)
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications that come within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
A compound of Formula (I):
Figure imgf000168_0001
wherein
Rl i IS
(1) -H,
(2) -Cχ_6 alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-Cθ-6 alkyl-N(RaRb), N(Ra)-C(=O)-Cθ- 6 alkyl-N(RbRc), -SO2R , -N(Ra)SO2Rb, -SO2N(RaRb),
-N(Ra)-C(=O)Rb,
Figure imgf000168_0002
, or -N(R2)C(=O)C(=O)N(RaRb),
(3) -Rk,
(4) -Cι_6 alkyl-Rk, wherein:
(i) the alkyl is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -O-Cι_6 alkyl, -O-Ci-6 haloalkyl, -N(RaRb), -N(Ra)CO2R , -N(Ra)C(=O)-Co-6 alkyl-N(RbRc), or -N(Ra)-C2-6 alkyl-OH with the proviso that the -OH is not attached to the carbon alpha to N(Ra); and
(ii) the alkyl is optionally mono-substituted with -Rs, -Ci-6 alkyl-Rs, -N(Ra)-C(=O)-Cθ-6 alkyl-Rs, -N(Ra)-Cθ-6 alkyl-Rs, -O-Co-6 alkyl-Rs, or -N(Ra)-C(=O)-CQ-6 alkyl-RS; wherein Rs is
(a) aryl which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -Cι_6 alkyl, -Cι_6 alkyl-ORa, -Cι_6 haloalkyl, -O-Cι_6 alkyl, -O-Ci-6 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or aryl; (b) a 4- to 8- membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with one or more substituents each of which is independently halogen, -Ci_6 alkyl, -Cι_β alkyl-ORa, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C(=O)R
-CO2Ra, -C(=O)-Co-6 alkyl-N(RaRb), -SO2Ra, oxo, aryl, or -Ci-6 alkyl-aryl; or
(c) a 5- to 7-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with one or more substituents each of which is independently halogen, -C\-β alkyl, -Cj_6 alkyl-ORa, -Cι_6 haloalkyl, -O-Cι_6 alkyl, -O-Cι_6 haloalkyl, oxo, or aryl; (5) -Co-6 alkyl-O-Co-6 alkyl-Rk, (6) -Co-6 alkyl-S(O)n-Co-6 alkyl-Rk,
(7) -O-Ci-6 alkyl-ORk,
(8) -O-Ci-6 alkyl-O-Ci-6 alkyl-Rk,
(9) -O-Ci-6 alkyl-S(O)nRk
(10) -Co-6 alkyl-N(Ra)-Rk, (11) -Co-6 alkyl-N(Ra)-Cι_6 alkyl-Rk,
(12) -Co-6 alkyl-N(Ra)-Cι_6 alkyl-ORk,
(13) -Co-6 alkyl-C(=O)-Rk
(14) -Co-6 alkyl-C(=O)N(Ra)-Co-6 alkyl-Rk,
(15) -Co-6
Figure imgf000169_0001
alkyl-Rk, (16) -Co-6 alkyl-N(Ra)C(=O)-O-Co-6 alkyl-Rk, or
(17) -Co-6 alkyl-N(Ra)C(=O)C(=O)Rk;
R2 is -C\-β alkyl which is optionally substituted with one or more substituents each of which is independently (1) halogen,
(2) -OH,
(3) -CN,
(4) -O-Ci-6 alkyl, (5) -O-Ci-6 haloalkyl,
(6) -C(=O)Ra,
(7) -CO2Ra,
(8) -SRa,
(9) -S(=O)Ra, (10) -N(RaRb),
(11) -C(=O)N(RaRb),
(12) -N(Ra)-C(=O)-Cι_6 alkyl-N(RbRc),
(13) -SO2Ra,
Figure imgf000170_0001
(16) -N(Ra)-C(Rb)=O,
(17) -C3_8 cycloalkyl,
(18) aryl, wherein the aryl is optionally substituted with one or more substituents each of which is independently halogen, -Ci-6 alkyl, -C i -6 haloalkyl, -O-C i -6 alkyl, -O-C 1 -6 haloalkyl,
-Co-6 alkyl-N(RaRb), or -Ci-6 alkyl substituted with a 5- or 6- membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C\-β alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or
(19) a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heterocycle is optionally substituted with one or more substituents each of which is independently -C -β alkyl, -O-Ci-6 alkyl, oxo, phenyl, or naphthyl; with the proviso that none of the following substituents is attached to the carbon atom in the -Ci-6 alkyl group that is attached to the ring nitrogen: halogen, -OH, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -SRa, -S(=O)Ra, or -N(Ra)-C(Rb).--:O;
R3 is -H or -C 1-6 alkyl;
R4 is
(1) H,
(2) Ci_6 alkyl which is optionally substituted with one or more substituents each of which is independently halogen, -OH, O-Ci-g alkyl, -O-Ci-6 haloalkyl, -NO2, -N(RaRb), -C(=O)Ra -CO2Ra, -SRa, -S(=O)Ra, -SO2Ra, or -N(Ra)CO2Rb,
(3) Ci_6 alkyl which is optionally substituted with one or more substituents each of which is independently halogen, -OH, or O-Ci-4 alkyl, and which is substituted with 1 or 2 substituents each of which is independently:
(i) C3-8 cycloalkyl,
(ii) aryl,
(iii) a fused bicyclic carbocycle consisting of a benzene ring fused to a C5..7 cycloalkyl,
(iv) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(v) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N,
O and S, or
(vi) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic,
(4) C2-5 alkynyl optionally substituted with aryl,
(5) C3-8 cycloalkyl optionally substituted with aryl,
(6) aryl,
(7) a fused bicyclic carbocycle consisting of a benzene ring fused to a C5-7 cycloalkyl,
(8) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(9) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
(10) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic; wherein each aryl in (3)(ii) or the aryl (4), (5) or (6) or each fused carbocycle in (3)(iii) or the fused carbocycle in (7) is optionally substituted with one or more substituents each of which is independently halogen, -OH, -C -β alkyl, -Cι_6 alkyl-ORa, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -CN, -NO2, -N(RaRb), -Ci-6 alkyl-N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO2Ra, -Ci-6 alkyl-C02Ra, -OCO2Ra, -SRa, -S(=O)Ra, -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), -N(Ra)C(=O)Rb -N(Ra)CO2Rb, -Ci-6 alkyl-N(Ra)CO2Rb, aryl, -Cι_6 alkyl-aryl, -O-aryl, or -Cθ-6 alkyl-het wherein het is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with one or more substituents each of which is independently -Ci-6 alkyl, -Ci-6 haloalkyl, -O-Cι_6 alkyl, -O-Ci-6 haloalkyl, oxo, or -CO2Ra; each saturated heterocyclic ring in (3)(iv) or the saturated heterocyclic ring in (8) is optionally substituted with one or more substituents each of which is independently halogen, -Ci-6 alkyl, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Cι_6 haloalkyl, oxo, aryl, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and each heteroaromatic ring in (3)(v) or the heteroaromatic ring in
(9) or each fused bicyclic heterocycle in (3)(vi) or the fused bicyclic heterocycle in (10) is optionally substituted with one or more substituents each of which is independently halogen, -Ci-6 alkyl, -Ci-6 haloalkyl, -O-Ci-g alkyl, -O-Cι_6 haloalkyl, oxo, aryl, or -Ci-6 alkyl-aryl;
or alternatively R3 and R4 together with the N to which both are attached form a C3-7 azacycloalkyl which is optionally substituted with one or more substituents each of which is independently -C -β alkyl or oxo;
each Ra, Rb, Re, and Rd is independently -H or -Ci_6 alkyl;
Rk is carbocycle or heterocycle, wherein the carbocycle or heterocycle is optionally substituted with one or more substituents each of which is independently
(1) halogen,
(2) -OH,
(3) -CN,
(4) -Ci-6 alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN,
-O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa
Figure imgf000173_0001
N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O, (5) -O-Cι_6 alkyl, which is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra, -CO2R , -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-(CH2)0-2N(RaRb), N(Ra)-C(=O)-(CH2)0-2N(RbRC), -SO2Ra, -N(R )SO2Rb, -SO2N(R Rb), or -N(Ra)-C(Rb)=O,
(6) -NO2,
(7) oxo,
(8) -C(=O)R ,
(9) -CO2Ra (10) -SRa,
(11) -S(=O)Ra
(12) -N(RaRb),
(13) -C(=O)N(R Rb),
(14) -C(=O)-Ci-6 alkyl-N(RaRb), (15) -N(Ra)C(=O)Rb,
(16) -SO2Ra,
Figure imgf000174_0001
(19) -Rm,
(20) -Ci-6 alkyl-Rm, wherein the alkyl is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -Cι_6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -N(Ra)CO2Rb, -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), 0r
-N(Ra)-C(Rb)=O,
(21) -Co-6 alkyl-N(Ra)-Co-6 alkyl-Rm,
(22) -Co-6 alkyl-O-Cθ-6 alkyl-Rm,
(23) -Co-6 alkyl-S-Co-6 alkyl-Rm,
(24) -Co-6 alkyl-C(=O)-Co-6 alkyl-Rm,
(25) -C(=O)-O-Co-6 alkyl-Rm,
(26) -C(=O)N(Ra)-Co-6 alkyl-Rm,
(27) -N(Ra)C(=O)-Rm,
(28) -N(Ra)C(=O)-Ci-6 alkyl-Rm, wherein the alkyl is optionally substituted with one or more substituents each of which is independently halogen, -OH, -CN, -Cι_6 haloalkyl, -O-Ci-6 alkyl, -O-Cι _6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -N(Ra)CO2Rb, -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(29) -N(Ra)-C(=O)-N(Rb)-Co-6 alkyl-Rm,
(30)
Figure imgf000174_0002
alkyl-Rm,
(31) -N(Ra)-C(=O)-N(Rb)-SO2-Co-6 alkyl-Rm,
(32) -C(=O)-C(=O)-N(RaRb),
(33) -C(=O)-Ci_6 alkyl-SO2Ra or
(34) -C(=O)-C(=O)Rm;
carbocycle in Rk is (i) a C3 to C8 monocyclic, saturated or unsaturated ring, (ii) a C7 to C12 bicyclic ring system, or (iii) a Cn to Ci6 tricyclic ring system, wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated;
heterocycle in Rk is (i) a 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a 7- to 12-membered bicyclic ring system, or (iii) an 11 to 16-membered tricyclic ring system; wherein each ring in (ii) or (iii) is independent of or fused to the other ring or rings and each ring is saturated or unsaturated; the monocyclic ring, bicyclic ring system, or tricyclic ring system contains from 1 to 6 heteroatoms selected from N, O and S and a balance of carbon atoms; and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally be oxidized, and any one or more of the nitrogen heteroatoms is optionally quatemized;
each Rm is independently C3-8 cycloalkyl; aryl; a 5- to 8-membered monocyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; or a 9- to 10-membered bicyclic heterocycle which is saturated or unsaturated and contains from 1 to 4 heteroatoms independently selected from N, O and S; wherein any one or more of the nitrogen and sulfur heteroatoms in the heterocycle or bicyclic heterocycle is optionally oxidized and any one or more of the nitrogen heteroatoms is optionally quatemized; and wherein the cycloalkyl or the aryl defined in Rm is optionally substituted with , one or more substituents each of which is independently halogen, -C\-β alkyl optionally substituted with -O-Ci-4 alkyl, -Cι_6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -N(RaRb), aryl, or -Ci-6 alkyl-aryl; and the monocyclic or bicyclic heterocycle defined in Rm is optionally substituted with one or more substituents each of which is independently halogen, -C -β alkyl, -Ci-6 haloalkyl, -O-Ci-6 alkyl, -O-Cι_6 haloalkyl, oxo, aryl, -C -β alkyl-aryl, -C(=O)-aryl, -Cθ2-aryl, -CO2-Ci_6 alkyl-aryl, a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and
each n is independently an integer equal to zero, 1 or 2;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein Rl is:
(1) -H,
(2) -Cι_4 alkyl, which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -CN, -O-Ci-4 alkyl, -O-Ci-4 haloalkyl, -C(=O)Ra, -CO2R , -SRa, -S(=O)Ra -N(RaRb), -C(=O)-Cθ-4 alkyl-N(RaRb), N(Ra)-C(=O)-Co-4 alkyl-N(RbRc), -SO2Ra, -N(Ra)SO2Rb,
-SO2N(RaRb), _N(Ra)-C(=O)Rb,
Figure imgf000176_0001
, -N(Ra)C(=O)Rk, or -N(Ra)C(=O)C(=O)N(RbRc)
(3) -Rk,
(4) -Ci-4 alkyl-Rk, wherein:
(i) the alkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -CN, -O-Cι_4 alkyl, -O-Ci-4 haloalkyl, -N(RaRb), -N(Ra)CO2R -N(Ra)C(=O)-Co-4 alkyl-N(RbRc), 0r -N(Ra)-(CH2)2-4~OH; and (ii) the alkyl is optionally mono-substituted with -Rs, -N(Ra)-C(=O)-Co-4 alkyl-Rs, -N(Ra)-Cθ-4 alkyl-Rs, -O-Cθ-4 alkyl-Rs, or -N(Ra)-C(=O)-Co-4 alkyl-RS; wherein Rs is
(a) aryl which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -OH, -Cι_4 alkyl, -Cι_4 alkyl-ORa -Ci-4 haloalkyl, -O-Ci-4 alkyl, -O-C 1-4 haloalkyl, methylenedioxy attached to two adjacent carbon atoms, or phenyl;
(b) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Ci-4 alkyl, -Cl-4 alkyl-ORa, -C1-.4 haloalkyl, -O-Cι_4 alkyl, -O-Ci-4 haloalkyl, oxo, or phenyl; or (c) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Ci_4 alkyl, -Ci-4 alkyl-ORa,
-Ci-4 haloalkyl, -O-Ci-4 alkyl, -O-Ci-4 haloalkyl, -C(=O)Ra -Cθ2Ra, -C(=O)-Co-4 alkyl-N(RaRb), -SO2Ra, oxo, or phenyl, or (5) -(CH2)0-3-C(=O)N(Ra)-(CH2)0-3-Rk;
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, wherein Rl is:
(1) -H,
(2) -Ci-4 alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -O-Cι_4 alkyl, -O-Ci-4 haloalkyl, -C(=O)Ra, -CO2Ra -N(RaRb), or -C(=O)-(CH2)0-2-N(RaRb),
(3) -Rk,
(4) -(CH2)l-4-Rk, wherein:
(i) the -(CH2)l-4- moiety is optionally substituted with 1 or 2 substituents each of which is independently halogen, -OH, -O-Ci-4 alkyl, -O-C1.4 haloalkyl, or -N(RaRb); and
(ii) the -(CH2)l-4- moiety is optionally mono-substituted with -Rs or -N(Ra)-(CH2)l-2-Rs; wherein Rs is
(a) phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -C1-4 alkyl, -Ci-4 alkyl-ORa -Ci-4 haloalkyl, -O-Ci-4 alkyl, or -O-C 1-4 haloalkyl; or
(b) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Ci_4 alkyl, -Ci-4 alkyl-ORa, -Cι_4 haloalkyl, -O-Ci-4 alkyl, or -O-Ci-4 haloalkyl; or
(c) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Ci_4 alkyl, -C1.4 alkyl-ORa, -Ci-4 haloalkyl, -O-Ci-4 alkyl, -O-C1.4 haloalkyl, -C(=O)Ra, or -Cθ2Ra,
(5) -C(=O)N(Ra)-(CH2)0-3-Rk,
(6) -C(CH3)2N(Ra)C(=O)Rb,
(7) -C(CH3)2N(Ra)C(=O)Rk, or
(8) -C(CH3)2N(Ra)C(=O)C(=O)N(RbRc);
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1, wherein
Rk is C3-8 cycloalkyl; aryl selected from phenyl and naphthyl; a bicyclic carbocycle selected from indanyl and tetrahydronaphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the cycloalkyl, aryl, bicyclic carbocycle, saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently (1) halogen,
(2) -OH,
(3) -CN,
(4) -C1-4 haloalkyl,
(5) -Ci-4 alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently -OH, -CN, -O-Ci-4 alkyl, -O-C1.4 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-(CH2)θ-2N(RaRb), N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra, -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(6) -O-C I-4 haloalkyl
(7) -O-Ci_4 alkyl, which is optionally substituted with from 1 to 3 substituents each of which is independently -OH, -CN, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, -C(=O)Ra -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -C(=O)-(CH2)θ-2N(RaRb),
N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2Ra, -N(Ra)SO2Rb -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(8) -NO2,
(9) oxo,
(10) -C(=O)Ra,
(11) -CO2R
(12) -SRa,
(13) -S(=O)Ra,
(14) -N(RaRb),
(15) -C(=O)N(RaRb),
(16) -C(=O)-Cι_6 alkyl-N(RaRb),
(17) -N(Ra)C(=O)Rb,
Figure imgf000179_0001
(20) -Rm,
(21) -C1-4 alkyl-Rm,
(22) -(CH2)0-2-N(Ra)-(CH2)0-2-Rm,
(23) -(CH2)0-2-O-(CH2)0-2-Rm,
(24) -(CH2)0-2-S-(CH2)0-2-Rm,
(25) -(CH2)0-2-C(=O)-(CH2)0-2-Rm,
(26) -C(=O)-O-(CH2)0-2-Rm,
(27) -C(=O)N(Ra)-Rm, or
(28) -C(=O)-C(=O)N(R Rb); or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4, wherein
each Rm is independently C3-7 cycloalkyl; aryl selected from phenyl and naphthyl; a
5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein any N is optionally oxidized to form an N-oxide; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered, saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S; wherein the cycloalkyl or the aryl defined in Rm is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cι_4 alkyl, -C1-4 haloalkyl, -O-Ci-4 alkyl, -O-Cι_4 haloalkyl, -N(RaRb), phenyl, or
-(CH2)l-2-phenyl; the saturated heterocyclic ring defined in Rm is optionally substituted with from 1 to 4 substituents each of which is independently -Ci-4 alkyl optionally substituted with -O-Ci-4 alkyl, -C1-4 haloalkyl, -O-Ci_4 alkyl, -O-Ci-4 haloalkyl, oxo, phenyl, -(CH2)l-2-phenyl, -C(=O)-phenyl,
-CO2-phenyl, -CO2-(CH2)l-2~phenyl, a 5- or 6-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and the heteroaromatic ring or the bicyclic heterocycle defined in Rm is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Ci-4 alkyl, -Cι_4 haloalkyl, -O-Ci-4 alkyl, -O-C 1.4 haloalkyl, oxo, phenyl, or -(CH2)l-2-phenyl;
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 4, wherein Rk is phenyl; a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; a 5- or 6-membered heteroaromatic ring containing 1 or 2 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; or a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated heterocyclic ring containing 1 or 2 nitrogen atoms; wherein: (a) the phenyl, the saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently
(1) fluoro,
(2) chloro, (3) bromo,
(4) -OH
(5) -CF3,
(6) -Ci-4 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -OH, -CN, -O-Ci-4 alkyl, -OCF3, -N(RaRb), -C(=O)N(RaRb), or
N(Ra)-C(=O)-(CH2)0-2N(RbRc),
(7) -OCF3,
(8) -O-C1-4 alkyl
(9) -C(=O)Ra, (10) -C02Ra
(11) -SRa,
(12) -SRa,
(13) -N(RaRb),
(14) -C(=O)N(RaRb),
Figure imgf000181_0001
(16) -N(Ra)C(=O)Rb or
(17) -SO2Ra;
(b) the phenyl is optionally mono-substituted with (1) -(CH2)l-2-Rm, or (2) -(CH2)0-2-N(Ra)-(CH2)0-2-Rm; an
(c) the saturated heterocyclic ring, heteroaromatic ring, or bicyclic heterocycle is optionally mono- or di-substituted with
(1) oxo
(2) -(CH2)l-2-Rm (3) -O-(CH2)l-2-Rm, or
(4) -(CH2)0-l-C(=O)-(CH2)0-2-Rm;
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 6, wherein
each R is independently cyclopropyl; phenyl; a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, imidazolidinyl, pyrazoUdinyl, piperidinyl, piperazinyl, and morpholinyl; or a 5- or 6-membered heteroaromatic ring selected from thienyl, pyridyl optionally in the form of an N-oxide, imidazolyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, triazolyl, tetrazolyl, furanyl, and pyridazinyl; wherein the cyclopropyl is unsubstituted; the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cι_4 alkyl, -CF3, -O-Ci-4 alkyl, -OCF3, or -N(RaRb); the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently -Ci-4 alkyl, -CF3, -O-Cι_4 alkyl, -OCF3, oxo, phenyl, -(CH2)l-2-phenyl, -C(=O)-phenyl, -CO2-phenyl, or
-CO2-CH2-phenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently -Cι_4 alkyl, -CF3, -O-Ci-4 alkyl, -OCF3, oxo, phenyl, or -(CH2)l-2~phenyl;
or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1, wherein R2 is:
(1) -Ci-6 alkyl,
(2) -Ci-6 alkyl substituted with -N(RaRb), with the proviso that -N(RaRb) is not attached to the carbon atom in the -Ci-6 alkyl group that is attached to the ring nitrogen,
(3) -Ci-6 alkyl substituted with phenyl, wherein the phenyl is: (a) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cι_4 alkyl, -Cι_4 haloalkyl, -O-Ci-4 alkyl, -O-Ci-4 haloalkyl, or -Co-4 alkyl-N(RaRb); and (b) optionally mono-substituted with -Cι_4 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently
-Ci-6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atom, and 0 or 1 S atom; or (4) -Ci-6 alkyl optionally substituted with -OH and substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from
1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently -Cι_6 alkyl, -O-Cι_6 alkyl, oxo, or phenyl; or (5) -Ci_6 alkyl substituted with a 5- or 6-membered heteroaromatic ring which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -Cι_6 alkyl, -O-Ci-6 alkyl, oxo, or phenyl;
or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 9, wherein R2 is methyl; or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 1, wherein R3 is -H or -Ci-4 alkyl; or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 10, wherein R is -H or methyl; or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 11, wherein R3 is -H; or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 1, wherein R4 is Cι_4 alkyl substituted with an aryl, which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -Cι_4 alkyl, -Ci-4 alkyl-ORa, -Cl-4 haloalkyl, -O-Ci-4 alkyl, -O-Ci-4 haloalkyl, -CN, -NO2, -N(RaRb), -Cι_4 alkyl-N(RaRb), -C(=O)N(RaRb), -C(=O)Ra -CO2Ra, -Ci-4 alkyl-CO2Ra, -OCO2Ra, -SRa, -S(=O)Ra -SO2R , -N(Ra)SO2Rb, -SO2N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO2Rb, -Ci-4 alkyl-N(Ra)CO2Rb, methylenedioxy attached to two adjacent ring carbon atoms, phenyl, -Ci_4 alkyl-phenyl, -O-phenyl, or -(CH2)0-2-het; wherein het is a 5- or 6-membered heteroaromatic ring containing from
1 to 4 heteroatoms independently selected from N, O and S, and het is optionally fused with a benzene ring, and is optionally substituted with 1 or 2 substituents each of which is independently -Cι_4 alkyl, -Ci-4 haloalkyl, -O-Cι_4 alkyl, -O-Ci-4 haloalkyl, or -CO2Ra;
or a pharmaceutically acceptable salt thereof.
14. The compound according to claim 13, wherein R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cl-4 alkyl, -Ci-4 fluoroalkyl, -O-Cι_4 alkyl, -O-C1.4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra -(CH2)0-2-CO2Ra, -(CH2)0-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) or phenyl; and
each Ra and Rb is independently is H or -Cl-4 alkyl;
or a pharmaceutically acceptable salt thereof.
15. The compound according to claim 14, wherein R is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents, each of which is independently -F, -Br, -CI, -OH, -Ci_4 alkyl, -Cl-4 fluoroalkyl, -O-Ci-4 alkyl, -SO2-C1-4 alkyl, -S-Ci-4 alkyl, -N(CH3)2, or -O-Ci-4 fluoroalkyl;
or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 15, wherein R4 is p-fluorobenzyl or 2,3-dimethoxybenzyl;
or a pharmaceutically acceptable salt thereof.
17. The compound according to claim 1, wherein:
Rl is -Rk;
Rk is phenyl which is
(a) optionally substituted with from 1 to 3 substituents each of which is independently:
(1) halogen, (2) -Ci-6 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -O-Ci-6 alkyl, -O-Cι_6 haloalkyl, -C(=O)Ra, -CO2Ra, -SRa,
Figure imgf000185_0001
N(Ra)-C(=O)-(CH2)0-2N(RbRC), -SO2Ra -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)=O,
(3) -Ci-6 haloalkyl,
(4) -O-Ci-6 haloalkyl,
(5) -C(=O)Ra,
(6) -CO2R , (7) -C(=O)N(RaRb), or
(8) -C(=O)-Ci_6 alkyl-N(RaRb); and
(b) optionally mono-substituted with
(1) -Ci-4 alkyl-Rm, or
(2) -Co-4 alkyl-N(Ra)-Co-4 alkyl-Rm; wherein Rm is aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the aryl defined in Rm is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Cι_4 alkyl, -CF3, -O-C1-4 alkyl, -OCF3, or -N(RaRb); the saturated heterocyclic ring defined in Rm is optionally substituted with from 1 to 3 substituents each of which is independently -Ci_4 alkyl or oxo, and is additionally optionally mono-substituted with phenyl, -(CH2)l-2-phenyl, -C(=O)-phenyl, -CO2-phenyl, -CO2-(CH2)l-2-phenyl, or a
5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; and the heteroaromatic ring defined in Rm is optionally substituted with 1 or 2 substituents each of which is independently -Ci-4 alkyl or oxo;
or a pharmaceutically acceptable salt thereof.
18. The compound according to claim 17, wherein
R2 is methyl;
R3 is -H;
R4 is:
(1) -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cl-4 alkyl, -Ci-4 fluoroalkyl, -O-Ci-4 alkyl, -O-C1.4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2R
-(CH2)0-2~CO2Ra, -(CH2)θ-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) or phenyl; or
(2) a fused bicyclic carbocycle selected from
Figure imgf000187_0001
wherein Zl is -H or -OH; and
each Ra and Rb is independently is H or -Ci_4 alkyl;
or a pharmaceutically acceptable salt thereof.
19. The compound according to claim 18, wherein R4 is 4-fluorobenzyl or 2,3-dimethoxybenzyl;
or a pharmaceutically acceptable salt thereof.
20. The compound according to claim 1, which is a compound of Formula (II):
Figure imgf000187_0002
wherein
Q is:
(1) methyl which is optionally substituted with 1 or 2 of -O-Cι_4 alkyl, (2) phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently -F, -CI, Br, -Ci-4 alkyl, -CF3, -O-Ci-4 alkyl, -OCF3, methylenedioxy attached to two adjacent carbon atoms, or phenyl, or
(3) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently -F, -CI, -Br, -Cl-4 alkyl, oxo, phenyl, or -C(=O)-phenyl;
T is:
(1) -H,
(2) -OH,
(3) methyl or ethyl, optionally substituted with -OH or -O-C ι_4 alkyl, (4) -O-Ci-4 alkyl
(5) -N(RaRb),
(6) -N(Ra)-(CH2)2-OH,
Figure imgf000188_0001
(8) -N(Ra)-C(=O)-(CH2)l-2-N(RaRb), (9) -Rs,
(10) -(CH2)l-2-Rs, or
(11) -(CH2)0-2-N(Ra)-(CH2)0-3-Rs;
Rs is: (1) phenyl optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Ci-4 alkyl, -Ci-4 alkyl-ORa, -Ci_4 haloalkyl, -O-Ci-4 alkyl, -O-Ci-4 haloalkyl, or -N(RaRb);
(2) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with from 1 to 4 substituents each of which is independently -Cι_4 alkyl, -Cl-4 alkyl-ORa, -C1.4 haloalkyl, -O-Cl-4 alkyl, -O-C1.4 haloalkyl, -C(=O)Ra, oxo, phenyl, or -CH2-phenyl; or
(3) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with from 1 to 4 substituents each of which is independently -Ci_4 alkyl, -Ci-4 alkyl-ORa -Ci_4 haloalkyl, -O-Ci-4 alkyl, -O-Cl-4 haloalkyl, or oxo; (1) -Ci-4 alkyl,
(2) -Ci-4 alkyl substituted with -N(RaRb), with the proviso that -N(RaRb) is not attached to the carbon atom in the -Cι_4 alkyl group that is attached to the ring nitrogen, or
(3) -Cl-4 alkyl substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the saturated heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently a -Ci_4 alkyl;
R3 is -H or -Cl-4 alkyl;
R is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Ci_4 alkyl, -Ci-4 fluoroalkyl, -O-Ci-4 alkyl, -O-Ci-4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)0-2-CO2Ra -(CH2)0-2~N(R )CO2Rb -NO2, -SRa, -N(RaRb) or phenyl;
each Ra and Rb is independently -H or -Ci-4 alkyl; and
s is an integer equal to zero, 1, or 2;
or a pharmaceutically acceptable salt thereof.
21. The compound according to claim 20, wherein
Q is phenyl;
T is:
(1) -H, (2) -N(RaRb),
(3) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; which is optionally substituted with 1 or 2 substituents each of which is independently -Cl-4 alkyl or -C(=O)Ra, or (4) -N(Ra)-(CH2)l-2-heteroaromatic, wherein the heteroaromatic is a 5- or 6-membered ring containing 1 or 2 N atoms;
R2 is methyl;
R3 is -H; and
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents each of which is independently -F, -CI, -Br, -Cι_4 alkyl, -CF3, -O-Ci-4 alkyl, -SO2CH3, -SCH3, -N(CH3)2 or -OCF3;
each Ra and Rb is independently -H, methyl or ethyl; and
s is an integer equal to zero or 1;
or a pharmaceutically acceptable salt thereof.
22. The compound according to claim 1, wherein
Rl is -Rk;
Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen atoms and from 1 to 3 nitrogen atoms or (ii) a bicyclic heterocycle which is a benzene ring fused to a 5- or 6-membered saturated heterocyclic ring containing from 0 to 1 oxygen atoms and from 1 to 3 nitrogen atoms; wherein the saturated heterocyclic ring or bicyclic heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently
(1) -Cl-4 alkyl, which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -O-C1-4 alkyl, -O-Ci-4 haloalkyl, -C(=O)Ra -CO2Ra,
-SRa, -S(=O)Ra, -N(RaRb),
Figure imgf000190_0001
N(Ra)-C(=O)-(CH2)0-2N(RbRc), -SO2R , -N(Ra)SO2Rb, -SO2N(RaRb), or -N(Ra)-C(Rb)---:O,
(2) -OH, (3) -C(=O)Ra,
(4) -CO2Ra,
(5) -C(=O)N(RaRb),
(6) -C(=O)-Cι_6 alkyl-N(RaRb), (7) -SRa,
(8) -S(=O)Ra,
(9) -SO2Ra,
(10) -N(RaRb),
(11) -Rm, (12) -Ci-4 alkyl-Rm, wherein the alkyl is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -OH, -CN, -C1.4 haloalkyl, -O-Ci-4 alkyl, -O-C1-4 haloalkyl, -C(=O)Ra -CO2Ra, -SRa, -S(=O)Ra, -N(RaRb), -N(Ra)CO2Rb, -SO2Ra, -N(Ra)SO2R , -SO2N(RaRb), 0r -N(Ra)-C(Rb)=0,
(13) -Co-4 alkyl-N(Ra)-Co-4 alkyl-Rm,
(14) -Co-4 alkyl-O-Cθ-4 alkyl-Rm,
(15) -Co-4 alkyl-S-Co-4 alkyl-Rm,
(16) -Co-4 alkyl-C(=O)-Co-4 alkyl-Rm, (17) -C(=O)-O-Co-4 alkyl-Rm, 0r
(18) -C(=O)N(Ra)-Co-4 alkyl-Rm;
wherein each R is independently -C3_6 cycloalkyl; aryl selected from phenyl and naphthyl; a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S; or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein any N is optionally oxidized to form an N-oxide; wherein the aryl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, -Ci_4 alkyl, -CF3, -O-Ci-4 alkyl, -OCF3, or -N(RaRb); the saturated heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Ci_4 alkyl or oxo, and is additionally optionally mono-substituted with phenyl, -(CH2)l-2-phenyl, -C(=O)-phenyl, -CO2-phenyl, or -CO2-(CH2)l-2-phenyl; and the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently halogen, -Ci_4 alkyl, or oxo;
or a pharmaceutically acceptable salt thereof.
23. The compound according to claim 22, wherein
RU is:
Figure imgf000192_0001
RS is:
(1) -H,
(2) -Cl-4 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -OH, -O-Cι_4 alkyl, -OCF3, -C(=O)R -CO2Ra, -SRa, -N(RaRb), or -C(=O)N(RaRb),
(3) -C(=O)Ra,
(4) -CO2Ra,
(5) -C(=O)N(RaRb), (6) -C(=O)-(CH2)l-2-N(RaRb),
(7) -Sθ2Ra,
(8) -(CH2)l-2-Rm,
(9) -(CH2)0-2-C(=O)-(CH2)0-2-R , (10) -C(=O)-O-(CH2)0-2-Rm, or
(11) -C(=O)N(Ra)-(CH2)0-2-Rm;
RlO is -H, -OH, -Ci-4 alkyl, -O-C1.4 alkyl, -N(RaRb), or -O-(CH2)l-2-Rm ;
Rl2 is
(1) -H,
(2) -Cl-4 alkyl, which is optionally substituted with 1 or 2 substituents each of which is independently -OH, -O-Cl-4 alkyl, -OCF3, -C(=O)Ra, -CO2Ra, -SRa, -N(RaRb), or
-C(=O)N(RaRb),
(3) -C(=O)Ra,
Figure imgf000193_0001
(5) -C(=O)-(CH2)l-2-N(RaRb), or
(6) -SO2Ra;
R2 is methyl;
R3 is -H or methyl;
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cι_4 alkyl, -Ci-4 fluoroalkyl, -O-Ci-4 alkyl, -O-C1.4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)0-2-CO2Ra, -(CH2)θ-2-N(R )Cθ2Rb, -NO2, -SRa, -N(RaRb) or phenyl; and
each Ra and Rb is independently -H or -C1.4 alkyl;
or a pharmaceutically acceptable salt thereof.
24. The compound according to claim 1, which is a compound of Formula (HI):
Figure imgf000194_0001
wherein R2 is:
(1) -Ci-6 alkyl, (2) -C i -6 alkyl substituted with -N(RaRb), with the proviso that -N(RaRb) is not attached to the carbon atom in the -Cι_6 alkyl group that is attached to the ring nitrogen,
(3) -Ci-,6 alkyl substituted with phenyl which is:
(a) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cl-4 alkyl, -Cl-4 haloalkyl, -O-Ci_4 alkyl, -O-Ci-4 haloalkyl, or -Co-6 alkyl-N(RaRb); and
(b) optionally mono-substituted with -Cl-4 alkyl substituted with a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Ci-6 alkyl, oxo, or a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atom, and 0 or 1 S atom;
(4) -Ci-6 alkyl optionally substituted with -OH and substituted with a 5- or 6-membered saturated monocyclic heterocycle which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 4 substituents each of which is independently -Cι_6 alkyl, -O-C 1-6 alkyl, oxo, or phenyl; or
(5) -Ci-6 alkyl substituted with a 5- or 6-membered heteroaromatic ring which contains from 1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -Cι_6 alkyl, -O-Cι_6 alkyl, oxo, or phenyl;
or a pharmaceutically acceptable salt thereof.
25. The compound according to claim 24, wherein
R2 is: (1) -Cι_4 alkyl,
(2) -(CH2)l-3-N(RaRb),
(3) -(CH2) 1-3 -phenyl, wherein the phenyl is:
(a) optionally substituted with from 1 to 3 substituents each of which is independently fluoro, chloro, bromo, -Ci-4 alkyl, -CF3, -O-C1.4 alkyl, -O-CF3, or
-(CH2)l-3-N(RaRb); and
(b) optionally mono-substituted with -(CH2)l-3-saturated heterocycle which is a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms selected from 1 or 2 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms, wherein the heterocyclic ring is optionally substituted with from 1 to 3 substituents each of which is independently -Cl-4 alkyl or pyridyl;
(4) -(CH2) 1 -3-saturated heterocycle, wherein the -(CH2) 1-3- moiety is optionally substituted with an -OH and the saturated heterocycle is a 5- or 6-membered saturated monocyclic heterocycle which contains from
1 to 3 heteroatoms selected from 1 to 3 N atoms, 0 or 1 O atoms, and 0 or 1 S atoms; wherein the heterocycle is optionally substituted with from 1 to 3 substituents each of which is independently a -Cι_4 alkyl; or
(5) -(CH2)l-3-pyridyl;
R3 is -H or methyl; R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cl-4 alkyl, -Ci-4 fluoroalkyl, -O-Ci-4 alkyl, -O-Ci-4 fluoroalkyl, -(CH2)l-2-N(RaRb), -SO2Ra, -(CH2)0-2-CO2Ra -(CH2)0-2-N(Ra)CO2R , -NO2, -SRa, -N(RaRb) or phenyl; and
each Ra and Rb is independently -H or -Cι_4 alkyl;
or a pharmaceutically acceptable salt thereof.
26. The compound according to claim 1, wherein
Rl is -C(=O)NH-(CH2)l-2-Rk ; and
Rk is (i) a 5- or 6-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S;
or a pharmaceutically acceptable salt thereof.
27. The compound according to claim 26, wherein
R2 is methyl;
R3 is -H or methyl;
R4 is -CH2-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently fluoro, bromo, chloro, -OH, -Cι_4 alkyl, -Cl-4 fluoroalkyl, -O-Cι_4 alkyl, -O-C1-.4 fluoroalkyl, -(CH2)l-2"N(RaRb), -SO2Ra, -(CH2)0-2-Cθ2Ra, -(CH2)0-2-N(Ra)CO2Rb, -NO2, -SRa, -N(RaRb) 0r phenyl; and
each Ra and Rb is independently -H or -Cl-4 alkyl;
or a pharmaceutically acceptable salt thereof.
28. A compound according to claim 1, which is a compound selected from the group consisting of
N-(2-ethoxybenzyl)-5-hydroxy-l-methyl-2-(4-methylphenyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-2-(4-methylphenyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide ;
N-(2,3-dimethoxybenzyl)-2-{4-[(dimethylamino)methyl]phenyl}-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-{4-[(dimethylamino)methyl]phenyl}-5-hydroxy-l-methyl-6- oxo-1 ,6-dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-2-[4-(pyrrolidin-l- ylmethyl)phenyl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo-2- [4-(pyrrolidin- 1 -ylmethyl)phenyl] - 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[4-(piperidin-l-ylmethyl)phenyl]- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4-ylmethyl)phenyl]-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-[4-(morpholin-4-ylmethyl)phenyl]-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{4-[(4-methylpiperazin-l- yl)methyl]phenyl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; 2-{4-[(diethylamino)methyl]phenyl}-N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2- { 4-[(diethylamino)methyl]phenyl } -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- l,6-dihydropyrimidine-4-carboxamide;
2-[(dimethylamino)(phenyl)methyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2- [(4-f ormylpiperazin- 1 -yl)(phenyl)methyl] -5-hydroxy- 1 -methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-{phenyl[(pyridin-3- ylmethyl)amino]methyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
2-benzyl-l-[2-(dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
l-[2-(dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-2-(2-methylphenyl)-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylphenyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-benzyl-N-(2,3-dimethoxybenzyl)-l-[2-(dimethylamino)ethyl]-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-{4-[(4-ethylpiperazin-l-yl)methyl]phenyl}-N-(4-fluorobenzyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo-2- { 4- [(2-pyridin-3-ylpiperidin- 1 - yl)methyl]phenyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4- carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxamide;
N- [4-fluoro-2-(trifluoromethyl)benzyl] -5 -hydroxy- 1 -methyl-6-oxo- 1,6- dihydropyrimidine-4-carboxamide;
N-(3-chloro-4-methylbenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4- carboxariiide;
5-hydroxy-N-[(lR,2S)-2-hydroxy-2,3-dihydro-lH-inden-l-yl]-l-methyl-2-{4-[(4- methylpiperazin- 1 -yl)methyl]phenyl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-(4- { [(2R)-2-(methoxymethyl)pyrrolidin- 1 - yl]methyl}phenyl)-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-(4-{[(2S)-2-(methoxymethyl)pyrrolidin-l- yl]methyl}phenyl)-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-(4-{[(4-fluorobenzyl)amino]methyl}phenyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-benzyl-N-(4-fluorobenzyl)-5-hydroxy-l-(2-morpholin-4-ylethyl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
l-[2-(dimethylamino)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-6-oxo- 1 -(pyridin-3-ylmethyl)- 1 ,6-dihydropyrimidine- 4-carboxamide;
2-benzyl-N-(4-fluorobenzyl)-5 -hydroxy-6-oxo- 1 -(2-pyrrolidin- 1 -ylethyl)- 1 ,6- dihydropyrimidine-4-carboxamide; 2-benzyl-N-(4-fluorobenzyl)-5 -hydroxy-6-oxo- 1 -(2-piperidin- 1 -ylethyl)- 1,6- dihydropyrimidine-4-carboxamide;
2-( 1 -benzylpiperidin-2-yl)-N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo- 1,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methylpiperidin-2-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-(l-benzylpiperidin-3-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
1 - { 3-[(dimethylamino)methyl]benzyl } -N-(4-fluorobenzyl)-5-hydroxy-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-l-[2-(dimethylamino)ethyl]-5-hydroxy-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(2,3-dimethoxybenzyl)-5-hydroxy-6-oxo-l-(pyridin-3-ylmethyl)-l,6- dihydropyrimidine-4-carboxamide;
N4-(4-fluorobenzyl)-5-hydroxy-l-methyl-N2-(2-morpholin-4-ylethyl)-6-oxo-l,6- dihydropyrimidine-2,4-dicarboxamide;
N-(4-fluorobenzyl)-5 -hydroxy-6-oxo- 1 - [3-(pyrrolidin- 1 -ylmethyl)benzyl] -1,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 - [3-(morpholin-4-ylmethyl)benzyl] -6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 - { 3 -[(4-methylpiperazin- 1 -yl)methyl]benzyl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l-{3-[(4-pyridin-2-ylpiperazin-l- yl)methyl]benzyl } - 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-[2-(morpholin-4-ylmethyl)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-6-oxo-l-{2-[(4-pyridin-2-ylpiperazin-l- yl)methyl]benzyl } - 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo-2-pyrrolidin-2-yl- 1,6- dihydropyrimidine-4-carboxamide;
N4-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-N2-(pyridin-2-ylmethyl)-l,6- dihydropyrimidine-2,4-dicarboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -(2-hydroxy-3-morpholin-4-ylpropyl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-[4-(morpholin-4-ylmethyl)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(2-morpholin-4-ylethyl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide ;
2-(2,2-dimethoxyethyl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-(2,3-dihydro- lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-[2-(4-benzoylpiperazin-l-yl)ethyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2- [ 1 -(N,N-dimethylglycyl)piperidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-2,3-dihydro-lH-indol-2-yl)-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-(l,2,3,4-tetrahydroquinolin-2-yl)- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-l,2,3,4-tetrahydroquinolin-2-yl)- 6-oxo- l,6-dihydropyrimidine-4-carboxamide;
tert-butyl (2S,4R)-4-(benzyloxy)-2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy- l-methyl-6-oxo-l,6-dihydropyrimidin-2-yl)pyrrolidine-l-carboxylate;
tert-butyl (2S,4R)-2-(4-{ [(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6- oxo-l,6-dihydropyrimidin-2-yl)-4-hydroxypyrrolidine-l-carboxylate;
2-[(2S,4R)-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo-l,6-cUhydroρyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2- [(2S ,4R)-4-hydroxypyrrolidin-2-yl] - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[(2S,4R)-4-hydroxy-l-methylpyrrolidin-2-yl]-l- methyl-6-oxo-l ,6-dihydroρyrimidine-4-carboxamide;
2-[(2S,4R)-4-(benzyloxy)-l-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-l-benzoyl-4-(benzyloxy)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[l-(N,N-dimethylglycyl)-2,3-dihydro-lH-indol-2-yl]-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; 2-(l-benzoyl-2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)-2,3- dihydro- 1 H-indol-2-yl] - 1 ,6-dihydropyrimidine-4-carboxamide ;
tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidin-2-yl)-4-methylpiperazine- 1 -carboxylate;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
(+)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide
(-)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(4-methylmorpholin-3-yl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide
2-(l-ethyl-2,3-dihydro-lH-indol-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(l-benzoylpiperidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)piperidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(2-methyl-l,2,3,4-tetrahydroisoquinolin-3- yl)-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-(l-benzoylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide; N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)pyrrolidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methylpyrrolidin-2-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-4-(benzyloxy)-l-(pyridin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[l-(dimethylamino)-2-phenylethyl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2- [(2S ,4R)- 1 -benzoyl-4-hydroxypyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-(l -isobutyl-2,3-dihydro- lH-indol-2-yl)- 1 -methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-(l-isopropyl-2,3-dihydro-lH-indol-2-yl)-l-methyl-6- oxo-1 ,6-dihydropyrimidine-4-carboxamide;
2-[l-(N,N-dimethylglycyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-{ l-[(6-bromopyridin-2-yl)carbonyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-(l -methylpiperazin-2-yl)-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-(l-benzoyl-4-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridin-2-ylcarbonyl)-l,2,3,4- tetrahydroquinolin-2-yl] - 1 ,6-dihydropyrimidine-4-carboxamide ;
2-(l-acetylpyrrolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-[l-(cyclopropylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- [ 1 -(methylsulf onyl)pyrrolidin-2-yl]-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ l-[(4-methylmorpholin-3- yl)carbonyl]pyrrolidin-2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(l,4-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo-2-[ 1 -(pyridin-3-ylcarbonyl)pyrrolidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
2- [(2S ,4R)- 1 -acetyl-4-(benzyloxy)pyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hy droxy- 1 - methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-( 1 -isonicotinoylpyrrolidin-2-yl)- 1 -methyl-6-oxo- 1,6- dihydropyrimidine-4-carboxamide;
2-{l-[(ethylamino)carbonyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy-l-methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ l-[(l-methyl-lH-imidazol-2- yl)carbonyl]pyrrolidin-2-yl}-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S,4R)-l-acetyl-4-hydroxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ; 2- [ 1 -(anilinocarbonyl)pyrrolidin-2-yl] -N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(4-ethyl-l-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-2- { 1 - [( 1 -oxidopyridin-2- yl)carbonyl]pyrrolidin-2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyrazin-2-ylcarbonyl)pyrrolidin- 2-yl]-l,6-dihydropyrimidine-4-carboxamide;
2-[(4R)-3-acetyl-l,3-thiazolidin-4-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-[l-methyl-4-(methylsulfonyl)piperazin-2- yl]-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(4-methylthiomorpholin-3-yl)-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N- [4-fluoro-2-(methylsulf onyl)benzyl] -5-hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyrazin-2- ylcarbonyl)pyrrolidin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(3-acetyl-l,3-thiazolidin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2- [ 1 -(acetylamino)- 1 -methylethyl] -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide; 2-(l -acetylpyrrolidin-2-yl)-N-(2-ethoxybenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6- dihydropyrimidine-4-carboxamide;
2-(4-acetyl- 1 -methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2- [ 1 -methyl-4-(pyrazin-2- ylcarbonyl)piperazin-2-yl]-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-5-hydroxy-l-methyl-N-[2-(methylthio)benzyl]-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydiOxy-2-{ l-[(lH-imidazol-5-ylcarbonyl)amino]-l- methylethyl } - 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[l-benzoyl-4-(pyrazin-2-ylcarbonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(4-benzoyl-l-methylpiperazin-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[4-(benzyloxy)-l-(pyrazin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
2-(l-acetylpyrrolidin-2-yl)-5-hydroxy-N-(2-methoxybenzyl)-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N 1 - [ 1 -(4- { [(4-fluorobenzyl)amino] carbonyl } -5-hydroxy- 1 -methyl-6-oxo- 1,6- dihyckopyrimidin-2-yl)-l-methylethyl]-N2,N2-dimethylethanediamide;
2-(l-acetylpyrrolidin-2-yl)-N-[2-(dimethylamino)benzyl]-5-hydroxy-l-methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-l-acetylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[4-hydroxy-l-(pyrazin-2-ylcarbonyl)pyrrolidin-2-yl]- 1 -methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N- [ 1 -(4- { [(4-fluorobenzyl)amino] carbonyl } -5-hydroxy- 1 -methyl-6-oxo- 1,6- dihydropyrimidin-2-yl)- 1 -methylethyl]imidazo[2, 1-b] [ 1 ,3]thiazole-6-carboxamide;
2-[(2S ,4S )- 1 -acetyl-4-fluoropyrrolidin-2-yl] -N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-2- { 1 -methyl-4- [(1 -methyl- lH-imidazol-2- yl)carbonyl]piperazin-2-yl}-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-2-( 1 -methyl- 1 - { [(5-methyl- 1 ,3 ,4-oxadiazol- 2-yl)carbonyl] amino } ethyl)-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
Nl-{ l-[4-({ [4-fluoro-2-(methylsulf onyl)benzyl] amino } carbonyl)-5 -hydroxy- 1 - methyl-6-oxo- 1 ,6-dihydropyrimidin-2-yl] - 1 -methylethyl } -N2,N2- dimethylethanediamide;
2-(4-acetyl- 1 ,2-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6- oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5 -hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyrimidin-4- ylcarbonyl)pyrτolidin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy- 1 -methyl-6-oxo-2- [ 1 -(pyrimidin-5 - ylcarbonyl)pyrrolidin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ l-methyl-l-[(lH-pyrazol-5- ylcarbonyl)an- no]ethyl}-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2R,4R)-l-acetyl-4-methoxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
2-{ l-[(dimethylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-{ l-[4-({ [4-fluoro-2-(methylsulfonyl)benzyl]amino }carbonyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidin-2-yl] - 1 -methylethyl } imddazo [2, 1 -b] [ 1 ,3] thiazole-6- carboxamide;
2-[(2R,4R)-l-benzoyl-4-methoxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2-[4-(isopropylsulfonyl)-l-methylpiperazin-2-yl]-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[l,2-dimethyl-4-(methylsulfonyl)piperazin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-2- [(2S ,4R)-4-methoxy- 1 -methylpyrrolidin-2-yl] - 1 - methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ l-[(methylsulfonyl)acetyl]pyrrolidin-2- yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-l-acetyl-4,4-difluoropyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2R,4R)-l-acetyl-4-ethoxypyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-methylpyrrolidin-2-yl]-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide ;
N-(2,3-dimethoxybenzyl)-5-hydroxy-l-methyl-6-oxo-2-[l-(pyridazin-3- ylcarbonyl)pyιrolidin-2-yl]-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-l-{[morpholin-4- yl(oxo)acetyl]amino}ethyl)-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2R,4R)-l-[(dimethylamino)(oxo)acetyl]-4-methoxypyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-(pyrazin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{ (2S,4S)-l-methyl-4-
[(methylsulfonyl)amino]pyrrolidin-2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4- carboxamide;
2-{l-[(dimethylamino)sulfonyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5-hydroxy-l- methyl-6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-{(2R,4R)-4-ethoxy-l-[(methylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-(pyridazin-3-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-[(2S)-4,4-difluoro-l-(pyridin-2-ylcarbonyl)pyrrolidin-2-yl]-N-(4-fluorobenzyl)-5- hydroxy-1 -methyl-6-oxo-l ,6-dihydropyrimidine-4-carboxamide;
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]-4,4-difluoropyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-{l-[morpholin-4-yI(oxo)acetyl]pyrrolidin- 2-yl } -6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4-fluorobenzyl)-5- hydroxy-l-methyl-6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2S)-l-[(dimethylamino)(oxo)acetyl]pyrrolidin-2-yl}-N-(4-fluoro-2- methoxybenzyl)-5-hydroxy-l-methyl-6-oxo-l,6-dihydropyri idine-4-carboxamide;
Nl-[l-(4-{[(4-fluorobenzyl)amino]carbonyl}-5-hydroxy-l-methyl-6-oxo-l,6- dihydropyrimidin-2-yl)-l-methylethyl]-Nl,N2,N2-trimethylethanediamide;
2-[(2S)-l-acetylpyrrolidin-2-yl]-N-(4-fluoro-2-methoxybenzyl)-5-hydroxy-l-methyl- 6-oxo- 1 ,6-dihydropyrimidine-4-carboxamide;
N-(4-fluorobenzyl)-2-[(2S,4S)-4-fluoro-l-methylρyrrolidin-2-yl]-5-hydroxy-l-methyl- 6-oxo-l,6-dihydropyrimidine-4-carboxamide;
2-{(2S,4S)-l-[(dimethylamino)(oxo)acetyl]-4-fluoropyrrolidin-2-yl}-N-(4- fluorobenzyl)-5-hydroxy-l-me yl-6-oxo~l,6-dihydroρyrimidine-4-carboxamide;
N 1 - [ 1 -(4- { [(3 -chloro-4-fluorobenzyl)amino]carbonyl } -5-hydroxy- 1 -methyl-6-oxo- l,6-dihydropyrimidin-2-yl)-l-methylethyl]-N2,N2-dimethylethanedi amide;
and pharmaceutically acceptable salts thereof.
29. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
30. A method of inhibiting HTV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
31. A method for preventing or treating infection by HTV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
32. A pharmaceutical composition which comprises the product prepared by combining an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
33. A combination useful for treating or preventing infection by
HIN, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an an antiviral selected from the group consisting of HIV protease inhibitors, non- nucleoside HTV reverse transcriptase inhibitors and nucleoside HTV reverse transcriptase inhibitors.
PCT/GB2002/004753 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase WO2003035077A1 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
US10/493,280 US7169780B2 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
MEP-2008-637A ME00427B (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
EA200400585A EA007060B1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
UA20040503960A UA77454C2 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
BRPI0213522A BRPI0213522C1 (en) 2001-10-26 2002-10-21 hydroxypyrimidinone derivative compounds, pharmaceutical composition, and use of a compound
SI200230296T SI1441735T1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DE60209381T DE60209381T2 (en) 2001-10-26 2002-10-21 N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF THE HIV INTEGRASE
HU0401740A HU230248B1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
CN028257650A CN1700918B (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
EP02801950A EP1441735B1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
AU2002334207A AU2002334207B8 (en) 2001-10-26 2002-10-21 N-substituted hydroxpyrimidinone carboxamide inhibitors of HIV integrase
IL16133702A IL161337A0 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
NZ533057A NZ533057A (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
MXPA04003932A MXPA04003932A (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase.
JP2003537644A JP3927175B2 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide HIV integrase inhibitor
CA002463976A CA2463976C (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DE200812000016 DE122008000016I1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide-inhibiting HIV integrase.
DE122009000048C DE122009000048I1 (en) 2001-10-26 2002-10-21 N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF THE HIV INTEGRASE
KR1020047006234A KR100862879B1 (en) 2001-10-26 2002-10-21 N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
IS7213A IS2436B (en) 2001-10-26 2004-04-07 N-substituted hydroxypyrimidinone carboxamide inhibits HIV integrase
IL161337A IL161337A (en) 2001-10-26 2004-04-09 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
ZA2004/02796A ZA200402796B (en) 2001-10-26 2004-04-13 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
HRP20040373AA HRP20040373B1 (en) 2001-10-26 2004-04-26 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
NO20042165A NO325206B1 (en) 2001-10-26 2004-05-25 N-substituted hydroxypyrimidinone carboxamide inhibitors for HIV integrase, pharmaceutical compositions comprising such compounds, and use of the compounds in the manufacture of drugs for HIV and AIDS.
HK06105678.2A HK1085665A1 (en) 2001-10-26 2006-05-16 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US11/491,815 US7217713B2 (en) 2001-10-26 2006-07-24 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US11/641,508 US7435734B2 (en) 2001-10-26 2006-12-19 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
NL300340C NL300340I2 (en) 2001-10-26 2008-03-31 N-substituted hydroxypyrimidone carboxamide inhibitors of HIV integrase
LU91428C LU91428I2 (en) 2001-10-26 2008-04-08 ISENTRESSrealtegravir
CY200800008C CY2008008I1 (en) 2001-10-26 2008-04-11 N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integration
LTPA2008007C LTC1441735I2 (en) 2001-10-26 2008-04-18 N-substituted hydroxypyrimidinone carboxamide HIV integrase inhibitors
NO2008007C NO2008007I1 (en) 2001-10-26 2008-06-06 Raltegravir or a pharmaceutically acceptable salt salt, especially the potassium salt
FR08C0026C FR08C0026I2 (en) 2001-10-26 2008-06-17 N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE HIV INTEGRASE INHIBITORS
US12/214,595 US7820660B2 (en) 2001-10-26 2008-06-20 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US12/884,734 US20110034449A1 (en) 2001-10-26 2010-09-17 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
HUS1600016C HUS1600016I1 (en) 2001-10-26 2016-04-07 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
NO2020026C NO2020026I1 (en) 2001-10-26 2020-08-10 Raltegravir or a pharmaceutically acceptable salt thereof, especially the potassium salt

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33956801P 2001-10-26 2001-10-26
US60/339,568 2001-10-26
US36219102P 2002-03-06 2002-03-06
US60/362,191 2002-03-06

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10493280 A-371-Of-International 2002-10-21
US11/491,815 Division US7217713B2 (en) 2001-10-26 2006-07-24 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US11/641,508 Division US7435734B2 (en) 2001-10-26 2006-12-19 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase

Publications (1)

Publication Number Publication Date
WO2003035077A1 true WO2003035077A1 (en) 2003-05-01

Family

ID=26991691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004753 WO2003035077A1 (en) 2001-10-26 2002-10-21 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase

Country Status (35)

Country Link
US (5) US7169780B2 (en)
EP (1) EP1441735B1 (en)
JP (1) JP3927175B2 (en)
KR (1) KR100862879B1 (en)
CN (3) CN102229605B (en)
AT (1) ATE318140T1 (en)
BR (1) BRPI0213522C1 (en)
CA (1) CA2463976C (en)
CO (1) CO5580777A2 (en)
CY (1) CY2008008I1 (en)
DE (3) DE60209381T2 (en)
DK (1) DK1441735T3 (en)
EA (1) EA007060B1 (en)
ES (1) ES2258668T3 (en)
FR (1) FR08C0026I2 (en)
GE (1) GEP20063848B (en)
HK (1) HK1085665A1 (en)
HR (1) HRP20040373B1 (en)
HU (2) HU230248B1 (en)
IL (2) IL161337A0 (en)
IS (1) IS2436B (en)
LT (1) LTC1441735I2 (en)
LU (1) LU91428I2 (en)
ME (1) ME00427B (en)
MX (1) MXPA04003932A (en)
NL (1) NL300340I2 (en)
NO (3) NO325206B1 (en)
NZ (1) NZ533057A (en)
PL (1) PL212914B1 (en)
PT (1) PT1441735E (en)
RS (1) RS51542B (en)
SI (1) SI1441735T1 (en)
UA (1) UA77454C2 (en)
WO (1) WO2003035077A1 (en)
ZA (1) ZA200402796B (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058757A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
EP1509507A2 (en) * 2002-05-23 2005-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2005061490A1 (en) * 2003-12-22 2005-07-07 Shionogi & Co., Ltd. Hydroxypyrimidinone derivative having hiv integrase inhibitory activity
WO2005061501A2 (en) * 2003-12-12 2005-07-07 Merck & Co., Inc. Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US6921759B2 (en) 2000-10-12 2005-07-26 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
US6924282B2 (en) 2001-08-17 2005-08-02 Merck & Co., Inc. Sodium salt of an HIV integrase inhibitor
WO2005070901A2 (en) * 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
WO2005113562A1 (en) * 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Hiv integrase inhibitors: cyclic pyrimidinone compounds
WO2005118593A1 (en) * 2004-05-28 2005-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2006060711A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
WO2006060681A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
WO2006060730A3 (en) * 2004-12-03 2006-08-17 Merck & Co Inc Potassium salt of an hiv integrase inhibitor
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2006060731A3 (en) * 2004-12-03 2006-09-28 Merck & Co Inc Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7135467B2 (en) * 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7211572B2 (en) 2003-08-13 2007-05-01 Japan Tobacco Inc. Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2007064619A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Pyrimidine derivatives as hiv integrase inhibitors
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
US7399763B2 (en) 2002-09-11 2008-07-15 Merck & Co., Inc. 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors
US7435735B2 (en) 2003-10-20 2008-10-14 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors
WO2008154246A1 (en) * 2007-06-06 2008-12-18 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
US7517532B2 (en) 2002-09-11 2009-04-14 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009088729A1 (en) * 2008-01-08 2009-07-16 Merck & Co., Inc. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US7598264B2 (en) 2004-03-09 2009-10-06 Merck & Co., Inc. HIV integrase inhibitors
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
WO2010000030A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
US7820680B2 (en) 2004-03-09 2010-10-26 Merck & Co., Inc. HIV integrase inhibitors
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
WO2011127244A2 (en) 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
WO2012103105A1 (en) * 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
WO2014023691A1 (en) * 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8742105B2 (en) 2009-06-02 2014-06-03 Hetero Research Foundation Polymorphs of raltegravir potassium
WO2013098854A3 (en) * 2011-12-26 2014-10-02 Emcure Pharmaceuticals Limited Synthesis of raltegravir
EP2796458A1 (en) * 2010-04-01 2014-10-29 Teva Pharmaceutical Industries Ltd. Crystalline raltegravir sodium salts
US8962833B2 (en) 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
EP2875024A4 (en) * 2012-07-20 2015-12-23 Merck Sharp & Dohme Hiv treatment with amido-substituted pyrimidinone derivatives
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9260413B2 (en) 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016149058A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
US9572813B2 (en) 2001-08-10 2017-02-21 Shionogi & Co., Ltd. Antiviral agent
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9649311B2 (en) 2009-10-26 2017-05-16 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US20170253585A1 (en) * 2014-02-03 2017-09-07 Mylan Laboratories Ltd. Processes for the preparation of intermediates of raltegravir
WO2017220208A1 (en) 2016-06-21 2017-12-28 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
EP3235818A3 (en) * 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
US10357481B2 (en) 2015-07-01 2019-07-23 Merck Sharp & Dohme Corp. Substituted triazolo bicyclic compounds as PDE2 inhibitors
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035076A1 (en) * 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
MXPA04003932A (en) * 2001-10-26 2004-06-18 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase.
US20050090668A1 (en) * 2003-10-28 2005-04-28 Dreher Spencer D. Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds
EP1756114B1 (en) * 2004-05-07 2014-11-19 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
EP1866313A1 (en) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
CA2607151C (en) 2005-05-10 2012-06-19 Merck & Co., Inc. Hiv integrase inhibitors
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
CA2622639C (en) * 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
AU2006306355A1 (en) * 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
AU2007275816A1 (en) * 2006-07-17 2008-01-24 Merck Sharp & Dohme Corp. 1-hydroxy naphthyridine compounds as anti-HIV agents
AU2007313293A1 (en) * 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
CN101206209B (en) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 Method for analyzing cidofovir raw material and preparation thereof by HPLC method
ES2360336T3 (en) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company COMPOSITIONS IN TABLETS CONTAINING ATAZANAVIR.
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EA201170537A1 (en) * 2008-10-06 2011-12-30 Мерк Шарп Энд Домэ Корп. HIV INTEGRASE INHIBITORS
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2011003684A1 (en) * 2009-07-06 2011-01-13 Syngenta Participations Ag Insecticidal compounds
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
DE102009056636A1 (en) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir polymorphs
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
BR112012021652A2 (en) * 2010-03-04 2016-06-21 Merck Sharp & Dohme compound use thereof and pharmaceutical composition
EP2542077A4 (en) * 2010-03-04 2013-08-21 Merck Sharp & Dohme Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
NO2542084T3 (en) * 2010-03-04 2018-05-19
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
CN101914067B (en) * 2010-08-26 2012-07-11 陈岱岭 Method for synthesizing N-methyl pyrimidone
EP2694497A1 (en) 2011-04-06 2014-02-12 Lupin Limited Novel salts of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2529741B1 (en) 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
CN103130787B (en) * 2011-11-24 2015-06-10 南开大学 Pyrimidone amide compound, and preparation method, anti-HIV activity and anti-TMV activity thereof
CN103130788B (en) * 2011-11-24 2015-09-02 南开大学 Pyrimidine amides and preparation method thereof, HIV (human immunodeficiency virus)-resistant activity and anti-TMV are active
BR112014013224B1 (en) 2011-11-30 2023-03-07 Emory University ANTIVIRAL JAK INHIBITORS USEFUL IN THE TREATMENT OR PREVENTION OF RETROVIRAL AND OTHER VIRAL INFECTIONS
WO2013111100A1 (en) 2012-01-25 2013-08-01 Lupin Limited Stable amorphous raltegravir potassium premix and process for the preparation thereof
CN102911124B (en) * 2012-10-25 2015-11-25 山东大学 Hydroxy pyrimidine ketone compounds and preparation method thereof and application
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
PL2997033T3 (en) 2013-05-17 2018-04-30 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
SG11201602217XA (en) 2013-09-27 2016-04-28 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
CA2942239C (en) 2014-03-21 2020-09-22 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US10259778B2 (en) 2014-11-10 2019-04-16 Aurobindo Pharma Ltd Process for the preparation of raltegravir
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2018051239A1 (en) 2016-09-15 2018-03-22 Lupin Limited Process for the preparation of pure and stable crystalline raltegravir potassium form 3
JOP20190130A1 (en) 2016-12-02 2019-06-02 Merck Sharp & Dohme Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
HRP20220613T1 (en) 2017-11-14 2022-06-24 Cambrex Profarmaco Milano S.R.L. Process for the preparation of raltegravir
WO2021148992A1 (en) 2020-01-23 2021-07-29 Lupin Limited Pharmaceutical compositions of raltegravir

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051990A1 (en) * 1999-03-04 2000-09-08 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
WO2002006246A1 (en) * 2000-07-19 2002-01-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1508A (en) 1985-03-16 1990-08-03 Wellcome Found Antiviral nucleosides
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
DE4029654A1 (en) 1990-09-19 1992-04-02 Hoechst Ag 2-PHENYL-PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING IT AND THEIR USE AS FUNGICIDES
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
TW287160B (en) 1992-12-10 1996-10-01 Hoffmann La Roche
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
ID26031A (en) * 1998-03-26 2000-11-16 Shionogi & Co INDOL DAMAGES THAT HAVE AN ANTIVIRAL ACTIVITY
US6306891B1 (en) * 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
JP2002517390A (en) 1998-06-03 2002-06-18 メルク エンド カムパニー インコーポレーテッド HIV integrase inhibitor
EP1082121A4 (en) 1998-06-03 2003-02-05 Merck & Co Inc Hiv integrase inhibitors
NZ509748A (en) 1998-08-20 2003-01-31 Toyama Chemical Co Ltd Nitrogenous heterocyclic carboxamide derivatives or salts useful as antiviral agents
KR20010089708A (en) * 1998-12-25 2001-10-08 시오노 요시히코 Aromatic heterocycle compounds having hiv integrase inhibiting activities
CA2370500A1 (en) 1999-06-25 2001-01-04 Lekhanh O. Tran 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
EA200300449A1 (en) * 2000-10-12 2003-10-30 Мерк Энд Ко., Инк. AZA- AND POLYAZA-NAPHTHALINILKARBOXAMIDES USEFUL AS HIV-INTEGRASES INHIBITORS
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
JP2004517860A (en) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Aza- and polyaza-naphthalenylcarboxamides useful as HIV integrase inhibitors
ES2287170T3 (en) 2000-10-12 2007-12-16 MERCK & CO., INC. AZA- AND POLIAZA-NAFTALENIL-CARBOXAMIDAS UTILIES AS INHIBITORS OF INTEGRATED HIV.
BR0207809A (en) * 2001-03-01 2004-03-09 Shionogi & Co Nitrogen-containing heteroaryl compounds having inhibitory activity against hiv integrase
DK2266958T1 (en) * 2001-08-10 2016-04-04 Shionogi & Co antiviral
MXPA04003932A (en) * 2001-10-26 2004-06-18 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase.
WO2003035076A1 (en) 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
DE60329318D1 (en) 2002-11-20 2009-10-29 Japan Tobacco Inc 4-OXOCHINOLINE COMPOUNDS AND THEIR USE AS HIV INTEGRASE INHIBITORS
US7135467B2 (en) 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051990A1 (en) * 1999-03-04 2000-09-08 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
WO2002006246A1 (en) * 2000-07-19 2002-01-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAUSS ET AL: "Influence of HIV protease inhibitors on hepatitis C viral load in individuals with HIV and HCV coinfection", PROGRAM AND ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, XX, XX, 1997, pages 218, XP002095185 *
SUNDERLAND, CHRISTOPHER J. ET AL: "6-Carboxamido-5,4-Hydroxypyrimidinones: A New Class of Heterocyclic Ligands and Their Evaluation as Gadolinium Chelating Agents", INORGANIC CHEMISTRY (2001), 40(26), 6746-6756, XP002223645 *

Cited By (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US6921759B2 (en) 2000-10-12 2005-07-26 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
US9572813B2 (en) 2001-08-10 2017-02-21 Shionogi & Co., Ltd. Antiviral agent
EP2266958B1 (en) 2001-08-10 2017-03-15 Shionogi & Co., Ltd. Antiviral agent
US6924282B2 (en) 2001-08-17 2005-08-02 Merck & Co., Inc. Sodium salt of an HIV integrase inhibitor
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
US7482343B2 (en) 2002-05-09 2009-01-27 Cytokinetics, Inc. Compounds, methods and compositions
EP1509507A2 (en) * 2002-05-23 2005-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1509507A4 (en) * 2002-05-23 2006-09-13 Merck & Co Inc Mitotic kinesin inhibitors
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
US7399763B2 (en) 2002-09-11 2008-07-15 Merck & Co., Inc. 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors
US7517532B2 (en) 2002-09-11 2009-04-14 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
US7414045B2 (en) 2002-12-27 2008-08-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors
JP2006513200A (en) * 2002-12-27 2006-04-20 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Tetrahydro-4H-pyrido [1,2-a] pyrimidines and related compounds useful as HIV integrase inhibitors
WO2004058757A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004058756A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
JP4733986B2 (en) * 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Tetrahydro-4H-pyrido [1,2-a] pyrimidines and related compounds useful as HIV integrase inhibitors
US7968553B2 (en) 2002-12-27 2011-06-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors
US7135467B2 (en) * 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
US7211572B2 (en) 2003-08-13 2007-05-01 Japan Tobacco Inc. Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP2042502A1 (en) 2003-08-13 2009-04-01 Japan Tobacco Inc. Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7435735B2 (en) 2003-10-20 2008-10-14 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors
WO2005061501A2 (en) * 2003-12-12 2005-07-07 Merck & Co., Inc. Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds
WO2005061501A3 (en) * 2003-12-12 2006-04-06 Merck & Co Inc Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
JP4798608B2 (en) * 2003-12-22 2011-10-19 塩野義製薬株式会社 Hydroxypyrimidinone derivatives having HIV integrase inhibitory activity
US7745453B2 (en) 2003-12-22 2010-06-29 Shionogi & Co., Ltd. Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase
WO2005061490A1 (en) * 2003-12-22 2005-07-07 Shionogi & Co., Ltd. Hydroxypyrimidinone derivative having hiv integrase inhibitory activity
WO2005070901A2 (en) * 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
WO2005070901A3 (en) * 2004-01-12 2006-05-04 Gilead Sciences Inc Pyrimidyl phosphonate antiviral compounds and methods of use
JP2007517900A (en) * 2004-01-12 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド Pyrimidinephosphonate antiviral compounds and methods of use
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
US7820680B2 (en) 2004-03-09 2010-10-26 Merck & Co., Inc. HIV integrase inhibitors
US7598264B2 (en) 2004-03-09 2009-10-06 Merck & Co., Inc. HIV integrase inhibitors
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
JP2007537251A (en) * 2004-05-12 2007-12-20 ブリストル−マイヤーズ　スクイブ　カンパニー HIV integrase inhibitor: cyclic pyrimidinone compound
US7419969B2 (en) 2004-05-12 2008-09-02 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
WO2005113562A1 (en) * 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Hiv integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
EP1756069A4 (en) * 2004-05-18 2007-11-28 Bristol Myers Squibb Co Hiv integrase inhibitors
EP1756069A2 (en) * 2004-05-18 2007-02-28 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR101097623B1 (en) 2004-05-28 2011-12-22 브리스톨-마이어스 스큅 컴퍼니 Bicyclic heterocycles as hiv integrase inhibitors
WO2005118593A1 (en) * 2004-05-28 2005-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1749008A4 (en) * 2004-05-28 2010-07-07 Bristol Myers Squibb Co Bicyclic heterocycles as hiv integrase inhibitors
EP1749008A1 (en) * 2004-05-28 2007-02-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
AU2005311652B2 (en) * 2004-12-03 2010-12-02 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
WO2006060730A3 (en) * 2004-12-03 2006-08-17 Merck & Co Inc Potassium salt of an hiv integrase inhibitor
WO2006060681A3 (en) * 2004-12-03 2006-10-12 Merck & Co Inc Pharmaceutical composition containing an anti-nucleating agent
EA012418B1 (en) * 2004-12-03 2009-10-30 Мерк Энд Ко., Инк. Potassium salt of an hiv integrase inhibitors
US8852632B2 (en) 2004-12-03 2014-10-07 Merck Sharp & Dohme Corp. Pharmaceutical formulation containing a release rate controlling composition
WO2006060731A3 (en) * 2004-12-03 2006-09-28 Merck & Co Inc Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
US8771733B2 (en) 2004-12-03 2014-07-08 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
WO2006060712A3 (en) * 2004-12-03 2006-09-21 Merck & Co Inc Potassium salt of an hiv integrase inhibitor
NO338784B1 (en) * 2004-12-03 2016-10-17 Merck Sharp & Dohme Anhydrous crystalline monocalcium salt of an HIV integrase inhibitor, its pharmaceutical composition, its use in therapy, and its use in the manufacture of a medicament for the treatment or prevention of HIV infection, or for the treatment, prevention or delay of the onset of AIDS.
US7754731B2 (en) 2004-12-03 2010-07-13 Merck Sharp & Dohme Corp. Potassium salt of an HIV integrase inhibitor
AU2005311672B2 (en) * 2004-12-03 2010-07-22 Merck Sharp & Dohme Corp. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
AU2005311714B2 (en) * 2004-12-03 2010-09-30 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
WO2006060711A3 (en) * 2004-12-03 2006-09-08 Merck & Co Inc Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
EP1819323B1 (en) 2004-12-03 2016-11-16 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
AU2005311671B2 (en) * 2004-12-03 2011-01-27 Merck Sharp & Dohme Llc Potassium salt of an HIV integrase inhibitor
AU2005311671B8 (en) * 2004-12-03 2011-02-10 Merck Sharp & Dohme Llc Potassium salt of an HIV integrase inhibitor
KR101351059B1 (en) * 2004-12-03 2014-02-17 머크 샤프 앤드 돔 코포레이션 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
CN101068550B (en) * 2004-12-03 2011-03-30 默沙东公司 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
CN101068533B (en) * 2004-12-03 2011-04-27 默沙东公司 Pharmaceutical composition containing an anti-nucleating agent
CN101068793B (en) * 2004-12-03 2011-05-25 默沙东公司 Potassium salt of an HIV integrase inhibitor
JP4705956B2 (en) * 2004-12-03 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Potassium salt of HIV integrase inhibitor
JP2008521932A (en) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド Pharmaceutical formulations of carboxamide HIV integrase inhibitors containing release rate modifying compositions
WO2006060681A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
EP3165220B1 (en) 2004-12-03 2019-04-03 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
WO2006060711A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
JP2008521933A (en) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド Potassium salt of HIV integrase inhibitor
EP2586444A1 (en) 2004-12-03 2013-05-01 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition
EP3165220A1 (en) 2004-12-03 2017-05-10 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
JP2012184250A (en) * 2004-12-03 2012-09-27 Merck Sharp & Dohme Corp Pharmaceutical composition containing anti-nucleating agent
JP2008521929A (en) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド Pharmaceutical composition containing antinucleating agent
US8357798B2 (en) 2004-12-03 2013-01-22 Merck Sharp & Dohme Corp. Process for preparing N-alkylated hydroxypyrimidinone compounds
JP2013063999A (en) * 2004-12-03 2013-04-11 Merck Sharp & Dohme Corp Pharmaceutical composition containing anti-nucleating agent
US8410103B2 (en) 2005-04-28 2013-04-02 Shionogi & Co., Ltd. (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
US11267823B2 (en) 2005-04-28 2022-03-08 Shionogi & Co., Ltd. Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity
US9051337B2 (en) 2005-04-28 2015-06-09 Shionogi & Co., Ltd. Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides
US10927129B2 (en) 2005-04-28 2021-02-23 Shinogi & Co., Ltd. N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
US8778943B2 (en) 2005-04-28 2014-07-15 Shionogi & Co., Ltd. Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-α]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides
US9273065B2 (en) 2005-04-28 2016-03-01 Shionogi & Co., Ltd. Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors
WO2007064619A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Pyrimidine derivatives as hiv integrase inhibitors
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
WO2008154246A1 (en) * 2007-06-06 2008-12-18 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2008346833B2 (en) * 2008-01-08 2014-07-17 Merck Sharp & Dohme Corp. Process for preparing N-substituted hydroxypyrimidinone carboxamides
WO2009088729A1 (en) * 2008-01-08 2009-07-16 Merck & Co., Inc. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US8686141B2 (en) 2008-01-08 2014-04-01 Merck Sharp & Dohme Corp. Process for preparing N-substituted hydroxypyrimidinone carboxamides
WO2010000030A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
US8742105B2 (en) 2009-06-02 2014-06-03 Hetero Research Foundation Polymorphs of raltegravir potassium
US9649311B2 (en) 2009-10-26 2017-05-16 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
US10772888B2 (en) 2009-10-26 2020-09-15 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
US9260413B2 (en) 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
EP3235818A3 (en) * 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
EP2796458A1 (en) * 2010-04-01 2014-10-29 Teva Pharmaceutical Industries Ltd. Crystalline raltegravir sodium salts
WO2011127244A2 (en) 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
US8962833B2 (en) 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir
WO2012103105A1 (en) * 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
WO2013098854A3 (en) * 2011-12-26 2014-10-02 Emcure Pharmaceuticals Limited Synthesis of raltegravir
EP2875024A4 (en) * 2012-07-20 2015-12-23 Merck Sharp & Dohme Hiv treatment with amido-substituted pyrimidinone derivatives
US8921388B2 (en) 2012-08-06 2014-12-30 European Molecular Biology Laboratory Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN104619699A (en) * 2012-08-06 2015-05-13 萨维拉制药有限公司 Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014023691A1 (en) * 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US10689399B2 (en) 2012-12-21 2020-06-23 Gilead Sciences, Inc. Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
US11548901B2 (en) 2012-12-21 2023-01-10 Gilead Sciences, Inc. Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
US9663528B2 (en) 2012-12-21 2017-05-30 Gilead Sciences, Inc. Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections
US9732092B2 (en) 2012-12-21 2017-08-15 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
US10035809B2 (en) 2012-12-21 2018-07-31 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
US11213523B2 (en) 2013-07-12 2022-01-04 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US11883397B2 (en) 2013-07-12 2024-01-30 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10668064B2 (en) 2013-07-12 2020-06-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
US20170253585A1 (en) * 2014-02-03 2017-09-07 Mylan Laboratories Ltd. Processes for the preparation of intermediates of raltegravir
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US11202780B2 (en) 2014-06-20 2021-12-21 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10385067B2 (en) 2014-06-20 2019-08-20 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
US10098886B2 (en) 2014-06-20 2018-10-16 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US10646486B2 (en) 2014-12-23 2020-05-12 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9795602B2 (en) 2014-12-23 2017-10-24 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10358435B2 (en) 2015-03-17 2019-07-23 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as PDE2 inhibitors
WO2016149058A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
US10357481B2 (en) 2015-07-01 2019-07-23 Merck Sharp & Dohme Corp. Substituted triazolo bicyclic compounds as PDE2 inhibitors
WO2017220208A1 (en) 2016-06-21 2017-12-28 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents

Also Published As

Publication number Publication date
CO5580777A2 (en) 2005-11-30
EP1441735B1 (en) 2006-02-22
DE122008000016I1 (en) 2011-12-01
CY2008008I1 (en) 2009-11-04
ZA200402796B (en) 2005-03-30
IS7213A (en) 2004-04-07
ES2258668T3 (en) 2006-09-01
CN102229605B (en) 2015-01-14
CN102229605A (en) 2011-11-02
KR20040047981A (en) 2004-06-05
PL369223A1 (en) 2005-04-18
NO2020026I1 (en) 2020-08-10
UA77454C2 (en) 2006-12-15
LU91428I2 (en) 2008-06-09
IS2436B (en) 2008-10-15
HU230248B1 (en) 2015-11-30
ME00427B (en) 2011-10-10
ATE318140T1 (en) 2006-03-15
BR0213522A (en) 2004-09-08
DE60209381T2 (en) 2006-10-05
LTC1441735I2 (en) 2020-06-25
CN1700918A (en) 2005-11-23
CN102219750B (en) 2013-05-29
FR08C0026I1 (en) 2008-07-18
NO325206B1 (en) 2008-02-25
US20110034449A1 (en) 2011-02-10
NL300340I1 (en) 2008-06-02
YU35604A (en) 2006-08-17
CA2463976C (en) 2007-02-13
CA2463976A1 (en) 2003-05-01
US7435734B2 (en) 2008-10-14
NO20042165L (en) 2004-05-25
DE122009000048I1 (en) 2010-04-08
HUP0401740A3 (en) 2009-06-29
US7217713B2 (en) 2007-05-15
HK1085665A1 (en) 2006-09-01
MXPA04003932A (en) 2004-06-18
IL161337A (en) 2010-02-17
HUS1600016I1 (en) 2018-05-02
JP2005511543A (en) 2005-04-28
HRP20040373B1 (en) 2012-09-30
FR08C0026I2 (en) 2010-01-22
DK1441735T3 (en) 2006-06-12
DE60209381D1 (en) 2006-04-27
PT1441735E (en) 2006-06-30
US20070123524A1 (en) 2007-05-31
BRPI0213522C1 (en) 2021-05-25
CN102219750A (en) 2011-10-19
AU2002334207A2 (en) 2003-05-06
NZ533057A (en) 2005-11-25
EP1441735A1 (en) 2004-08-04
RS51542B (en) 2011-06-30
EA007060B1 (en) 2006-06-30
US7169780B2 (en) 2007-01-30
JP3927175B2 (en) 2007-06-06
GEP20063848B (en) 2006-06-12
BR0213522B8 (en) 2017-07-04
NO2008007I2 (en) 2010-09-27
HUP0401740A2 (en) 2004-12-28
US7820660B2 (en) 2010-10-26
US20080275004A1 (en) 2008-11-06
AU2002334207B2 (en) 2006-02-23
HRP20040373A2 (en) 2005-08-31
PL212914B1 (en) 2012-12-31
NO2008007I1 (en) 2008-06-23
SI1441735T1 (en) 2006-06-30
BR0213522B1 (en) 2017-06-13
CN1700918B (en) 2011-06-08
US20060258860A1 (en) 2006-11-16
KR100862879B1 (en) 2008-10-15
EA200400585A1 (en) 2004-10-28
US20050025774A1 (en) 2005-02-03
LTPA2008007I1 (en) 2020-05-11
IL161337A0 (en) 2004-09-27
NL300340I2 (en) 2008-08-01

Similar Documents

Publication Publication Date Title
EP1441735B1 (en) N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
EP1441734B1 (en) Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2002334205A1 (en) Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
AU2003267098B2 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
EP1539714B1 (en) 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
AU2002334207B8 (en) N-substituted hydroxpyrimidinone carboxamide inhibitors of HIV integrase
AU2002334207A1 (en) N-substituted hydroxpyrimidinone carboxamide inhibitors of HIV integrase
AU2003302382B2 (en) 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200400347

Country of ref document: VN

Ref document number: P-356/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002801950

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 161337

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004/02796

Country of ref document: ZA

Ref document number: 200402796

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002334207

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500540

Country of ref document: PH

Ref document number: 2463976

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10493280

Country of ref document: US

Ref document number: DZP2004000106

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 04036632

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003932

Country of ref document: MX

Ref document number: 868/CHENP/2004

Country of ref document: IN

Ref document number: 2003537644

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: P20040373A

Country of ref document: HR

Ref document number: 1020047006234

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 533057

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 5592

Country of ref document: GE

Ref document number: 8227

Country of ref document: GE

Ref document number: 200400585

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20028257650

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002801950

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 533057

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002801950

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 533057

Country of ref document: NZ